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Introduction and Overview
Monique C. Braude, Ph.D., and
Harold M. Ginzburg, M.D., J.D., M.P.H.
Ten years have passed since the Proceedings of the first Conference
on Interactions of Drugs of Abuse, held at the New York Academy of
Sciences, was published (Vesell and Braude 1976). Some of the
participants in the 1976 conference, such as Drs. Hollister. Kreek,
Mitchell, and Vesell, who have continued and expanded their interest
in the interaction area, also participated in the Technical Review
on "Strategies for Research on the Interactions of Drugs of Abuse"
which was held in Rockvllle, Maryland, October 29-30, 1984. This
Research Monograph is a summary of the papers and discussions of the
invited experts who participated in this 2-day meeting.
In the past two decades a large part of the counterculture has been
involved in self-experimentation with drugs, and the concurrent
self-administration of multiple substances of abuse, by a variety of
routes, has become normative behavior. Recently, for instance, the
use on the street of a combination of tripelennamlne and pentazocine
(Ts and Blues) elicited concern which was promptly remedied by the
pharmaceutical industry by the addition of naloxone to pentazoclne.
Since the early 1970s the National Institute on Drug Abuse (NIDA)
has supported a program encompassing interactions of drugs of abuse
(such as marijuana, stimulants, and depressants) or of new
therapeutic modalities. such as naltrexone, with other compounds
used either on the street or therapeutically. The need for this
type of research has increased with the use of polypharmacy by drug
abusers and also their simultaneous use of alcohol, which has proved
in many cases to be a potentiating agent for abused substances.
While the literature dealing with drug interactions from the
pharmaceutical standpoint is extensive, it often consists of
testimonial reports of adverse interactions and lacks in-depth
studies of the mechanisms underlying these effects. A more recent
approach has been to investigate interactions not simply from a
forensic standpoint but rather to obtain epidemiological and
clinical data to study pharmacological and behavioral interactions.
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In as much as the first conference was about equally divided between
preclinical and clinical studies, the emphasis at this second
meeting was on clinical experimental and epidemiological data and
strategies to be used for future studies in this research area.
In the opening chapter of this monograph, Dr. Adler lists the
critical factors that would have to be adhered to in order to obtain
reproducible and meaningful information about interactions among
drugs of abuse. These include the necessity of performing full dose
response curves as most of these drugs, such as the barbiturates and
the cannabinoids, may have biphaslc effects at different dose
levels. This was discussed at length by the group, and it was the
general feeling that clinical studies cannot adhere to the rigorous
criteria set by Dr. Adler for preclinical studies. For instance, a
full dose response range may not be practical and would be too
expensive to use in clinical studies if one would want to look only
at the therapeutic (or abuse) range for treatment compounds.
However, for illicit drugs, often used in the street in the toxic
dose range, interaction studies cannot be done clinically and animal
models have to be used.
The group also noticed that basic science studies have not provided
any complex models for understanding drug interactions and that no
model to replicate the "street environment" of multiple drug use has
been developed. Too often, most of the preclinical studies have
used a single-drug or at most a two-drug dosing regimen while,
actually, street abusers as well as therapeutic users often use
multiple drugs simultaneously or sequentially. On the other hand,
clinicians have had difficulty in developing research protocols with
a definite set of hypotheses which would not be too costly to be
approved with high priority by a review committee.
Initial epidemiologic studies, which are descriptive, can provide
evidence of what types of drug interactions will precipitate
individuals into seeking treatment as well as demonstrate the
generallzabllity of laboratory findings. In the second chapter, Dr.
Hubbard and colleagues describe the multiple use patterns of a
treatment population of drug abusers, observed in the Treatment
Outcome Prospective Study (TOPS). This data, coupled with the Drug
Abuse Warning Network (DAWN) data, provides the basis for
determining new toxic drug interactions that will require careful
study both to develop therapeutic interventions that will minimlze
morbidity and to better understand the pharmacological reasons for
individuals wanting to use a given set of psychoactive substances.
Dr. Hubbard also emphasizes that, in order to understand the complex
nature of multiple drug use, a multidisciplinary approach is needed
with greater collaboration between epidemiologists, clinicians, and
pharmacologists.
Dr. Mitchell describes step by step the statistical approaches which
can be used to measure interaction quantitatively. Most often used
are the potency ratio and the isobolographlc methods. Both
approaches have the same conceptual basis. but the lsobolographic
method is more tedious and more difficult to use in clinical studies.
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Dr. Frecker brought an interesting new perspective to the group,
that of an ophthalmologist with a doctorate in pharmacology who is
interested in developing engineering systems for biomedical studies
in humans. He identified some critical elements of the "man-machine
interface" as they relate to drug-effect measurements and described
what he considers to be the attributes of an "ideal" pharmacodynamic
measurement technique. Although his paper is mainly on pharmaco-
dynamics, i.e., the study of drugs in organisms, he also reminds us
that pharmacokinetic parameters which provide indicators on, for
instance, the time course of drug effects should be taken into
consideration.
The pharmacokinetic mechanisms of alcohol-psychotropic drug
interactions were described by Ciraulo and Barnhill and relevant
examples cited. Alcohol alters drug metabolism through its effects
on hepatic biotransformation, and the concept of hepatic extraction
is important in predicting the effects of metabolic interactions.
(Excellent reviews on the pharmacokinetics of drug interactions by
G. Levy and J.R. Gillette were also included in the 1976 publication
of the New York Academy of Sciences and can be referred to for
additional information on that topic.)
The importance of dietary factors which can alter drug response by
changing several pharmacokinetic factors was reviewed by Dr.
Vesell. Large individual variations, from three to elevenfold, can
be observed in different subjects even when the same dose of a drug
is given by the same route and under the same environmental
conditions. Furthermore, food affects the absorption of drugs by
enhancing gastric blood flow and retarding gastric emptying. In
this monograph, Dr. Vesell discusses various approaches to
assessment of dietary contributions to the interindivldual
variations in drug disposition observed in many clinical studies.
The next two papers, by Dr. Hollister and Drs. Mendelson, Mello, and
Lex, illustrate the problem of making positive conclusions about
possible interactions of two drugs of abuse such as alcohol and
marijuana. In reviewing the interactions of cannabis with other
drugs in man, Dr. Hollister reports that only THC. the psychoactive
component of marijuana, shows a significant pharmacodynamic
interaction in man and animals with alcohol and that the interactive
effect tends to be additive. However, the data presented by Drs.
Mendelson and Mello regarding the concordant use of marijuana by men
and women shows that when alcohol and marijuana are concurrently
available, marijuana appears to affect alcohol use more dramatically
than alcohol influences marijuana use, and that the consumption of
alcohol is reduced during marijuana use even in heavy alcohol
drinkers. These data indicate that the simultaneous availability of
two recreational psychoactive drugs does not necessarily increase
drug use. As THC is known to affect cell membranes, Dr. Hollister
also feels that it would be of interest to study interactions
between THC and drugs, such as
Dr. Reese Jones in his critical
reminded the group that both 
lithium. that alter
 review of cocaine
nicotine and caffeine
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membrane lipids.
Interactions
to be taken into account when investigating the effects of cocaine
with other drugs. He believes that the most realistic conditions
for studying cocaine and other drug interactions are after repeated
use of both drugs of interest. Rapidly acquired tolerance and the
likelihood of cross tolerance to other drugs complicates any design
involving repeated administration of a drug in drug interaction
studies. In a repeated dose paradigm lasting more than a few days,
new signs and symptoms appear which are different from those
observed after acute or early drug effects. The mechanisms of these
long-term interactions are complex and difficult to delineate.
The chapter by Drs. Mello and Mendelson further demonstrates the
complexity of interaction studles. In studying the effect of
cigarette smoking on alcohol, opiates (heroin and buprenorphine),
and marijuana use, they confirm that a number of drugs from diverse
pharmacological classes influence tobacco smoking. Alcohol and
opiates increase cigarette smoking, whereas marijuana has no
apparent effect on tobacco use. Opiate antagonists like naltrexone
do not appear to alter cigarette smoking significantly. They
suggest that polydrug use may have less to do with the pharmaco-
logical properties of the drugs or their anticipated effects than
with their capacity to produce some change in subjective states.
Change may be the goal of the polydrug user, as it appears that any
drug or drug combination that has definitive stimulus properties and
behavioral effects for the user may have abuse potential.
Dr. Kornetsky reports the results of a series of experiments on the
effects of various drug combinations on the threshold for
brain-stimulation reward and brain-stimulation escape (pain). These
studies show that combinations of drugs often lead to synergism or
potentiation of effects which are manifested not only in the
euphoriant action of drugs but also in their analgesic action, as
with the enhancement of morphine analgesia by d-amphetamine.
Dr. Kreek in her extensive review of the interactions of methadone
with various drugs in humans shows that combined treatment of a
methadone-maintained patient with a second drug, such as rifampin or
phenytoin, can produce severe withdrawal symptoms due to
pharmacoklnetic interactions. In developing a strategy to identify,
define, and elucidate the mechanisms of interactions between drugs of
abuse or those used in treatment, Dr. Kreek concludes that the most
urgently needed studies are those which can be carried out in humans
to document pilot data obtained in in vitro or preclinical studies.
In the final analysis, however, the question is: What do we want to
learn from interaction studies? Are we interested in understanding
the cellular effects of drug interactions to develop better
treatment interventions or are we interested in the pathophyslology
of multiple concurrent drug use, independent of developing
therapeutic interventions? On the other hand, are we interested in
being able adequately to describe the phenomena as markers for the
effectiveness of interventions (primary, secondary, and tertiary)?
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In summary, the review participants were very enthusiastic about
continuing research in the drug interactions area. They felt,
however, that this field needs to be encouraged by NIDA and that the
supportive group of clinical and preclinical research scientists
already involved in this type of research needs to be nurtured and
its ranks enlarged.
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Critical Factors in Studying Drug
Interactions
Martin W. Adler, Ph.D.
INTRODUCTION
This technical review met to develop etrategies that can be used
to study interactions involving drugs of abuse. The need for
information on this subject is obvious, both from a therapeutic
and a toxicological viewpoint. If we look at the list of phar-
macological agents that we consider under the heading of drugs
of abuse, we see a variety of drugs and drug classes, including
the opioids, cannabinoids, alcohol, cocaine, amphetamine, PCP,
hallucinogens, barbiturates, anxiolytics, and nicotine. Many of
these agents have important therapeutic uses, while others are
of interest primarily because of their nomedical use. While
there is a paucity of information about the interactions of
these substances with all sorts of other drugs, perhaps the
greatest deficiency in knowledge lies in interactions among the
various drugs of abuse. When there drugs are used therapeu-
tically, interactions can lead to either a desired increase in
efficacy or to adverse effects. When used nonmedically, they
can interact to alter the euphoric or dysphoric effects. If one
thinks in terms of basic pharmacological principles, it is often
possible to predict what will occur if two or more drugs are
administered concurrently or, at least, to understand unexpected
consequences of drug combinations. With that in mind, I will
review some of the factors that should be considered.
GENERAL CONSIDERATIONS
In general, one drug may be synergistic with (additive or poten-
tiated) or antagonistic to another drug by acting at the same
receptors, by acting at different receptors or systems, by
interacting chemically or physically, or by altering phar-
macokinetics. A word of caution should be given at this point,
however. Just because an interaction occurs, one rhould not
necessarily conclude that the interaction is meaningful either
in terms of clinical efficacy or toxicological consequencer;
that determination is dependent on a variety of considerations,
such as the degree of interaction, the therapeutic ratio, the
shape of the dose-response curve, and the general status of the
subject.
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A natural way to proceed in this discussion might be to dissect
and explore in detail the pharmacokinetic and pharmacodynamic
factors which are vital elements in evaluating and predicting
drug interactions. For example, a consideration of drug absorp-
tion, distribution, metabolism, and excretion is important.
Good discussions of these pharmacokinetic factors may not only
be found in any authoritative text in pharmacology, but also in
three excellent papers presented at the New York Academy of
Sciences symposium entitled “Interactions of Drugs of Abuse”
(Reidenberg 1976; Levy 1976; Gillette 1976). Although this
chapter will address these and other basic considerations, they
will be used in a somewhat different way in order to focus
attention on those aspects that may be moat important in terms
of preclinical and clinical studies with the drugs of abuse.
CRITICAL FACTORS
Table 1 summarises some of the factors which should be taken
into account when conducting drug interaction studies.
TABLE 1
Critical Factors in Drug Interactions
1.
2.
3.
4 .
5.
6.
7.
8.
9.
10.
11.
12.
Ability of a Drug to Reach its Site of Action
Time Course of Drug Effects
Full Dose-Response Curves
Circadian and Seasonal Variations
Environment
Sex and Age
Choice of Endpoint
Route of Drug Administration
Choice of Vehicle and Proper Controls
Tolerance and Cross-tolerance
Effects on Neurotransmitter Systems
Appropriate Statistical Analysis
Reaching the Site of Action
The abili ty of the drugs to reach their si tes of action is a
vital concern in interpreting the interaction or lack of
interaction Of drugs. Figure 1 diagrams the pharmacokinetics of
a drug in relation to i ts  r i te of action. Anything that might
affect the absorption of a drug, its binding to plasma proteins,
its metabolism, or its penetration into the central nervous
system could affect the final result and assessment.
Time Course
Due consideration must be given to the time course of the effects
of the drugs in terms of onset of action, time of peak effect, and
duration of action. The investigator must make aure that the
pharmacological effects of the drugs are being evaluated at a
time when both drugs are exerting their maximal effects, Looking
at interactions when one drug is just beginning to exert its
effects and the other drug’s effects are on the wane can result
in meaningless conclusions.
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FIGURE 1
Schematic Representation of the Interrelationship of the Absorp-
tion, Distribution, Binding, Biotransformation, and Excretion of
a Drug and its Concentration at its Locus of Action. Possible
distribution and binding of metabolites are not depicted.
From Mayer, S.E.; Melmon, K.L.; and Gilman, A.G. Introduction:
The dynamics of drug absorption, distribution and elimination.
In: Gilman et al. 1980. Copyright 1980, Macmillan Publishing Co.
Dose-Response Relationship
The necessity of utilizing full dose-response curves when eval-
uating drug interactions is too often ignored. Conclusions are
sometimes reached on the basis of experiments using only one or
two doses of the drugs involved. Not only can such experiments
yield false negatives in terms of drug interactions, but they
also fail to provide the quantitative data needed for a full
evaluation of a positive effect. AS an example, one can take
the question of whether there is an interaction between the
opioid drugs and the barbiturates, using analgesia (or antinoci-
ception) as the endpoint. Various reports in the literature
concluded that there was synergism (Barlow and Duncan 1933;
Keats and Beecher 1950; Lesher and Spratto 1978; Smith et al.
1943), l antagonism (Clutton-Brock 1961; Dundee 1960; Neal 1965;
Shapero and Wilson 1964), or no interaction (Hart and Weaver
1948) between the drugs in terms of analgesia. The studies dif-
fered from each other in terms of the particular drugs used, the
doses, the species, the dose range tented, and the number of
times the drugs were administered. We decided to investigate
the problem by using the rat,
(tail-pressure), a full dose range of morphine, a full sub-
one test of antinociception
anesthetic dose range of pentobarbital, and by giving the drugs
at the time of peak effect. One study was done in animals that
were drug naive and another in rats tolerant to morphine.
Although we raw an isolated instance of decreased analgesia in
one dose pair, the results were clear-- subanesthetic doses of Na
pentobarbital had neither antinociceptive nor hyperalgesic prop-
erties, and the barbiturate had no effect on the antinociceptive
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action of morphine in either morphine-tolerant or
nontolerant rats (Geller et al. 1979). Bad we chosen only one
dose combination, we might have concluded otherwise.
Circadian and Seasonal Effects
The influence of circadian and seasonal variations on the
effects of one or both drugs must be assessed. Some drugs may
have markedly different quantitative actions depending on the
time of day the drug is administered. For instance, there is a
diurnal rhythm in responsiveness of mice to the hyperalgesic
activity of naloxone (Frederickson et al. 1977) and in
lorazepam-induced neurologic deficits (Henauer et al. 1984). A
study by Morris (1980) in mice and rats is intriguing. He found
that several drugs (e.g., cocaine, PCP, and morphine), when com-
bined with alcohol, markedly increased lethality depending not
only on time of day, but also on the phase of the moon. The
circadian variations in drug effect are thus important to con-
sider in evaluating drug interactions. Likewise, seasonal
variations in response to drugs have long been known in animals
and are likely to occur in human subjects as well. As an
extreme example, I can cite recent studies demonstrating that
dependence to morphine could not be produced in hibernating ani-
mals (Beckman et al. 19811.
Environment
The environment of the subject can play an important role in the
response to drugs. Thus, housing has been found to be one of
the determinants of the lethal dose of amphetamine; low humidity
may lead to infections and the consequent general debilitation
may modulate drug effects; high humidity can add to stress-
induced effects of high temperatures; lighting can alter cir-
cadian rhythms; and ambient temperature can affect a variety of
measures such as the changes in body temperature produced by
morphine in rodents. Alterations in any of these environmental
conditions could thus markedly modify the results seen with
interactions of drugs of abuse.
Sex and Age
Sex and age of the subject are important considerations in
looking at interactions. One must be aware that a drug can have
markedly different effects depending on the sex of the subject.
For example, the toxicity of drugs such as cocaine seems to be
determined, in part, by the sex of the subject (Thompson et al.
19841. Based on studies which reveal a differential sensitivity
of leutinizing hormone to naloxone and morphine in males and
females at different points in development, it has been recently
postulated (Cicero et al., in press) that opioids may be respon-
sible for the regulation of endocrine profiles. As for age, we
are becoming increasingly aware that the response of older indi-
viduals to drugs, especially those affecting the CNS, is
markedly different from that seen in younger adults because of a
combination of pharmacokinetic and pharmacodynamic factors. We
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have long known that subjects with immature nervous systems
respond differently to centrally acting drugs than do mature
subjects . Yet, these factors are too often ignored, especially
in studies with mice and rats.
Endpoint
Choice of the endpoint to be rtudied is extremely important.
Drugs usually have multiple effects mediated through a variety
of different receptors and systems. Drug interactions may thus
be seen for some effects but not others.
Route of Administration
Route of drug adminstration is important in determining if
interactions occur. Not only does the route of administration
affect the amount of drug reaching its site of action and thus
influence the quantitative effect, but the route may alter the
qua l i ta t ive  e f fec t . For example, studies in rats in our labora-
tory have demonstrated that meperidine increases brain
excitability vhen administered subcutaneously (s,c.) but
decreases excitability when given intracerebroventricularly
(i.c.v.) (Tortella et al. 1984). Table 2 compares effects on
flurothyl seizure thresholds and the action of naloxone on these
responses for several opioids given by the two routes.
Similarly, body temperature studies reveal that high doses of
morphine s.c. produce hypothermia, but these doses administered i.c.v.
produce only hyperthermia (Adler et al. 1985b). Whether the dif-
ferences are due to the temporal sequence in which the drugs
reach the receptors or to some other mechanism in not yet known.
In any case, interactions may occur between drugs given by one
route but not by another.
TABLE 2
Influence of Route of Administration on Opioid-Induced
Changes in Flurothyl Seizure Threshold in Rats
ROUTE OF CHANGE IN EFFECT WITH
DRUG AMINISTRATION SEIZURE THRESHOLD NALOXONE
Morphine
Meperidine
Pentaxocine
Normeperidine
SC
ICV
SC
ICV
SC
ICV
SC
ICV
Blocked
Blocked
Potentiated
Blocked
Potentiated
Unchanged
Unchanged
Potentiated
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Vehicle and Controls
Choice of vehicle and proper controls for the possibility of
interactions between the vehicles and the drugs is often
overlooked or given scant attention. Many chemicals used as
vehicles have effects by themselves and the possibility exists
that, when given together, those compounds can synergize with or
antagonize the actions of the drug or drugs being tested. As an-
example, one can refer to studies involving delta-9-THC. This
agent is usually administered either in alcohol, emulphor, Tween
80, pluronic, or some combination of the above. All of these
agents have effects on the CNS. What started out as a straight-
forward experiment in our laboratory to determine the effects of
THC on the pupil in the rat became a major effort when we dis-
covered that accompanying the change in pupil size with THC was an
increase in pupillary oscil lat ions. The vehicles themselves
also caused some oscillation, although less than that seen with
the vehicle-THC combination (Adler et al. 1985a). In attempting
to determine whether there is an interaction between opioids and
THC on the pupil, we face a problem because opioids also produce
very profound pupillary fluctuations in the rat. In fact,  the
degree of fluctuation is one means we use in postulating whether
an effect is exerted at a mu, kappa, or sigma receptor (Robin et
al. 1985).
Tolerance and Cross-Tolerance
Tolerance to a drug as well as cross-tolerance to other drugs
may develop. The tolerance may be due to pharmscokinetic or to
pharmacodynamic factors and may occur as the result of the
administration of a single drug or the previous or concurrent
administration of other drugs. There may be tolerance to some
of the effects of a drug and not to other effects, and there may
be reverse tolerance (increased responsiveness to an action of a
drug). A good example is seen with amphetamine vhere tolerance
occurs to effects such as the hyperthermic and the anorexic
actions (Gilman et al. 1980), while an increased sensitivity to
some stereotypic behaviors (Segal et al. 1980) can develop.
Repeated administration of cocaine leads to an increase in sen-
s i t iv i ty  to  i t s  l e tha l  e f fec ts . Such factors are of obvious
significance in evaluating the drug interactions that may occur.
Effects on Neurotransmitters
Effects on a neurotransmitter system by one drug may affect the
actions of another drug. Thus, a drug affecting the adrenergic
system by altering levels of norepinephrine or by acting at
postsynaptic receptors can markedly modify the actions of drugs
of abuse, such as cocaine or amphetamine.
Statistical Analysis
Finally,  correct statistical analysis of the data is not an easy
problem. This is especially true if one is trying to determine
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if an interaction between drugs is an additive effect, an effect
that is something less than additive, or an effect that is
greater than additive, a true potentiation. There are several
ways that this problem can be approached and Dr. Mitchell
addresses this topic elsewhere in this volume.
CONCLUDING REMARKS
If future studies adhere to the criteria set forth above, I
believe that we will obtain reproducible and meaningful infor-
mation about interactions among drugs of abuse. To conduct such
studies properly is admittedly tedious, time-consuming, and
expensive. Of course, not all studies can control all of the
factors I have discussed. This is especially true of clinical
studies with all  their inherent difficulties. In such
situations, however, it would be useful if the investigators at
least took these factors into consideration when drawing conclu-
sions. Pointing out potential  pitfalls  in interpretation vould
be most helpful to other researchers in the field and would aid
in resolving differences between studies and in determining the
significance of the drug interactions.
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Issues in the Assessment of Multi-
ple Drug Use Among Drug Treat-
ment Clients
Robert L. Hubbard, Ph.D.; Robert M. Bray, Ph.D.; S. Gail
Craddock, M.S.; Elizabeth R. Cavanaugh, B.A.; William E.
Schlenger, Ph.D.; and J. Valley Rachal, M.S.
Use of such drugs as marijuana, cocaine, and heroin continues to
be a significant problem, crosscutting health, legal, and behav-
ioral domains. The use of multiple drugs of abuse, especially
marijuana and cocaine in combination with alcohol, appears to be
increasing in some segments of the population. Among persons
entering treatment, patterns of use are becoming more complex.
More effective approaches to prevention, intervention, and treat-
ment may be developed and implemented with a better understanding
of multiple drug abuse patterns. Increased understanding of use
patterns of "street pharmacologists" could suggest hypotheses for
pharmacological studies in the laboratory. In addition, epidemi-
ological studies can demonstrate the generalizability of labora-
tory findings.
Drug abuse treatment clients are the extreme in the continuum of
the drug-using population. Information on their muliple use
patterns may be useful and important. The Treatment Outcome
Prospective Study (TOPS) obtained detailed drug use histories of
11,750 clients entering 41 detoxification, methadone, residen-
tial, and outpatient drug-free treatment programs in 10 cities
from 1979-81 (Hubbard et al. 1984). A sample of 5,000 of these
clients was followed up 1 to 3 years after treatment.
The purpose of this chapter is, first, to describe the multiple
use patterns of treatment population; second, to outline factors
that need to be considered in epidemiological studies of multiple
drug use; and, finally, to suggest some strategies for a compre-
hensive and integrated approach to the study of multiple drug
use.
A COMPREHENSIVE ASSESSMENT OF DRUG USE
The complexity of current drug use patterns requires a thorough
assessment of use of alcohol and a variety of types of licit and
illicit drugs. The information needed for assessment includes
specific data on medical and nonmedical use of different types of
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drugs as well as specific drugs. The history of use for the
major types of drugs should include the initiation of use, cur-
rent use, and the termination of use. Frequency, quantity,
route, and concurrent use of other drugs provide data critical
for assessment of multiple use pattern.
Assessment of Drugs Used in TOPS
Clients were asked to provide information about their back-
grounds, alcohol and drug use treatment, mental health, criminal
behavior, and employment in personal interviews conducted when
they applied for admission to a TOPS program. The data used to
develop drug use measures in TOPS are from the comprehensive
assessments of nonmedical drug use obtained in the interviews.
Clients were told, "In this section we would like to ask about
your nonmedical use of drugs--without a doctor's prescription or
not according to directions." Clients were then asked, "Have you
ever used [drug type]?" for each of the types of drugs listed
below.
1.
2.
3.
4.
5.
6
7.
8.
9.
10.
11.
12.
13.
Marijuana, hashish, THC
Inhalants-such as glue, gasoline, paint thinner
Hallucinogens or psychedelics-such as LSD, DMT,
mescaline, PCP
Cocaine
Heroin
Street or illegal methadone
Other narcotics or opiates-such as opium,
morphine, codeine, Demerol, Dilaudid, Talwin
Minor tranquilizers-such as Librium, Valium,
Miltown, Equanil
Major tranquilizers-such as Thorazine, Stelazine,
Lithium, Mellaril
Barbiturates-such as Nembutal, Seconal, Tuinal
Sedatives and hypnotics - such as Doriden,
Noludar, Quaalude, Sopor
Amphetamines, speed or diet pills - such as
Benzedrine, Dexedrine, Preludin
Any other drugs (Specify)
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The drug type and examples of each type were read to the client.
Color pictures of tranquilizers, barbiturates, sedatives and
amphetamines were shown to the client.
of hallucinogens,
If a client reported use
minor tranquilizers or amphetamines, he or she
was asked about use of a specific drug within the general type-
PCP, Librium/Valium and Preludin, respectively.
Frequency of use of alcohol and frequency of use of drugs for
nonmedical purposes during the 3 months and 12 months before
treatment were obtained for all drug types. Clients were asked
to report their frequency of use on the following 9-point scale:
0
1
2
3
4
5
6
7
8
None
Less than 1 time a month
1 to 3 times a month
1 time a week
2 to 3 times a week
4 to 6 times a week
Daily/1 time a day
2 to 3 times each day
4 or more times each day
The 12-month period preceding treatment was chosen as the base
period for the TOPS analyses because it should allow a more
complete assessment of drug use than the 3 months immediately
preceding treatment. Although a client's life history of drug
use could also be considered, a period of a year prior to treat-
ment should be a more appropriate baseline for examining change
during and after treatment. Detailed questions were asked on the
initiation of use. The nature of the drug problem and the types
of problems associated with use were also addressed.
At months 1, 3, and quarterly thereafter for up to 2 years while
the clients remained in treatment, additional indepth assessments
of drug use and other behaviors were conducted. These assess-
ments are being continued in the posttreatment period by followup
interviews up to 3 years after termination.
Types of Drugs Used by Treatment Clients in TOPS
The need for a comprehensive assessment of drug use is shown in
table 1. In the year before treatment, clients in all modalities
used a variety of drugs weekly or more often. Weekly use of
alcohol and marijuana was quite common. Given the extent of
multiple drug use, weekly rather than daily use provides a more
appropriate measure for multiple use. The great variety of drugs
used suggests that use patterns may be episodic and considerable
substitution may occur. Consequently, a focus only on consistent
daily use may seriously understate the extent of multiple use and
the potential for drug interactions.
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TABLE 1
Weekly or More Frequent Drug Use in Year
Before Intake: 1979 and 1980 Cohorts
Drug(s)
Outpatient Outpatient
Methadone Drug-Free Residential
(n=2660) (n=2014) (n=1789)
Alcohol
Marijuana
Inhalants
Hallucinogens
(PCP)
Cocaine
Heroin
Methadone
Other narcotics
Minor tranquilizers
(Chlordiazepoxide/Oiazepam)
Major tranquilizers
Barbiturates
Sedatives
Amphetamines
(Phenmetrazine)
46.8%
57.3
0.4
1.3
0.5
27.4
63.9
19.8
26.8
25.3
23.9
1.3
6.4
5.6
10.2
5.0
62.0%
67.5
1.4
5.6
2.6
15.6
10.5
2.0
15.6
18.1
16.6
1.9
7.9
11.2
22.0
3.6
63.8%
65.9
2.0
10.6
8.1
28.1
30.2
5.0
29.2
28.3
27.4
3.9
15.1
16.5
28.5
11.9
In table 2, we see that, even after treatment, many clients con-
tinued their use of multiple substances. Marijuana was used
weekly by almost half of the former clients. These data on the
extensive use of a variety of drugs provide the base from which a
description of multiple drug use must be made.
TABLE 2
Clients' Drug Use Weekly or More Often
During the First Year After Treatment:
Followup Samples of 1979 and 1980 Cohorts
Drug(s)
Outpatient Outpatient
Methadone Residential Drug-Free
(n=835) (n=731) (n=854)
Heroin
Cocaine
Marijuana
Other non-
opiates*
21.4% 14.5% 7.5%
18.0 17.5 9.8
47.0 49.1 53.4
21.8 24.8 23.2
*Amphetamines. sedatives, barbiturates, minor tranquilizers
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DESCRIPTION OF MULTIPLE USE PATTERNS
Many research efforts have been directed toward assessing mul-
tiple drug use, but no widely accepted system has emerged.
Numerous factors contribute to this situation: (1) many studies
focused on special populations or individual treatment programs
and have limited generalizability; (2) many studies have had
measurement shortcomings, mainly covering brief periods of use
that do not fully reflect the extent of multiple use; (3) the
number of possible drug combinations has resulted in varied and
complex patterns; (4) only a few drugs have been surveyed in some
research, e.g., Client Oriented Data Acquisition Process (CODAP)
data; and (5) selection of measures has varied, depending on the
purposes of research. In order to adequately assess and compare
the results of various studies, some common, comprehensive, and
meaningful measures are needed.
Issues in Describing Drug Use
Three key issues are central to the development of descriptions
of multiple drug use:
1. Emphasis on description of single drug use (such
as heroin) versus multiple drug use involvement;
2 Quantification (interval or ordinal scales) versus
classification (categories or patterns) of drug
use; and
3. Clinical versus analytic usefulness of the descrip-
tion.
In the following paragraphs, we discuss each issue and its impact
on the development of useful descriptions.
Single versus multiple drug use. Many previous studies have
focused on the use of a single drug, generally heroin or other
narcotics/opiates. Implicit in such studies is the belief that
heroin use is the most serious type of drug use and that knowing
the level of involvement with heroin or other narcotics/opiates
would be adequate for describing drug use involvement. The
parsimony of this approach must be weighed against evidence of
the prevalence of multiple drug use. Use of heroin and other
narcotics/opiates alone may no longer fully describe the inten-
sity of drug use. Many addicts, for example, substitute other
drugs when heroin is not available and use many other drugs at
various levels of intensity throughout their drug-using careers.
Thus, even the most complete data on use of a single drug may not
adequately describe the nature and extent of multiple drug use.
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Quantification versus classification. Approaches to assessing
drug use are, generally, either attempts to quantify the extent
of use or to develop classifications of use (i.e., patterns or
typologies). The resulting measures and classifications, for the
most part, have been developed independently by separate investi-
gators working with different data sets. To date, there has been
little effort to compare and contrast these measures or to ex-
amine their relative utility for research in different popula-
tions of drug users (Clayton and Voss 1981). For quantifiable
measures, comparisons of the composite indices that are based on
a linear combination methodology would be particularly useful to
demonstrate the utility and/or interchangeability of these mea-
sures. A quantifiable measure of multiple drug use also has
advantages for empirical analysis using parametric statistics.
Of course, it should be evident that, despite the advantages of
the composite indices, they also have limitations. They provide
a univariate summary of drug involvement, for example, but do not
permit the specification of which drugs or drug combinations are
involved. Since drug combinations are of considerable interest
in understanding multiple drug use, it is useful to be able to
identify which drugs contributed to the index score.
Classification of drug use by patterns and typologies has
focused, respectively, on frequency of use of selected drugs and
on the specification of comprehensive typologies of drug use. As
with the quantifiable measures, few comparisons have been made
across samples to test for the stability and generalizability of
patterns and typologies. Furthermore, the utility of clustering
approaches has not been adequately demonstrated on large samples
and complex use patterns. Clustering algorithms which are de-
signed to detect stable patterns and typologies within data sets
may not produce robust or stable solutions among clients with
complex multiple drug use patterns. Additional work is needed on
large samples that assess the full domain of drug use.
Clinical versus analysis use. The purpose for which a measure
will be used must be considered in its development. Two major
purposes of most drug abuse measures are: (1) to help make
judgments about treatment, and (2) to provide a useful analytic
tool. Ideally, a measure would serve both purposes. However,
the method of developing measures often emphasizes one purpose
over the other.
Approaches emphasizing clinical applications would more likely
focus on comprehensive use patterns or the use of particular
combinations of drugs. Such measures or patterns of use may not
be easily included in statistical analysis. Except for extreme
use patterns (such as heavy heroin and other drug use or solely
marijuana use), it may be difficult to scale or order these
categories for parametric analysis.
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The analytic method often relies on statistical techniques to
structure the data. While such methods provide data in a form
that may be very useful for statistical analysis, the data may
not be readily interpretable by clinicians or program managers.
In addition, the analytic methods may be susceptible to small
statistical variations in the data that would not reflect clini-
cally useful differences.
Measures of Single Drug Use
Measures that tap use of single drugs generally consist of the
percentages of persons who use particular drugs within a given
time frame (e.g., a week, a day) or examine use of the principal
problem drug. Such measures are useful when the focus is on use
of a particular drug (e.g., heroin) or when the primary drug
problem dictates the treatment strategy to be followed. Such
single use measures were predominant a decade and more ago when
intensive use of single drugs was the modal pattern among clients.
Primary drug of abuse was a major category of analysis in the
COOAP system. Tyler and Sheridan (1980) examined the relation-
ship of various demographic characteristics and primary use of
such drugs as heroin, amphetamines, cocaine, or marijuana for
162,062 CODAP clients. They observed an interesting relationship
between age at first use and primary drug used: clients who
began use at age 15 or younger showed most frequent use of mari-
juana (45%) followed by heroin, amphetamines, and cocaine;
clients who began use at age 16 and older showed heroin as the
primary drug most often (69%) followed by marijuana, ampheta-
mines, and cocaine. Blacks were found to abuse heroin more than
whites or Hispanics. Such data potentially have important impli-
cations for the targeting and focus of prevention and interven-
tion strategies.
The usefulness of primary drug as an outcome measure seems appar-
ent, though the exact nature of its usefulness is unknown. The
ability and willingness of clients to substitute other drugs in
whole or in part for the primary drug of abuse would greatly
diminish the usefulness of this measure. To better understand
the utility of primary drug as a measure, results from analyses
using only primary drug data and analyses using more Complete
drug use information should be compared.
Indices of Multiple Drug Use
Greater attention has been given recently to the development of
indices that capture multiple drug use. The approaches that have
been developed can be conveniently classified as procedures that
use scaling techniques or procedures that use some form of linear
combination of variables.
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Scaling approaches. The attempts to use scaling for indexing
drug involvement have typically relied on Guttman scaling proce-
dures (scalogram analysis) to form a unidimensional construct
(Guttman 1950). For drug use, such a scale assumes that differ-
ent drug types are nearly always used in a hierarchical progres-
sion, such as alcohol to marijuana to heroin. Successful scal-
ing indicates that users of any particular drug type are also
users of drug types preceding it in the ordering sequence. For
example, users of heroin in an ordering of alcohol, marijuana,
and heroin could be assumed to also use marijuana and alcohol.
Most of the studies that have successfully used Guttman scaling
procedures have focused on student and young adult populations.
Although they were unable to scale use patterns for their total
sample, Loiselle and Whitehead (1971) were successful in scaling
adolescent drug use patterns for the subset of subjects that had
smoked marijuana. The resulting four-item scale consisted of
stimulants, tranquilizers, hallucinogens, and opiates. Single
and coworkers (1974), analyzing survey data from 8,206 high
school students in New York State, found Guttman scaling useful
in describing drug use patterns in a series of analyses. The
best scale (based on a reproducibility coefficient of .98 and
scalability coefficient of .82) consisted of seven categories:
no drugs, any legal drug, cannabis, "pills," psychedelics,
cocaine, and heroin. Donovan and Jessor (1983) found problem
drinking to be a key stage after marijuana use in a Guttman
analysis of a national sample of high school students.
Other investigators have found Guttman scaling procedures useful
for identifying sequences and stages of drug use among high
school students (Gould et al. 1977; Kandel 1975; Kandel and Faust
1975; Kessler et al. 1976).
Linear combination approaches. The other tack followed in devel-
oping measures of multiple drug use has been to use some variant
of linear combinations. Two general approaches have been follow-
ed: (1) a multivariate procedure, such as factor analysis or
principal components analysis (e.g., Kessler et al. 1976); or
(2) a specially constructed index based on conceptually or empiri-
cally derived weights for drugs used by an individual. Most
efforts in this domain have followed the latter approach (Clayton
and Voss 1981: Douglass and Khavari 1978; Lu 1974; Phin 1978) and
are similar in that they have used a composite index of weighted
elements (drugs). These measures are distinct, however, in the
weighting scheme that is applied to the drugs to reflect the risk
or seriousness associated with the use of that drug.
Comparisons of multiple use indices. Five indices of multiple
drug use have been considered in TOPS: the Lu Index, the
Douglass/Khavari Index, the Number of Drugs Index, the Severity
Index, and the Illicit Drug Use Index. These indices share a
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linear combination methodology in their construction. They all
attempt to derive a single number that represents the extent of
user involvement with the entire array of drugs being considered.
In general, the methodology multiplies the frequency of use
scores by the weights assigned to each drug and then combines
these products either by summing or averaging across the set of
drugs to obtain a final index value.
The principal difference among the indices is the procedure used
to obtain the weights associated with the drugs. The Number of
Drugs Index uses equal (unit) weights for each drug; the Lu Index
uses an empirical derivation based on frequency of use of each
drug in the population; the Douglass/Khavari Index uses a stan-
dardization procedure; the Severity Index uses conceptually based
weights; and the Illicit Drug Use Index uses weights derived from
national data sets.1
The similarity in construction of the various indices suggests
that there may be considerable overlap among the measures them-
selves. To address this question more directly, the intercor-
relations of the indices were computed along with the correla-
tions of selected drugs and are presented in table 3. As shown,
the Number of Drugs Index, the Lu Index, the Douglass/Khavari
Index, and the Severity Index are all highly related. For these
four indices the correlations range from .80 to .93, with an
average correlation of .89. Thus, it appears that the various
weighting schemes used to construct these indices have very
little effect on the final index. These four indices provide
reasonably comparable estimates of multiple drug use. Relation-
ships are considerably lower, however, between these four indices
and the Illicit Drug Use Index which appears to be a better
indicator of heroin use than a total involvement index.
Table 3 also shows correlations between the five drug use
indices; the primary drug of abuse; the number of drug problems;
and the alcohol, marijuana, heroin, and barbiturate use during
the year prior to treatment. As already noted, heroin use is
strongly related to the Illicit Drug Use Index. For the other
indices, barbiturate use shows the highest relationship. Perhaps
barbiturates are a marker, in that clients who use barbiturates
tend also to use several other drugs, whereas those who do not
use barbiturates tend to use only a few drugs.
In selecting among indices, the three most important criteria are
construct validity, parsimony or simplicity, and conceptual
appeal. Examination of the five multiple use indices with re-
spect to these criteria in TOPS led to the conclusion that the
Severity Index is the preferred multiple use index in the drug
treatment population.
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TABLE 3
Correlations of Multiple Drug Use Indices
and Selected Other Drug Use Measures:
1979 Cohort
Selected Drug
Use Measure
Multiple Drug Use Index
Number of Douglass/ Illicit
Drugs Lu Khavari Severity Drug Use
Number of Drugs Index 1.00
Lu Index .80
Douglass/Khavari
Index .88
Severity Index .89
Illicit Drug Use
Index .48
Primary Drug Frequency .39
Number of Drug Problems .32
Alcohol Frequency .37
Marijuana Frequency .46
Heroin Frequency .34
Barbiturate Frequency .50
1.00
.91
.93
.42 .45 .59 1.00
.35 .39 .43 .55
.35 .36 .36 .19
.21 .17 .23 -.02
.52 .44 .38 . 10
.26 .24 .43 .90
.56 .62 .53 .08
1.00
.93 1.00
DRUG USE PATTERNS AND USER TYPES
Several approaches were used in TOPS analyses to examine drug use
patterns and user types based on use in the year prior to treat-
ment: primary drug of abuse, Guttman scaling, pattern frequency
counting, development of general drug use patterns, and cluster
analysis.
For the primary drug index, a frequency analysis was first con-
ducted to determine the pattern of drug use accompanying use of a
specified primary drug. Use of eight drug types (heroin/illegal
methadone, other narcotics, barbiturates/sedatives, cocaine,
amphetamines, minor tranquilizers, marijuana, alcohol) was
examined for clients who reported each of the primary drug group-
ings (heroin/illegal methadone, other narcotics, cocaine, barbi-
turates/sedatives/minor tranquilizers, amphetamines, alcohol/
marijuana). Discriminant analyses using these patterns mis-
classified 32% of the clients, thus showing this approach to be
insufficient.
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Guttman scaling analysis, which provides information to determine
if clients use drugs in a particular cumulative sequence, was
also explored. If the drugs are able to be scaled, the analysis
indicates hierarchy of use, and specifies the set of drugs ex-
pected to be used by a client who appears at any point in the
scale. Weekly or greater use of eight drug classes reported by
TOPS clients was examined: heroin, other narcotics, barbitu-
rates/ sedatives, cocaine, amphetamines, minor tranquilizers,
alcohol and marijuana. The results of the analysis showed that
clients use of these drug classes did not meet requirements for
Guttman scaling. The coefficient of scalability (which ranges
from 0 to 1) was only .22, far below the minimum acceptable level
of .60.
For pattern frequency counts, TOPS drug use data were first
recoded and compared to 28 patterns used in the Drug Abuse Re-
porting Program (DARP) (Simpson 1974, 1976). Eight of the major
drug classes were considered (heroin, other narcotics/ opiates,2
barbiturates, cocaine, amphetamines, hallucinogens, marijuana,
and other drugs) for four categories of use (no use, less than
weekly use, weekly use, daily use). Results showed that the DARP
patterns did not adequately describe the drug use of the TOPS
clients. The major difference was greater multiple drug use in
TOPS. Twenty-eight percent of DARP clients were heroin only
users as compared with 3% of TOPS clients. In contrast, 5% of
DARP clients fit the "poly" pattern (i.e., used heroin and other
narcotics [opiates] less than weekly and three or more nonnar-
cotics at any level) as compared with 19% of TOPS clients.
Similarly, 8% of OARP clients as compared with 14% of TOPS cli-
ents were classified in the pattern "opiates plus" (any use of
heroin or other opiates along with any use of one or two non-
opiates).
A second approach was to examine a set of 25 drug use patterns
adapted from the DARP classification scheme. These 25 patterns
were based on the eight frequently used drug classes: heroin,
other narcotics, barbiturates (including sedatives/hypnotics),
cocaine, amphetamines, minor tranquilizers, marijuana, and al-
cohol. This drug set was examined using the 4-point use scale
noted above. Results showed that two-thirds of the clients from
both the 1979 and 1980 cohorts fell into three complex multiple
use patterns. However, these patterns were viewed as unsatisfac-
tory because the classification rules (1) grouped clients to-
gether who had wide variability in amount and kind of drug use,
and (2) defined some patterns which did not appear discriminably
different from others.
Close examination of frequencies of the specific combinations of
use of the eight drug types revealed a complex picture. For
example, over 740 unique patterns were reported by the 3,389
clients of the 1979 cohort. This suggested that broad, rather
than specific, patterns may be required to describe drug use.
Thus, an alternate approach to using the eight drugs and the
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4-point use scale focused on a more limited set of clinically
useful patterns. Patterns were defined by hierarchical rules
that emphasized weekly or greater use of key drugs or drug types.
The conceptually based rules produced seven patterns, which
appear in table 4 along with their respective percentages of
clients from the 1979 and 1980 cohorts. It should be noted that
the greatest number of clients fell in the heroin class and that
the majority of clients (58%, 1979; 55%, 1980) fell in the first
three classes which describe heavy narcotics users.
The defining characteristics of the patterns do not describe all
drugs used by the clients. Rather, they indicate the key drugs
and the use levels of these particular drugs. Additional illus-
tration of the use of different types of drugs within the seven
patterns is provided in table 5.
It should be noted that a sizeable proportion of clients entering
treatment, including methadone treatment, were not active heroin
users in the year prior to their admission to the TOPS program.
We identified an eighth pattern of those who used heroin daily at
some time in their lives. Depending on the purposes of a study,
it might be advisable to separate these Former Daily Users from
individuals in the other pattern.
The last approach employed cluster analysis to identify some
general types of drug use clients. Several alternative cluster-
ings were conducted and assessed according to their reproduci-
bility and face validity. The best cluster solution based on
these criteria identified three major types of drug abuse cli-
ents. The first type, comprising 37% of the TOPS clients, was
viewed as traditional heroin users. The use pattern of this
group involved daily use of heroin coupled with periodic use of
cocaine, marijuana, and alcohol. The second type, comprising 23%
of the clients, was described as heavy multiple users, character-
ized by weekly or more frequent use of the eight drugs. Finally,
the third type, which made up 40% of the sample, was character-
ized by low average frequency of use of all drugs except alcohol
and marijuana Multivariate analysis of variance and discrimi-
nant analysis results confirmed that the clients in these three
clusters were reliably different from one another in terms of
their drug use.
These analyses, however, did not provide discrimination among the
user types that would be very useful for clinicians or research-
ers. Thus, for descriptive purposes, the seven drug-use patterns
described above seem to be the most useful approach.
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TABLE 4
Distribution of Seven Patterns:
2979, 2980, and 1982 Cohorts
Drug Use
Patterns
Defining Characieristics
of Groupsa
Cohort Prevalence
1979 1980 1981
(n=3389) (n=3908) (n=3729)
Heroin/other-
narcotics
Heroin
Other narcoticsb
Multiple non-
narcoticsc
Single non-
narcoticc
Alcohol/
Marijuana
Minimal
(residual)
Weekly or greater use of
heroin or illegal methadone
and other narcotics
Weekly or greater use of
heroin or illegal methadone
and no use of other nar-
cotics as often as weekly
Weekly or greater use of
other narcotics but less
than weekly use of heroin/
methadone
Weekly or greater use of at
least two nonnarcotics in
addition to marijuana and
alcohol use
Weekly or greater use of
one nonnarcotic in addition
to marijuana and alcohol
use
Weekly or greater use of
alcohol and/or marijuana.
No other drug used as
often as weekly
All remaining clients
11.2% 10.3% 15.4%
37.1 33.0 34.0
9.7 12.1 11.6
6.0 6.7 7.4
10.4 13.5 11.9
19.5 17.7 14.2
6.1 6.7
100.0% 100.0%
5.5
100.0%
Note: Patterns were defined hierarchically in their tabled order. Thus,
for example, a client appears in a pattern 5 in the table only if he did
not qualify for any of the preceding patterns (1 to 4).
aDefining characteristics do not describe all drugs used by these clients.
Rather, they indicate the key drugs and use levels for classification.
b Other narcotics are defined as opioids other than heroin and methadone.
Included in this category are codeine, propoxyphene (Darvon), meperidine,
hydromorphone, morphine, opium, paregoric, oxycodone (Percodan), and
pentazocine.
cThe nonnarcotics included in constructing these patterns were barbiturates/
sedatives/hypnotics, cocaine, amphetamines, and minor tranquilizers.
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TABLE 5
Use of Selected Drugs within Drug
Pattern: 1979, 1980, and 1981 Cohorts
Drug Type
Use During 12 Months Before Intake
No Use Monthly Weekly Daily
Heroin/Other-Narcotics (n=1379)
Heroin
Other narcotics
Barbiturates/sedatives
Cocaine
Amphetamines
Minor tranquilizers
Marijuana
Alcohol
2.1%
0.0
49.8
26.3
52.2
28.7
15.8
16.0
Heroin (n=3854)
Heroin
Other narcotics
Barbiturates/sedatives
Cocaine
Amphetamines
Minor tranquilizers
Marijuana
Alcohol
Other Narcotics (n=1259)
Other narcotics
Barbiturates/sedatives
Cocaine
Amphetamines
Minor tranquilizers
Marijuana
Alcohol
2.6% 29.0% 66.3%
0.0 40.0 60.0
27.0 14.3 8.9
40.1 20.3 13.3
20.9 12.2 14.7
26.0 23.9 21.4
21.1 25.2 37.9
27.9 29.7 26.4
3.8 2.7
80.5 19.5
81.8 11.7
29.2 29.3
84.3 9.4
59.9 22.5
22.1 20.9
23.1 22.8
66.4
0.0
46.5
42.5
45.9
32.3
17.1
14.7
33.6
0.0
25.6
39.8
20.6
26.5
19.5
26.8
Multiple Nonnarcotics (n=750)
Heroin 78.9
Other narcotics 54.6
Barbiturates/sedatives 18.1
Cocaine 18.1
Amphetamines 20.3
Minor tranquilizers 19.9
Marijuana 7.5
Alcohol 6.3
21.1
45.4
16.1
29.2
17.1
23.1
12.2
21.4
20.9
0.0
4.4
21.1
3.4
11.4
27.9
30.1
72.6
0.0
2.1
20.4
2.9
6.2
29.0
23.9
0.0 0.0
40.0 60.0
15.7 12.1
11.1 6.5
16.4 17.1
24.5 16.7
23.7 39.7
32.5 26.0
0.0
0.0
42.8
36.4
34.7
35.5
26.5
36.7
0.0
0.0
22.9
16.3
27.8
21.5
53.8
35.6
(Continued)
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Table 5 (Continued)
Drug Type
Use During 12 Months Before Intake
No Use Monthly Weekly Daily
Single Nonnarcotic (n=1334)
Heroin 83.1
Other narcotics 73.8
Barbiturates/sedatives 52.9
Cocaine 33.9
Amphetamines 43.5
Minor tranquilizers 49.4
Marijuana 13.7
Alcohol 11.9
0.0
0.0
7.3
7.1
15.3
9.2
38.3
25.1
Alcohol/Marijuana (n=1901)
Heroin 85.0
Other narcotics 81.2
Barbiturates/sedatives 74.5
Cocaine 58.4
Amphetamines 68.3
Minor tranquilizers 72.6
Marijuana 10.8
Alcohol 8.2
Minimal (n=675)
Heroin
Other narcotics
Barbiturates/sedatives
Cocaine
Amphetamines
Minor tranquilizers
Marijuana
Alcohol
85.7 14.3
91.6 8.4
89.6 10.4
81.4 18.6
92.2 7.8
86.2 13.8
58.0 42.0
46.4 53.6
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Former Heroin Users (n=2176)*
Heroin 60.4
Other narcotics 56.9
Barbiturates/sedatives 71.0
Cocaine 49.2
Amphetamines 70.0
Minor tranquilizers 54.5
Marijuana 23.2
Alcohol 22.1
16.9 0.0
26.2 0.0
27.6 12.2
41.0 18.0
20.4 20.9
30.4 11.0
17.9 30.1
24.4 38.7
15.0
18.8
25.5
41.6
31.7
27.4
13.7
21.1
0.0
0.0
0.0
0.0
0.0
0.0
39.4
46.4
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
39.6
15.9
17.7
34.6
15.9
23.5
22.9
27.9
0.0
9.2
6.3
10.9
6.8
12.7
26.6
27.4
0.0
0.0
0.0
0.0
0.0
0.0
36.1
24.3
0.0
18.0
4.9
5.3
7.2
9.3
27.3
22.6
Note: Rows sum to 100%.
*The Former Heroin Users pattern is a supplementary classification
which includes individuals from five of the seven patterns.
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DYNAMIC NATURE OF MULTIPLE USE PATTERNS
The patterns of multiple drug use are dynamic. In TOPS, the
focus was on the pattern in a 1-year period. Over an individ-
ual's life, however, a number of patterns may be experienced.
Three sets of results demonstrate the dynamic nature of drug use
patterns.
A Decade of Changing Patterns
As previously noted, the drug use patterns of OARP clients enter-
ing treatment in 1969-73 were markedly different from those for
TOPS clients entering treatment in 1979-81. As shown in table 6,
the TOPS clients were much less likely than DARP clients to use
only opioids on a daily basis regardless of the modality they
entered. In methadone programs, TOPS clients were more likely to
be daily opioid users who also used nonopioids. In the other
modalities, nonopioid use was much more common among TOPS clients
than among DARP clients. More detailed analysis also demonstrat-
ed the more extensive use of multiple substances among TOPS
clients than among DARP clients. These results suggest the need
for monitoring trends in multiple use patterns to determine
changes in patterns, especially patterns that might adversely
affect treatment outcomes.
Substitution
In TOPS, clients were asked about any drugs they used as a substi-
tute for heroin. As table 7 shows, substitution was common.
Over one-third of the clients who had a history of daily heroin
use reported using illegal methadone or other narcotics to sub-
stitute for heroin. About one in four used diazepam or chlor-
diazepoxide. These reports of substitution suggest that the life
history of use should be carefully considered in order to accu-
rately describe multiple use patterns. A number of clients
entering treatment had not used heroin in the year prior to
admission. Thus, a limited assessment might misclassify them as
nonopioid users. The TOPS data suggest that former daily heroin
users should be identified and their use patterns described
separately from users who have not used heroin. Reasons for
abstinence from heroin also need to be ascertained for the former
daily users to better understand the nature of their current use
patterns.
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TABLE 6
Classification of Pretreatment Drug Use:
DARP and TOPS Clients, 1979-1981
Drug Use
Classification
Outpatient Outpatient
Methadone Residential Drug Free
DARP TOPS DARP TOPS DARP TOPS
(n=11,023) (n=4505) (n=5785)
(n=3223) (n=1192) (n=1949)
Daily opioid 45 21 22 6 19 2
use only
Daily opioid use; 49 60 40 24 16 8
some nonopioids
Less-than-daily 5 15 20 29 17 26
opioid use
Nonopioid 1 4 17 41 48 64
use only
Total 100 100 99 100 100 100
Note: DARP data are for the 2 months before admission. TOPS data
are for the 3 months before admission. Data are for comparable
TOPS and DARP samples of clients using drugs in the 2 to 3
months before treatment.
TABLE 7
Nonmedical Use of Substitutes for Heroin by
Heroin and Cocaine Use in the Year Before Intake:
1979, 1980, and 1981 Cohorts
Substitute
Drug
Weekly Heroin Use Former Daily Users
Weekly No Weekly No
Cocaine Cocaine Cocaine Cocaine
(n=2069) (n=3069) (n=445) (n=2173)
Illegal methadone 44.9% 34.0% 33.8% 34.0%
Other narcotics 29.4 39.2 40.5 38.9
Diazepam or
chlordiazepoxide 19.5 23.8 25.0 23.0
Barbiturates 7.9 10.7 17.6 14.7
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Change in Patterns Before and After Treatment
Table 8 shows considerable shifting in use patterns. The data
for residential clients are presented because there is a distri-
bution of clients in each pattern. As can be seen from the data
for clients staying 1 week or less, about 65% of the opioid users
move to a less serious use pattern. However, 24% of nonopioid
users before treatment use opioids weekly in the year after
treatment. About one-third of the marijuana/ alcohol/minimal
user group increases use to weekly opioid or other nonopioid use.
The table also shows a clear tendency for clients with longer
treatment stays to move to less serious patterns of use. The
consideration of multiple use patterns after treatment provides a
more complete description of the effects of treatment on drug use
patterns.
TABLE 8
Drug Use Pattern in the Year After
Residential Treatment by Drug Use Pattern
in the Year Before Intake: Followup
Samples of 1979 and 1980 Cohorts
Weekly or Greater Pattern After Treatment
Duration of Non- Alcohol/
TOPS Treatment n Opioids opioids Marijuana Minimal
Weekly or Greater Heroin and/or Opioid Users (n=354)
1 week or less 26 35% 15% 23% 27%
2-13 weeks 153 39 19 25 17
153 39 1914-52 weeks 35 22
More than 2 years 48 13 10 40 37
Weekly or Greater Nonopioid Users (n=202)
1 week or less 25 24% 20%
2-13 weeks 79 13 25
14-52 weeks 65 9 29
More than 1 year 33 6 3
Alcohol/Marijuana or Minimal Users (n=164)
28% 28%
47 15
34 28
42 49
1 week or less 17 12% 18% 53% 17%
2-13 weeks 80 23 19 38 20
14-52 weeks 38 13 11 37 39
More than 1 year 29 3 21 31 45
Note: Rows sum to 100%.
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Conclusions and Recommendations
The results of these analyses of multiple drug use among
individuals entering publicly funded drug treatment suggest three
general conclusions:
1. Multiple use is complex, and it is increasing. In
addition to the TOPS data for drug treatment clients,
studies of youth in high schools (Johnston et al. 1984;
Rachal et al. 1980) show that marijuana and alcohol are
now commonly used together.
2. The pattern or configuration of use is the most empir-
ically and clinically useful approach to multiple drug
use assessment.
3. The results strongly suggest that multiple use requires
consideration of factors in addition to the pharma-
cological interactions.
The complex, often pharmacologically incompatible patterns of use
suggest that many users often do not know or care what they use.
The complex and rapidly changing array of substances used may
confound any statistical or biochemical approach. A considera-
tion of psychosocial factors, coupled with more detailed under-
standing of pharmacological effects, is needed to disentangle the
epidemiology of multiple use and to design more effective treat-
ment approaches.
After considering all of the evidence concerning measures of drug
use, several recommendations seem warranted for further research
on this critical issue of multiple drug use. First, it is clear
that there are a number of options available for measuring drug
use, each of which has strengths and weaknesses. Second, it is
also clear that the choice of a measure can be greatly influenced
by the clinician's, researcher‘s, and policymaker's purposes, the
population sampled, and the questions under consideration.
Third, basic and complex measures of multiple use are available,
depending on the level of specificity needed in research.
Recommended Measures
The simplest measures of drug use are the single use measures,
which are appropriate when the study focus is on one specific
drug. For treatment clients, heroin use and primary drug appear
to be the best single use measures. Heroin use is the focus of a
major proportion of the treatment effort and is still the most
serious problem treated in terms of social cost and personal
suffering. A measure of primary drug use can be calculated for
all clients. Since the use of the primary drug is likely to be
the focus of treatment, it may be an appropriate indicator of
treatment effectiveness. However, single use measures are not
able to reflect the broad spectrum of drug use.
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The multiple drug use indices are somewhat more complex and
attempt to reflect the full range of drug-taking behavior along a
single dimension. Such measures can provide a broad overview of
drug use. The Severity Index was judged to be the best unidi-
mensional multiple use index for the treatment population. While
such an index is helpful in indicating a general level of drug
use, it may be insensitive to patterns of use and drug substitu-
tion.
The most complex measures are those that attempt to reflect the
multiple dimensions of drug use behavior. A Multidimensional
Index was constructed using principal components analysis of drug
use among TOPS treatment clients. It indicated three factors
underlying clients' drug use: a polydrug factor, a heroin-
cocaine factor, and an alcohol-marijuana factor. The Multidimen-
sional Index provides a more detailed picture of drug use than is
possible with a single index, but it has limited clinical utility.
Clearly, multiple drug use is more common among clients entering
treatment today than it was when the DARP studies were initiated
or, even later, when the CODAP system was developed. The CODAP
system and much of drug treatment research has focused on the
primary drug of abuse as a descriptor of use patterns. Although
useful, classification by primary drug does not capture the full
scope of drug use. Based on the original work of Simpson (1974,
1976), the seven drug patterns developed for TOPS provide a
hierarchical classification of use patterns that can be readily
understood and used by clinicians, policymakers, and researchers.
Treatment Implications
Compared to drug use patterns observed in treatment populations
in the late 1960s and early 197Os, the increased use of multiple
drugs by current clientele indicates a need for careful consider-
ation of treatment approaches. The seven patterns provide a
framework for the design, conduct, and evaluation of current
treatment efforts. The patterns were chosen and defined with
treatment needs in mind and clearly separate heroin and narcotic
users from clients who abuse nonnarcotic drugs. Use of these
patterns can help answer such questions as:
1. Do clients with various patterns of use require dif-
ferent treatment approaches?
2. What types of users benefit most or least from partic-
ular modalities and environments?
3. Are different types of ancillary services required by
various types of users?
4. How do patterns of use change after a client enters
treatment?
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Given the prevalence of multiple drug use, descriptions based on
a single or a limited number of drugs would provide insufficient
information to address the more complex issues now facing treat-
ment programs. The patterns, in combination with information on
the severity of use and primary drug of abuse, could certainly
provide a more complete assessment of the nature and extent of
total drug use. Consequently, the increased information should
help treatment programs design and deliver services more effec-
tively.
Research Directions
In the TOPS analyses, drug use measures developed in prior re-
search have been examined and refined, and new measures have been
constructed, both for quantitative measures (e.g., Severity
Index) and for classification measures (e.g., the seven pat-
terns). The result has been a set of recommended measures to be
used in the further analyses of the TOPS data and in other re-
search. Major questions on the epidemiology of multiple drug
abuse and the association of multiple drug abuse with other
factors can now be examined more comprehensively with these
measures in the TOPS and other data sets. Epidemiological ques-
tions for general and treatment population include:
1. How do patterns of use develop?
2. Are patterns of use episodic, persisting, or random?
3. What are the demographic characteristics of different
types of users?
4. Has and will the prevalence of patterns change over
time?
The association of these measures with other variables should
provide important information on the causes and consequences of
multiple drug use.
Questions that are in need of careful examination include the
following:
1.
2.
3.
4.
What is the relationship between pattern classes and
drug-related problems?
Do such factors as depression, criminal behavior, and
employment vary systematically with drug use severity
or the pattern classes?
What individual characteristics or environmental condi-
tions are associated with patterns of use?
How are community and treatment factors related to
changes in the patterns of use over time?
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Further TOPS research has taken the next logical step of using
the drug use measures developed to address many of the questions
posed above for the drug treatment population. We would strongly
recommend the use of these measures in other appropriate studies
where multiple drug use is common. The use of these measures in
a variety of studies should significantly increase our under-
standing of the dynamics and nature of multiple drug abuse.
Coordination of Pharmacological, Epidemiological, and
Psychosocial Research
To advance the understanding of the complex nature of multiple
drug use, a multidisciplinary approach is needed. Increased
interaction of epidemiological, psychosocial, clinical, and
preclinical researchers should provide a stronger foundation for
research design and interpretation of study results. As a first
step, we suggest a focus on three areas for collaboration:
1. Identification of patterns of use and potential combina-
tions of drugs in the field and in the laboratory;
2. Confirmation of research findings in field, clinical,
and preclinical studies; and
3. Assessment of effect of patterns of multiple use on
dependency.
More specifically, we would suggest a series of meetings with
epidemiologists, clinicians, and pharmacologists. The objective
would be the development of known and potential patterns of
multiple drug use. Specific patterns could be identified for
monitoring in epidemiological or treatment studies and/or pharma-
cological analysis in the laboratory. Known and potential cor-
relates and consequences, particularly dependencies, of the
patterns could also be investigated across the multidisciplinary
settings. Such initial collaborative efforts should lead to
research that will expand our knowledge of both the basic mechan-
isms and multiple drug use and efficacy of therapies to ameliorate
adverse effects of multiple use patterns.
FOOTNOTES
1The weights developed for the Lu Index and the T-scores of the
Douglass/Khavari Index reflect both the importance of each drug
and the frequency of use of each drug by clients. Thus, these
values were used in computing the final index for these measures
(i.e., these weights were not multiplied by frequencies prior to
combining them).
2The term "other narcotics or opiates" is used in TOPS. The term
"other opiates" that was used in DARP generally describes the
same class of drugs.
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Statistical Analysis of Drug
Interactions
Clifford L. Mitchell, Ph.D.
INTRODUCTION
The study of drug interactions poses the problem of how best to
characterize the effects observed when two or more agents are
administered together. As with other types of experiments, the
experimental designs and statistical techniques used depend on
the questions asked. Clearly, any reasonable evaluation of a
drug interaction presupposes that a precise question is being
asked.
This article deals only with the question of whether to charac-
terize an interaction as one of addition, antagonism, synergism
or potentiation. In this discussion the following definitions
are used for these terms: (1) ADDITION - the situation in
which, within the limits of the dose-response curve, the effect
produced by the agents is the algebraic sum of their independent
actions; (2) ANTAGONISM - the situation in which the effect is
less than the algebraic sun of their independent action; (3)
SYNERGISM - the situation in which for drugs exhibiting the same
observable response, the effect produced is greater than the
algebraic sum of their independent actions, (4) POTENTIATION -
the enhancement of action of one drug by a second drug that
exerts no detectable response on the variable measured when it
is administered alone. In practice, the terms synergism and
potentiation are often used interchangeably, The terms under-
additive and overadditive have been used in place of antagonism,
synergism and potentiation (Pöch and Holzmann 1980). Also,
other definitions of addition are sometimes used (cf. Pöch
1981). The procedures discussed require the definition of
addition given above.
Much of the material in this article has been presented pre-
viously (Mitchell 1976). That article also contains a
discussion of experimental design and its statistical basis
which is not presented here.
NOTE : Portions of the text of this article and figures and tables
as noted were originally publlshed in Mitchell, C.L. The design and
analysis of experiments for the assessment of drug interactions.
Ann NY Acad Sci 281:118-135. Copyright 1976, The New York Academy
of Sciences. Reproduced by permission.
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IMPORTANCE OF CHARACTERIZING DRUG INTERACTIONS
Characterizing drug interactions as to addition, antagonism,
syngergism and potentiation is merely a descriptive exercise; it
does not yield information concerning the mechanism for the
interaction. Since one is presumably more interested in the
mechanism, why spend time and effort in characterizing the
interaction? Loewe (1957) answered this question succinctly when
he stated "the ‘why?’ of a phenomenon cannot be studied without
adequate knowledge of the ‘what?’, the phenomenon itself."
Defining a drug interaction as addition, antagonism, syngergism,
or potentiation is a problem of determining the quantitative
relationship between the doses of the combinations and the
effect observed. Since the nature of the interaction may change
depending on the doses and time intervals studied (cf. Gessner
1974) it behooves one to have dose-effect and time-effect data
for the combinations in order to have a rationale for the doses
and times to be utilized in mechanistic studies. This is no
different than what is expected in single drug studies. Unfor-
tunately, much of the drug interaction literature suffers from
a lack of quantitative evidence for the type of interaction
(cf. Mediphor 1984, for listing of unsubstantiated cases of drug
interactions) . Obviously the extent to which dose-effect and
time-effect studies are done should vary according to the ques-
tion(s) asked and the (perceived) importance of the interaction.
It is also important to obtain both dose-effect and time-effect
information about the substances individually on the responses
to be measured before designing the drug interaction experiment.
This is necessary for two reasons. First, this information pro-
vides a rationale for the doses used in the interaction studies
and the time after dosing at which the effect is to be measured.
Second, it aids in determining the statistical procedures to be
used in the interaction studies. These procedures depend on
whether only one or both of the substances affect the response
when given alone and whether the measurements are quantitative
or quantal in nature.
PROCEDURES WHICH MAY BE USED WHEN BOTH SUBSTANCES GIVEN ALONE
AFFECT ME MEASURED RESPONSE
Quantitative Data
The first step is to determine the potency of one substance
relative to the other in affecting the response. The purpose of
this is to provide a rational basis for the doses used in sub-
sequent studies. The most simple method assumes that the two
compounds yield dose-effect responses which are linear and
parallel. The most commonly used parallel line bioassays are 4
point (two dose levels of each substance) and 6 point (three
dose levels of each substance) assays (Finney 1952). The ad-
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vantage of the latter is that it provides a test for non-
linearity. Both, however, encompass a test for deviation from
parallelism. This is important because if the dose-response
curves are not parallel, then the relative potency will change,
depending on the doses used. If this is the case, then the
methods described in the paper are of limited value.
If the onset and duration of action of the compounds are dif-
ferent (a likely case), then obviously different relative poten-
cies will be obtained depending upon when the measurements are
taken. The two most common procedures utilize either the time
of peak effect or the area under the time-effect curve. For
drug interaction studies, the former is generally preferred since
it avoids some of the complications that can arise if the com-
pounds have grossly different time-effect curves. Better yet
might be to determine relative potencies at more than one time
interval. Most important, though, is to have a reason for the
time(s) examined, based on previous experiments or published
information.
Once the relative potency has been determined, subsequent stud-
ies involve combining fractional doses of the substances and
comparing the responses observed against those obtained using
standard doses of each substance individually. The hypothesis
to be tested is that, as far as the response being measured is
concerned, the two compounds behave as though they were dif-
ferent forms of the same substance. Thus, doses of the com-
bination and single substance(s) are picked such that equivalent
responses should be obtained if the effect of the two together
is additive. For example, given two compounds (A and B) in
which A is four times as potent as B, a mixture of one part A
and four parts B should yield a response equivalent to two parts
A or eight parts B when each is administered alone if the effect
of the two together is additive. If the effect of the mixture
is significantly greater than this, synergism is indicated; if
it is significantly less, one infers antagonism. The statisti-
cal procedures used depend upon the design of the experiment.
The Student's t-test can be used if one is only comparing two
means. If more than two means are being compared, a one or two
way analysis of variance(depending on the design) followed by
designated comparisons of means (i.e., multiple comparison pro-
cedures)  is more proper. If one has reason to believe that cer-
tain requirements of parametric tests are not met (e.g.,
equality of population variances and/or normal distribution of
data), non-parametric equivalents may be used (e.g., Mann-
Whitney U test instead of Student's t, Kruskal-Wallis one-way
analysis of variance instead of analysis of variance, the
Cochran Q Test, or Friedman two-way analysis of variance).
An example of this technique is presented in Figures 1 and 2.
The experiment involved determining the effect of morphine and
chlorpromazine alone and in combination on the escape response
elicited by tooth-pulp stimulation in cats (Mitchell 1966).
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Dose-Response Curves for Chlorpromazine Hydrochloride and
Morphine Sulfate as Determined in the 4 point bioassay.
C = chlorpromazine, M = morphine, and R = relative potency.
(Modified from Mitchell 1966).
Figure 1 shows the potency of morphine sulfate relative to
chlorpromazine hydrochloride when the measurements were taken at
the time of peak effect for both compounds. Since the two drugs
were virtually equipotent in this test, the combination of one
part morphine and one part chlorpromazine was compared against
two parts morphine and two parts chlorpromazine, each separa-
tely, as shown in figure 2. An analysis of variance was per-
formed on these data, following which the means were compared
using one of the multiple comparison procedures, Duncan’s new
multiple range test (Steel and Torrie 1960). No significant
difference (p>0.05) was obtained between the effect of morphine,
4 mg/kg, chlorpromazine, 4 mg/kg, and the mixture of 2 mg/kg of
each. Moreover, morphine, 2 mg/kg, chlorpromazine, 2 mg/kg, and
the mixture of 1 mg/kg of each were not significantly different
(p>0.05). Thus, it is inferred that the effects of morphine and
chlorpromazine are additive in this model under the conditions
of the experiment.
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Effect of Morphine Sulfate, Chlorpromazine Hydrochloride,
and Their Canbination on the Latency for an Escape Response
to Tooth-Pulp Stimulation in the Cat.
Bars represent mean change (± standard error) in the average
latency for 10 trials after drug and the average latency for 10
control determinations. The observations were made 45 minutes
following the administration of morphine and 60 minutes
following the administration of chlorpromazine. In all instan-
ces, the number of animals was 8. The doses were 2 and 4 mg/kg
of morphine (M) and chlorpromazine (C) and 1 and 2 mg/kg of each
for the combination (WC) (modified from Mitchell 1966).
Quantal Data
These data are first analyzed by probit or logit analysis, with
the relative potency determined by the ratio of one ED50 versus
the other (Finney 1952). This second step is sometimes neglect-
ed in practice, but it should not be since it encompasses a test
for deviation from parallelism. The methods outlined below
illustrate probit analysis and, like that for quantitative data,
assume parallel dose-effect curves. Again different ED50s may
be obtained, depending on when the effect is measured. Thus,
the comments made above are also relevant here. Once the ED5Os
(and, hopefully, the potency ratio) have been determined, sub-
sequent studies are conducted in a manner similar to that
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described for quantitative data except that the statistical pro-
cedures are different owing to the nature of the data.
Specifically, one might use either the chi-square or Fisher’s
exact probability tests, depending on the sample size and the
expected frequencies.
Tables 1 and 2 show an example of this technique. In this
experiment the effects of ethanol alone and in combination with
chlorpromazine or chlordiazepoxide on the ability of mice to
remain on an inclined screen were examined. Table 1 shows the
ED5Os and the potency ratios. Table 2 shows that when one-half
of the ED50s for ethanol and chlorprormazine were combined. addi-
tive effects were obtained. Potentiation was observed when one-
half of the ED50s for ethanol and chlordiazepoxide were combined.
This was determined by comparing the frequency of mice falling
from the inclined screen for the ethanol drug combination versus
the ED50s of ethanol alone. For the combination, each drug was
administered such that their time of peak effect coincided. It
should be emphasized that the findings of addition with the com-
bination of ethanol and chlorpromazine does not mean that under
other conditions potentiation might occur. Indeed, in the same
article Gebhart et al. (1969) did demonstrate potentiation using
another endpoint (see below). Also, the study would have been
more complete if other fractional doses had been combined and
compared with their predicted equivalent doses of the substances
alone.
PROCEDURES WHICH MAY BE USED WHEN ONLY ONE OF THE SUBSTANCES
GIVEN ALONE AFFECTS THE MEASURED RESPONSE
The condition in which one of the substances is inactive when
given alone results, on the one hand, in a simpler situation and
on the other  in a more complex situation than when both are
active. It is simpler because the potency of one substance
relative to the other need not (indeed, cannot) be determined.
It is more complex because the investigator must now search for
another rationale for the doses and times of measurement to be
used in the experiment. Once these parameters have been chosen,
the procedure is simply to compare the effects of the com-
binations with those for the active agent alone. The hypothesis
to be tested is that, as far as the response being measured is
concerned, the “inactive” substance exerts no influence on the
other when the two are given in combination. The statistical
procedures used depend upon the experimental design and whether
the data are quantitative or quantal in nature. In general, any
of those mentioned above may be used. It must be remembered,
however, that it is mandatory to demonstrate that the one
substance is inactive in the dose used unless it is known a
priori that it is.
46
TABLE 1
Effect of Drugs on the Ability of Mice to Remain on an Inclined
Screen*
Drug
50% Effective Dose †
(mg/kg) Potency Ratio+
Ethanol 1820 --
(1436-2043)§
Chlorpromazine 11
(9-14) (121-205)
Chlordiazepoxide 65 28
(57-78) (21-34)
* After Gebhart et al. 1969. Mice were placed on a 60° inclined
screen at the following times after drug administration: etha-
nol(5O% v/v), immediately; chlordiazepoxide, 30 min. and
chlorpromazine, 60 min. All drug injections were given intra-
peritoneally.
† The dose causing 50% of the mice to fall from the inclined
screen as determined by the probit method. For each agent, at
least 3 doses were used.
+ The potency ratios were calculated relative to ethanol.
§ 95% Confidence interval.
TABLE 2
Effect of Drugs in Combination with Ethanol on the Ability
of Mice to Remain on an Inclined Screen*
Nunber of Mice
Drug-Ethanol Combination Tested Respondingf p+
50% effective dose of ethanol 20 13
1/2 50% effective doses, 20 10 >0.30
ethanol + chlorpromazine
1/2 50% effective doses, 20 19 <O.05
ethanol + chlordiazepoxide
* After Gebhart et al. 1969. Chlorpromazine was given 60 min.
before ethanol: chlordiazepoxide 30 min before ethanol. Mice
were placed on the 60º inclined screen immediately after
ethanol administration.
† The number of mice falling from the 60º inclined screen.
+ Probability of X2 (ethanol-drug combinations versus ethanol
alone): p<0.05 is considered significant.
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TABLE 3
Sleeping Time of Mice Treated with Saline or Iproniazid
1 Hour Before Injection of Hexobarbital*
Drug
Sleeping Time
N (in min)+
Saline + hexobarbital 18 24 + 0.65
Iproniazid + hexobarbital 15 65 ± 4.78†
* The iproniazid dose was 100 mg/kg the hexobarbital dose, 80
mg/kg; all injections were administered i.p.
+ Defined as length of time between losing and regaining
righting reflex. Figures represent mean ± standard error.
† Significant difference at p <0.05, t' test.
From Mitchell 1976. Copyright (1976), New York Academy of
Sciences.
An example using quantitative data is illustrated in Table 3,
above, which shows the effect on the sleeping time of mice of
pretreatment with iproniazid or saline 1 hour prior to the
injection of hexobarbital. Iproniazed is a monoamine oxidase
inhibitor which, by itself does not produce sleep. Since the
data are quantitative in nature and only two groups are
involved, the first impression might be to analyze the data
using the Student's t-test. One of the assumptions of the
Student's t-test is that the samples are drawn from populations
having equal variances. There is a simple test for this assump-
tion which, unfortunately, is too often ignored by biologists.
For the data shown in Table 3 the assumption of equality of
variance is rejected at p<0.0005. In such a case either the t'-
test or a non-parametric method (in this instance, the
Mann-Whitney U test) might be used. Another option is to use an
appropriate transformation (logarithmic, square root or other)
which "normalizes" the data and meets the criteria for para-
metric tests. The purpose of this illustration was twofold;
first, to show how a simple statistical method can be used to
study drug interactions; and second, to caution you about ine-
quality of variance. Inequality of variance occurs more often
than recognized in biological data. Situations in which one
compound inhibits the metabolism of the other frequently present
such a case.
The results of an experiment using quantal data and the Fisher’s
exact probability test are shown in Table 4. An ED50 for etha-
nol producing a loss of righting reflex (LRR50) in mice was
determined and found to be 4.3 g/kg (95% Confidence interval of
3.9 to 5.2 g/kg; Gebhart et al, 1969). LRR50s for chlorproma-
zine and chlordiazepoxide could not be determined that did not
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also produce Varying degrees of lethality. The ED50s for the
three agents which caused mice to fall from an inclined screen
could be determined and were called PD50s (see above). One-
half of the LRR50 of ethanol was then given in combination
with one-half the PD50 for ethanol, chlorpromazine, or chlor-
diazepoxide. Singly, these doses produced no LLR. Statistical
comparisons were made using Fisher’s exact probability test
because the expected frequency in the cell number of mice
losing the righting reflex” was less than five. Otherwise a
chi-square test could have been used. Potentiation of the
effect of ethanol by both chlorpromazine and chlordiazepoxide
was concluded. It should be emphasized that doses of both
chlorpromazine and chlordiazepoxide much larger than those used
here are required to produce loss of righting reflex in mice.
TABLE 4
Ability of Drugs in Combination with Ethanol to Produce
a Loss of Righting Reflex (LRR)*
Number of Mice
Treatment
Tested Respondng† p+
* After Gebhart et al. 1969. Chlorpromazine was given 60 min.
before ethanol; chlordiazepoxide 30 min. before-ethanol. The
†
mice were tested immediately after ethanol administration.
The number of mice losing righting reflex.
Fisher’s exact probability (l/2 LRR50 ethanol + PD50 of etha-
nol versus l/2 LRR50 of ethanol + l/2 PD50 of drug): p<0.005
is considered significant.
§ One-half the dose causing 50% of the mice to fall from a 60°
inclined screen.
Probit analysis may also be used for studying drug interactions
where one of the compounds is inactive. One approach using this
method is shown in Table 5. These data from Chau et al. 1973,
illustrate the enhancement, by vasopression, of pentazocine
lethality.
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TABLE 5
Lethal Effect of Pentazocine and Vasopressin in
Unanesthetized Rats
Compounds i.m LD50 of
Pentazocine*
mg/kg
Pentazocine 153
(131-177)
Pentazocine and vasopressin 139
(5 U/kg) (115-168.2)
Pentazocine and vasopressin 39
(10 U/kg) (21.6-68.4)
Vasopressin alone at 100 U/kg no lethality
* Ten animals per dose level.
From Chau et al. 1973. Copyright (1973) American Society for
Pharmacology and Experimental Therapeutics.
Another example is shown in figure 3. These data, from a report
by Tulunay and Takemori (1974) illustrate the enhanced efficacy
of naloxone induced by pretreatment with morphine. The tail
flick analgesia assay in mice was used. The animal responses
were made quantal by establishing an end-point at the mean peak
effect which represented an increase in the reaction of an indi-
vidual animal of greater than three standard deviations of the
control mean reaction time for all animals used in the group.
In control animals, the ED50 ± 95% confidence intervals of
morphine sulfate, subcutaneously, 30 minutes after administra-
tion, were 4.1 (3.2-5.3) mg/kg without naloxone and 35.3
(28.2-41.0) mg/kg with concomitant administration of naloxone,
0.16 mg/kg. In animals pretreated 3 hours earlier with 30 mg/kg
of morphine sulfate the ED50s were 4.8 (3.7-6.2) mg/kg and 82.8
(65.1-108.4) mg/kg, respectively. Thus, pretreatment with a
single dose of morphine did not change the ED50 of morphine
alone but significantly altered the ED50 for the morphine plus
naloxone combination, demonstrating an increase in the antago-
nistic potency of naloxone.
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The Enhanced
Morphine
FIGURE 3
Efficacy of Naloxone Induced by Pretreatment with
See text for details. From Tulunay and Takemori (1974).
Copyright (1974) American Society for Pharmacology and
Experimental Therapeutics.
Had either Chau et al. (1973) or Tulunay and Takemori (1974)
desired, they could have quantified the degree of enhancement by
obtaining the ratio of the ED50s for the two naloxone groups.
Figure 4 illustrates this type of approach just mentioned.
Although the data concern the efficacy of morphine in adrenalec-
tomized versus nonadrenalectomized animals, the analogy to the
study of drug interactions is apparent. Analgesia was deter-
mined 30 minutes after the S.C. administration of morphine in
rats using the hot plate method. The 50% analgesic dose (AD50)
was defined as that dose permitting 50% of the animals to remain
on the heated plate for 30 seconds. As can be seen in figure 4,
under the condition of the experiment, adrenalectomized rats are
more sensitive to the analgesic effect of morphine than sham
operated animals. This is demonstrated by the fact that in sham
operated rats 1.7 (1.2-2.3) mg/kg of morphine is equivalent to 1
mg/kg in adrenalectomized animals.
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FIGURE 4
Dose-Response Curves Generated While Determining Equi-analgesic
Morphine Doses on the Hot Plate.
AD50 morphine analgesic &se in 50% of the animals. See text
for further details. From Gebhart and Mitchell 1972.
Copyright (1972) European Journal of Pharmacology.
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FIGURE 5
Dose-Response Curves as Determined in the 6 Point Bioassay. R;
Relative Efficacy.
See text for further details. From Gebhart and Mitchell 1972.
Copyright (1972) European Journal of Pharmacology.
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The bioassay technique may also be used for quantitative data as
shown in figure 5, from the same article by Gebhart and Mitchell
(1972) as cited above. The experimental procedure was the same
as that already described except that no cutoff time was used.
Before proceeding with the analysis it was verified that adrena-
lectomy alone did not alter the control reaction times. Thus
the data analyzed were the actual increases in reaction times
from the control determinations. Results similar to those seen
using quantal data were obtained. The utility of this technique
for drug interaction studies where one of the compounds is inac-
tive in the test procedure is, I trust, obvious. One advantage
of this method lies in the fact that it is possible to quantify
the potency of one agent relative to another in enhancing or
antagonizing the effects of the compound of central interest
(i.e., the one which is active in the model when given alone).
ISOBOLOGRAHIC METHOD
Loewe and Muischnek (1926) introduced the isobolographic method
several years before the statistical methods in biological assay
were formulated (Bliss 1939; Finney 1952). Until recently, the
method has never been widely accepted for a variety of reasons.
Among these are the complex and exotic terminology associated
with it; the tedious nature of the method; and the fact that, as
introduced by Loewe, it was never truly quantitative. Recent
drug interaction literature, however, indicates an increase in
its use (cf. Fircio et al. 1978; Yeung and Rudy 1980; Masuda et
al. 19811 Foltin et al. 1983; Marshall et al. 1983; Kissin et al.
1984) . The material which follows will point out the similari-
ties and differences between this approach and those presented
above. The reader interested in examining the method in more
detail should consult the articles by De Jongh (1960) and
Gessner (1974) for more complete discussions of the method and
for additional references to Loewe's work.
An isobole (from the Greek, isos [equal] and bolos [effect]) is
a line connecting equi-effective doses. To determine an iso-
bole, one first must choose an effect to be measured. This can
be any measurable effect, as for example, a decrease in blood
pressure of 20 mm mercury, sleeping time of 25 minutes, or the
incidence of oeath in 50% of the animals. Most uses of the
method have focused on quantal responses (e.g. determining
ED50s or LD50s). The amount of different mixtures of the two
substances necessary to produce the specified effect is then
determined. A graph is prepared using doses of one component as
the abscissa and doses of the other as the ordinate. Points
representing the various combinations tested and found to pro-
duce the specified effect are placed on the graph. The line
drawn to connect these points is called an isobole: its points
represent combinations which cause identical effects. A series
of such lines is called an isobologram (Loewe 1953). There are
several types of isoboles, of which only two will be presented
in this article.
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The first type (Type I) is represented by those situations in
which the desired effect can be produced by both substances
alone. Figure 6 shows a theoretical isobologram illustrating
addition, potentiation, and antagonism. If the effect of
substances A and B together is additive, the isobole is a
straight line connecting the two points obtained for each agent
alone (Figure 6a). In such a case the specified effect is
reached with three-quarters the effective dose of A in com-
bination with one-quarter the effective dose of B, or one-half
of each or one-quarter of A and three-quarters of B, and so on.
In other words, so far as the effect measured is concerned, one
compound is acting as an analytical concentration (or dilution)
of the other one. (N.B., This does not imply the same mechanism
of action for both substances, however.) If the substances
enhance each other’s effect, one needs less of both substances
in combination to produce the specified effect; hence, this
isobole is a curved line situated below the line for addition
(Figure 6b). If the substances have antagonistic effects, one
needs more of both in combination to produce the specified
effect; thus this isobole is a curved line situated above the
line for addition. One might also obtain isoboles which indi-
cate mixed effects. One example might be potentiation for a
certain range of combinations and addition over the remainder
(see below ).
A second type (Type II) of isobole occurs when only one of two
substances given alone produces the desired effect. A theoreti-
cal isobologram illustrating potentiation, antagonism, and no
effect for one substance on the other is shown in Figure 7.
When substance B has no influence on A, the isobole will run
parallel to the abscissa (Figure 7a). If substance B poten-
tiates A, then less of substance A is needed, and this isobole
will lie below the neutral isobole (Figure 7b). Antagonism
(Figure 7c) is indicated by an upward shift in the line.
Gessner (1974) has modified Loewe’s method in
order to apply a quasi-statistical treatment to the data. He
determines the ED50 and its 95% confidence interval for each
substance alone (if both are active), constructs the expected
isobole assuming additivity, and places a confidence interval on
it by connecting the lower and upper confidence limits for the
two compounds with dotted lines (see Figure 9). ED50s and their
confidence intervals for different doses of the combination are
then determined using either (1) different doses of both com-
pounds combined in various mixed ratios, or (2) different doses
of one compound in the presence of a fixed dose of the other.
Additivity or non-additivity is determined by comparing the
observed versus expected ED50s and the 95% confidence inter-
vals.
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FIGURE 6
Type I Isoboles Illustrating Addition (a). Potentiation (b).
Antagonism (c).
The numbers for the doses are in arbitrary units. See text for
further details. From Mitchell 1976. Copyright (1976) New York
Academy of Sciences.
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FIGURE 7
Type II Isoboles Illustrating No Effect of Substance B (a),
Potantiation (b), and Antagonism (c).
The numbers for the doses are in arbitrary units. See text for
further details.
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Actual examples of Gessner’s approach with Type I isoboles
illustrating addition only and both potentiation and addition
are shown in Figures 8 and 9, respectively. These data are from
Gessner and Cabana (1970). Figure 8 shows the isobole for the
interaction of the hypnotic effect of trichloroethanol and etha-
nol in mice. Each of the points represents the ED50 (± 95% con-
fidence interval) for trichloroethanol in producing loss of
righting reflex in the presence of a fixed dose of ethanol. It
is apparent from this graph that the experimental points do not
depart from simple additivity. The isobole for the interaction
of the hypnotic effects of chloral hydrate and ethanol in mice
is shown in Figure 9. The points represent the ED50 (± 95% con-
fidence interval) for either chloral hydrate (vertical con-
fidence interval lines) or ethanol (horizontal confidence
interval lines) in the presence of a fixed dose of the other
agent. Potentiation was concluded for all mixtures having a
chloral hydrate/ethanol ratio greater than 1:7. Addition was
concluded for ratios less than this value. The conclusions were
based upon a comparison of the observed versus expected ED50s
and their 95% confidence intervals.
The primary disadvantage of the isobolometric approach as
modified by Gessner is its tediousness. This arises due to the
requirement of determining the exact amounts of a series of mix-
tures needed to produce a specified effect. It is much easier
to measure the effects of given quantities of a mixture. This
latter approach is the one utilized in the methods described
earlier. It has an advantage, I suppose, in that it forces one
to examine numerous different concentrations of the mixtures.
This is not excluded in the other methods, however. Indeed, the
prudent investigator would do this anyway.
Conceptually, both approaches are similar. When the experimen-
tal substances, each alone, are active in the test preparation,
the working hypothesis is that the two compounds behave as
though they were different forms of the same substance, one of
which is possibly (depending on the potency ratio) diluted with
an inert substance. This is tested in one case by comparing the
responses of different portions of the mixtures to the. responses
obtained with certain doses of the compounds alone. In the
other (isobolometric) case, it is tested by determining the dose
of the mixture necessary to produce a response equivalent to
that for certain doses of the compounds alone. In either case,
the doses of both the mixtures and the compounds separately
which should give equal effects if the null hypothesis is true,
are specified by the potency of one compound relative to the
other in the test procedure. One infers additivity if the null
hypothesis is accepted. One infers either potentiation or anta-
gonism if the null hypothesis is rejected, depending upon the
direction of the deviation from additivity. When one substance
is inactive when given alone in the test situation, the null
hypothesis for both approaches is that it has no effect when
given with the other.
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FIGURE 8
Isobole for the Interaction of the Hypnotic Effect of
Trichloroethanol and Ethanol in Mice.
The ED50 points are plotted with their 95% confidence limits.
The expected location of the ED50 points, given the occurrence
of a simple additive synergism, s given by the solid diagonal.
See text for further details. From Gessner and Cabana (1970).
Copyright (1970) American Society for Pharmacology and
Experimental Therapeutics.
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FIGURE 9
Isobole for the Interaction of the Hypnotic Effects of Chloral
Hydrate and Ethanol in Mice.
ED50 points are plotted with their 95% confidence limits. The
expected location of the ED50 points, given the occurrence of a
simple additive synergism,is given together with the 95% con-
fidence limits by the solid and dotted straight line diagonals,
respectively. In the area of significant pdtentiation, the ED50
isobol has been generated by connecting adjacent points. See
text for further details. From Gessner and Cabana (1970).
Copyright (1970) American Society for Pharmacology and
Experimental Therapeutics.
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From the statistical point of view there is, however, a major
difference between Gessner’s modification of Loewe's isobolo-
metric technique and the more conventional methods. With con-
ventional techniques& both the expected response (assuming
additivity) and the real” response can be determined experimen-
tally. This is done by comparing the response of a given dose
of the mixture with the responses obtained for the appropriate
doses of the substances alone, the latter constitute the
expected response. (Of course, the experiment should be
designed such that possible differences due to the time of day
in which the three responses are measured are minimized.) With
the isobolometric technique, the expected dose cannot be-deter-
mined exoerimentallv. It can onlv be inferred from the line
drawn connecting the ED50s for the two compounds. Moreover,
because of the time-consumina nature of the method. this line is
generally based on historicai data rather than data obtained on
the same dav as that for the experimental ooints. From a prac-
tical point-of view, this may not matter in most cases, since
the evidence for potentiation or antagonism may be striking
enough that this is of no consequence.
Whatever approach one uses, it is important to be aware of the
underlying assumptions. Two specific problems deserve comment.
First, great day to day variation can exist in the determination
of 50% effective doses (LD50, ED50, etc.). Thus, the precision
with which these parameters are known may not be great (the 95%
confidence limits give some indication of this, however).
Second, dose response curves for 2 agents can appear to deviate
considerably from parallelism before one has statistical
evidence to reject the null hypothesis of parallelism. Thus,
deviation from parallelism may, in fact, be true even though the
data are treated as supporting parallelism of the two dose
response curves. Either of these conditions can result in arti-
facts interpreted as “significant interactions” due to the mis-
estimation of the parameters used in determining the
interactions. It is likewise important that all possible pre-
cautions be taken before, during, and after the experiment to
ensure that the reported results are meaningful. This respon-
sibility rests squarely upon the shoulders of the investigator.
SUMMARY
The design of drug interaction experiments focusing on whether
to characterize the interaction as addition, antagonism,
synergism or potentiation is based, in part, on whether or not
both substances when given alone affect the response. If both
substances are active, one determines the potency of one
substance relative to the other in affecting the response. This
can be done for either quantitative or quantal data. Once the
relative potency has been determined, subsequent studies involve
combining fractional doses of the substances and comparing the
results against those obtained using standard doses of the
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substances individually. Doses of the combination and the
single substances are picked such that equivalent responses
should be obtained if the effect of the two together is addi-
tive. The null hypothesis is that the two compounds behave as
though they were different forms of the same substance, one of
which is possibly (depending on the potency ratio) diluted with
an inert substance. Equivalence of response can be tested using
such parametric tests as Student’s t or analysis of variance (or
their nonparametric equivalents) for quantitative data. The
chi-square or Fisher’s exact probability test may be used for
quantal data. Additivity is inferred if the null hypothesis is
accepted. One infers either antagonism or synergism (depending
upon the direction of the diviation from additivity) if the null
hypothesis is rejected. If one substance is inactive when given
alone the null hypothesis is that it has no effect when given
with the other. This is tested using the same techniques as
mentioned above, except that there is no need, obviously, to
determine relative potency.
The isobolographic method for studying drug interactions was
compared with those mentioned above. Both approaches have the
same conceptual basis. The isobolographic method is more
tedious, however, since it entails determination of doses
required to cause a specific response, whereas the other methods
focus on the responses caused by specific doses.
It was cautioned that, whatever the approach, it is the investi-
gator’s responsibility to know what assumptions are being made
and to take all possible precautions before, during, and after
the experiment to ensure that the reported results are
meaningful.
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Problems of Pharmacodynamic
Measurement Related to Psychoac-
tive Drug Interactions in Humans
Richard C. Frecker, M.D., Ph.D.
INTRODUCTION
In measuring the effects of psychoactive drugs, a large number of
factors need to be taken into account. These relate to properties
of the drug itself (Netter 1983; Oates and Shand 1972), to the
organism upon which it is acting (Crooks 1983; Munte et al. 1984),
and to the measurement strategy being employed. In situations
where more than one active agent is present, a number of special
problems exist with respect to experimental design and the
interpretation of data (Vesell 1984; Oates and Shand 1972). These
arise fran both pharmacokinetic and phannacodynamic sources
(Brodie and Mitchell 1972; Ellinwood et al. 1984; Netter and
Netter 1983). The organism itself is constantly changing in
response to both its internal and external environments, and it is
adapting to the presence of exogenous substances which alter
arousal and a variety of processes serving physiological and
psychological equilibrium (Netter 1983; Vesell 1984; Munte et al.
1984). In these circumstances, sensitive and selective drug-
effect detection as well as inmunity fran measurement noise are
difficult to achieve.
This paper looks at some critical elements of the man-machine
interface as they relate to drug-effect measurement, and it
comments on problems which may arise because of the highly
adaptive nature of many biological control systems. Current
models of central neural processes still lack sufficient accuracy
to permit a genuine mechanistic interpretation of the measured
effects of psychoactive agents on human information processing,
affect, and cognition. An integrated, neurotransmitter-based
understanding of systems affected by mood-altering substances is
comnonly lacking.
Modern instrumentation techniques are becoming available which
have great temporal precision and high sensitivity to changes in
central nervous system (CNS) function--whether these perturbations
are produced by rhythmic biological activity, disease states, or
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the introduct ion of exogenous, pharmacologically active chemicals
(Aufdenbrinke 1982; Bigler 1977; Fink 1978; Grunberger et al.
1982; Itil 1978; Linnoila et al. 1978; Young and Sheena 1975). A
persistent problem is the difficulty of separating the effects of
concanitantly active drugs which act at related receptor sites,
and through similar basic mechanisms. This is especially so when
the drugs are pharmacokinetically interactive, share a cannon time
course of action, and act on processes which have poorly
characterized fluctuations in endogenous activity.
The author will identify sane critical elements of the man-machine
interface as they relate to drug-effect measurement and will
suggest what he considers to be the attributes of an “ideal”
pharmacodynamic measurement technique. From this will arise a
consideration of characteristics which render dependent variables
suitable for use as pharmacodynamic probes. A brief concluding
comment will be made concerning the special problems which arise
in drug-effect measurement when drugs interact.
PHARMACOKIKETICS versus PHARMACODYNAMICS
This paper is mainly about pharmacodynamics, but it would be
neither wise nor accurate to imagine that these two aspects of
pharmacology are functionally distinct or independent. To avoid
the possibility of confusion, the following definitions will
govern the sense in which these terms are used in this paper:
Pharmacokinetics is the study of the movement of drugs into,
through, and from an organism or system, including analysis
of data related to the absorption, distribution, metabolism,
and excretion of drugs and their metabolites, and to the
time course of drug effects. That is, pharmacokinetics is
the study of the effects of organisms on drugs.
Pharmacodynamics is the study of the mechanism of drug
action, and of the responses of an organism or system to the
administration of drugs, including analysis of the
relationship between drug concentration and effect. That is,
pharmacodynamics is the study of drugs on organisms.
THE MAN-MACHINE INTERFACE AND DRUG-EFFECT MEASUREMENT
Man and other animal forms are canplex biological entities which
contain many control systems which are highly integrated with each
other, and which are autoregulatory within certain limits.
Pharmacodynamic studies seek to measure drug-induced perturbations
in this complex of adaptive control. However, control is
frequently nonlinear, and input/output relations are frequently
incanpletely understood, and, in quantitative terms, poorly
modeled. Control parameters change over time, for a variety of
reasons, and the integrated system, and its functional sub-
systems, are subjected to a multitude of internal and external
sources of noise.
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Therefore, it is difficult to separate system responses which
result from “drug perturbation” from other forms of system
disturbance. Further, biological organisms (even unicellular ones
possessing irritability) do not “like” being probed. Engineered
physical systems, while they may “respond”, are indifferent to the
various sensing systems which are used to measure their
performance (even if, in so doing, they are either disrupted or
destroyed). [It is unlikely that one can measure any process
without taking “something” from it, even if only a few electrons
or photons.]
The various interfaces, and associated transducers, which are
established to permit the noninvasive acquisition of physiological
information can be unstable over time. In sane senses, the less
invasive the technique the more prone to degradation is the
information-containing signal , and the more information extraction
relies on inferential and probabilistic processes. An additional
cunplication is that in the clinical and clinical research
environments ergonanic considerations are often paramount. They
may dictate further reduction in the “direct coupling” which one
might logically seek between event, transducer, and data
acquisition system. It is not hard to imagine that in sane
circumstances an adequate level of “ecological validity” may be
difficult to secure.
SOME ATTRIBUTES OF THE MEASUREMENT TECHNIQUE
What then might be the attributes of an “ideal” pharmacodynamic
measurement technique? Perhaps the most obvious consideration is
that the detection technique ought not to pervert the response
unacceptably. An example of such “perversion” might occur in a
system for measuring finger tremor which employs a heavy
accelerometer attached to the finger. The alteration in mass of
the tremoring digit would be likely to lower artificially the
frequency or amplitude of the measured tremor.
While there may be a basis for argument about the importance or
relative importance of the following in particular circumstances,
it is necessary to consider the implications of whether or not
sensing the dependent variable is:
a. Without subject constraint;
b. Without attachment to the subject;
c. Without subject awareness;
d. Objective, autanatic, and rapid;
e. Accurate, and sufficiently precise; and
f. Immune to extraneous “environmental” influences.
The impact on experimental design and the validity of experimental
data will vary fran circumstance to circumstance, depending on the
care, attention, and relative weighting the above factors receive,
and on the robustness of the dependent variable. A lively debate
on the above would not be beyond the realm of possibility, but it
is beyond the scope of this paper.
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CHARACTERISTICS OF THE DEPENDENT VARIABLE
Less debatable, perhaps, would be the assertion that the following
characteristics of the dependent variable are highly desirable:
a.
b.
c.
d.
e.
f.
Low complexity for ease of extraction of single response
elements;
High sensitivity and selectivity for the drug(s) being
studied;
Appropriate differential sensitivity to such influences
as heat, humidity, pressure, light, sound, diet,
exercise, sleep, arousal, and other factors which may
themselves be components of the evoking stimulus or of
the response;
Low between- and within-day random variability ("random"
noise) ;
Infradian, circadian, and ultradian rhythms (where
present) which have been adequately characterized
("periodic" noise); and
Derivation directly from the relevant behavior, and
presentation in an ecologically valid manner.
Where it is not possible to achieve "f" (above), the dependent
variable should probably be derivative of involuntary responses
requiring little, if any, subject participation; and in turn,
would ideally have been shown on an empirical basis to be
sensitive to the drug(s) being investigated in a dose-response
manner . Of all the characteristics listed above, "b" and "c"
appear to be the most difficult to achieve in reality.
DATA ACQUISITION AND ANALYTICAL GENERALITIES
Much useful pharmacodynamic data can be collected by the use of
such instruments as questionnaires, visual analog scales, and a
variety of observational techniques using the usual sensory
modalities of the observer (vision, hearing, touch, etc.). While,
in sane senses, the following comments could be generalized to
cover that sort of data collection, they are more specifically
focused on data acquired using electronic, optoelectronic,
mechanical, and other sorts of transducers. In general, the term
"output signal" may be taken to mean a tine-varying electrical
event bearing a known or calibrated relationship to changes in the
dependent variable. It is not intended in this context to examine
the physical characteristics of various transducers; whether they
are resistive or capacitive devices; or whether the primary
transduction yields current, voltage, or a change in resistance.
The “output signal" may be thought of simply as the electrical
analog of information which indicates the state of the dependent
variable. It is usually a voltage, varying within a range
acceptable to the monitoring device.
However generated, output signals should be readily amendable to
available signal reduction and analysis techniques. Where copious
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information is made available by a particular measurement system,
it may need to be "reduced" in quantity by intermittent sampling
over time, by electronic preprocessing, or by other techniques--
to yield a set of "raw" data which can be accatmwdated by the
investigator. "Accommodated" may mean direct analog or digital
recording on magnetic tape, temporary residence in a computer's
main memory, long-term storage on one of a variety of mass media,
or even being directly recorded onto paper as a pen trace or a
series of nunbers.
Whenever possible, the raw data should be entered onto/into the
storage medium of choice as the experiment proceeds. This will
serve to minimize later translational errors, and immediately will
create a permanent record of the raw data. It may be desirable to
create a "back-up" copy of the original data set, or to copy it in
whole or in part to a medium which will facilitate later analysis
or re-analysis. While it is often desirable to perform parameter
extraction and to produce numerical or graphical sumnaries of
results within the time frame of the experiment, a number of
precautions need to be observed. Within the limits of the
available data storage and retrieval systems, the data should be
permanently stored in that state closest to "raw data" which is
practical. This facilitates subsequent re-analysis, and may, in
the future, permit the use of an analysis technique which was not
previously thought of or available. However, in instances where
parameter extraction is analytically trivial, proven, and robust,
it may be sufficient to store the parameters themselves, or even
their summary statistics.
The time frame in which graphical and statistical sumnaries are
made available, and the persons who will have access to these
data, will depend very much on local circumstances, system
capacity, the need for "real-tine" results, and both ethical and
scientific propriety.
CHANGES OBSERVED IN THE DEPENDENT VARIABLE
Generally, it should be possible to correlate observed changes in
the dependent variable with known indicators of a particular
drug's effects, at least for purposes of calibration. A problem
arises when there are no other known or accepted indicators. When
a new measure of drug effect has been developed which is either
more sensitive or selective, this may be ill-advised other than as
a means of pointing out differences. Further, the fact that a
given measure of drug effect is both well known and  well accepted
does not per se make it valid.
If one is monitoring drug concentrations in the course of a
pharmacodynamic experiment, it should be possible to correlate
observed changes in drug effect over time with changes in the
relevant effective drug concentration. The key word is relevant.
The relevant concentration/time profile (corrected for
distributional time lags) is that of the compound thought to
elicit the particular drug effect (whether receptor-mediated or
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not). It may be total plasma concentration of the parent drug
whch is in simple and rapid equilibrium with a known site of
action. On the other hand, it may be the "unbound" (free) drug
concentration distributed across a number of transporting
membranes (differentially distributed)-a minute portion of which
is actually in dynamic, time-varying equilibrium with a poorly
identified, but specific, receptor, which is, in turn, distributed
unequally among a variety of sites. A myriad of states of
intermediate complexity came to mind. Pharmacodynamic measures of
sufficient sensitivity and selectivity would be clearly preferable
in the more complex case; and what one would seek is a measure
which might be repeated sufficiently often to resolve, in time,
the drug's effect (however rapid).
TABLE 1
Examples of Pharmacodynamic Dependent Variables
A) COMPLEX VOLUNTARY
Autanobile Driving (real)
Various Task Simulators
Maze-following Equivalents
Cognitive Psychometrics
Affective Psychometrics
B) ENCEPHALOGRAPHIC
Spontaneous EEG
Evoked Potentials
Cortical
Brainstem
C) VISUAL SYSTEM
Flicker sensitivity
Pursuit movements
Vergence movements
Nystagmus (various)
Miniature movements
Microsaccades
Tremor
Drift
D) AUDITORY SYSTEM
Pitch discrimination
Threshold detection
Flutter fusion
Acoustic impedance
E) VOICE ANALYSIS
Vocal Tremor
Feature extraction
F) NEUROMUSCULAR
Tremor measurements
Standing steadiness
Reflex kinetics
G) REACTION TIMES
Various
H) CARDIOVASCULAR
Heart rate
Blood pressure
Photoplythysmography
I) RESPIRATORY
Respiratory rates
Carbon dioxide drive
Respiratory volumes
J) SKIN CHANGES
Color
Temperature
Impedance (GSR)
K) GASTROINTESTINAL
Bowel sounds
For further discussion of sane of the above variables, the
interested reader is referred to Aufdembrinke (1982), Bigler
(1977), Grunberger et al. (1982), Itil (1978), Linnoila et al.
(1978), and Young and Sheena (1975).
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In the real world of the intact human being, one has a limited
number of biological fluids in which to measure drug levels
(blood, urine, saliva, cerebrospinal fluid, bile, etc.). It is,
generally, not possible to measure drug concentration over time in
the micro-envirotxnent of the receptor, and the ideal pharmaco-
dynamic dependent variable awaits discovery. In the meantime,
available samples are taken, and corrections in timing are made to
accomodate known pharmacokinetic behavior. Newer nuclear
medicine techniques such as positron emission tomography and
nuclear magnetic resonance imaging will afford better
distributional information; and the search continues for more
accurate and more precise noninvasive  measures of drug effect with
which to correlate this new information. Sane examples of
currently available pharmacodynamic dependent variables are listed
in table 1.
WHEN PSYCHOACTIVE DRUGS INTERACT
The situation which exists when more than one drug OK substance is
active concurrently is somewhat more complex. If no kinetic
interaction occurs, and the drugs have distinct and different
mechanisms, sites, or time courses of action .(the simplest case),
the above principles apply in a fairly straightforward manner. In
the slightly more complex case of drugs with similar mechanisms of
action, but distinctly different time courses, it is sometimes
possible to separate their effects on a pharmacodynamic basis if
good kinetic data are also available. Due consideration must be
given to the difference between simple additive effects and those
which are produced by synergistic drug interaction. The phenomena
of cross-tolerance and inhibition further complicate the
situation.
Given these complexities, one is, perhaps, well advised to select
for investigation drugs whose dynamic and kinetic interaction are
particularly illustrative from a mechanistic perspective, or drugs
whose interactions pose special hazards for the exposed
population. It seems likely that the time is not too far distant
when the technical advances of modern noninvasive imaging will
greatly increase our ability to produce accurate kinetic models of
drug behavior within the CNS. Presently, there are pharmacodynamic
probes being developed which have greater precision, speed, and
selectivity. Given this convergence, one may reasonably expect
that increasing knowledge of the relationship of psychoactive drug
kinetics and dynamics will lead to a more perceptive and
mechanistically based view of psychoactive drug interactions in
general.
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Pharmacokinetic Mechanisms of
Ethanol-Psychotropic Drug
Interactions
Domenic A. Ciraulo, M.D., and Jamie Barnhill, Ph.D.
Given the ubiquitous nature of alcoholic beverages in our culture,
ethanol-drug interactions have substantial social importance, With
29% of women and 13% of men in the United States taking prescribed
psychotropic drugs (Parry et al. 1973), and a large number of
others taking nonprescribed psychotropics. the interaction of
ethanol* with psychoactive agents is particularly important. Yet,
the different kinds of interactions, their frequency, and the
clinical and social impact are not easily studied.
Although the problems of experimental investigatjon are somewhat
simplified by a pharmacokinetic/pharmacodynamic division of ethanol-
drug interactions, the patterns of alcohol and psychotropic drug
intake may confound the findings of even the most carefully
designed studies. In designing or evaluating clinical research
protocols, it is necessary to consider several factors which have
the potential to affect the results and applicability to real
life situations. Drug use or alcohol intake may be acute or
chronic, and may interact in the clinical situation in any of several
ways. An occasional social drinker with the acute onset of stress
may be prescribed a bentodiazepine and decide to take it with a
cocktail at a social gathering (acute ethanol/acute drug). An
alcoholic who has been hiding the severity of the problem from his
physician may be prescribed a benzodiazepine for "anxiety" or an
antidepressant for "depression" (chronic ethanol/acute drug).
Another example is the occasional drinker who is maintained on an
antidepressant and after having a cocktail finds the enhanced effects
impair his driving ability (acute ethanol/chronic drug). Another
common clinical situation is that of the polysubstance abuser with
pharmacodynamic and pharmacokinetic interactions'of alcohol and a
variety of abused drugs (chronic ethanol/chronic drug).
In addition to duration of drug or ethanol ingestion, other factors
such as the types of drugs taken, dosage combinations, routes of
administration, pharmacokinetic and pharmacodynamic characteristics
of the particular psychoactive agent and ethanol, and the presence
of coexisting organic or psychiatric illness also influence the
nature and importance of the interaction.
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There are several excellent reviews on ethanol-drug interactions
(Sellers and Holloway 1978; Linnoila et al. 1979; Weller and
Preskorn 1984), and this chapter will not be a repetition of those
efforts. Instead, the pharmacokinetic mechanisms of psychotropic
drug-ethanol interactions will be discussed and relevant examples
cited. It is hoped that this conceptualization will provide a
framework for understanding and evaluating the pharmacokinetic
mechanisms and clinical significance of ethanol-psychotropicdrug
interactions. Although the following discussion will be limited
to the effect of alcohol on pharmacokinetic processes, it should
be kept in mind that psychotropic medications may in turn alter
the metabolism and pharmacologic action of ethanol (Sellers et al.
1972; Mezey 19761.
Pharmacokinetic interactions arise from drug-induced alterations
in absorption, distribution, biotransformation, or excretion of
another drug. Acute alcohol intake inhibits gastric emptying
(Nimmo 1976), resulting in a lag in onset and decreased rate of
absorption (MacLeod et al. 1977; Greenblatt et al. 1978). The
clinical significance of these findings may not be as great as the
acute metabolic effects. Inhibition of "first-pass" effects can
result in greater systemic availability.
All orally administered drugs must pass first through the liver
before reaching the systemic circulation, so that inhibition of
metabolism by acute alcohol would produce greater systemic
availability of the drug dose. Acute alcohol intake inhibits
demethylation and/or hydroxylation of benzodiazepines, increasing
peak plasma levels of most drugs of this class (MacLeod et al.
1977; Laisi et al. 19791. Similar effects are seen when ethanol
and amitriptyline are given concurrently (Preskorn and Hughes
1983). Acute alcohol intake increases splanchnic blood flow,
irritates the gastric mucosa, and increases motility in the
duodenum (Magnussen 1968). Chronic intake results in structural
defects in the gastrointestinal tract and changes in enzymatic
activity (Findlay et al. 1976). Despite this, there is little
evidence to suggest that altered oral absorption is an important
mechanism of alcohol-drug interactions, particularly since acute
alcohol has been shown to decrease the clearance of intravenously
administered drugs, such as diazepam (Sellers et al. 1980a) and
lorazepam (Hoyumpa et al. 1981).
Drug distribution is another potential process that can be altered
by ethanol. After absorption, a drug is distributed to tissues
with high blood flow, such as brain, liver, and kidney, and then
to tissues with lower blood flow but higher affinity, such as
muscle or fat. Distribution factors are important in terminating
clinical action of single doses of such drugs as benzodiazepines
or thiopental. For example, despite a shorter elimination half-
life, the duration of action of intravenous lorazepam is greater
than that of diazepam because of the greater lipid solubility of
the latter drug (Arendt et al. 1982).
Ethanol may potentially affect drug distribution by altering
membrane permeability, cardiac output, and protein or tissue
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binding. Modification of albumin binding sites or alterations in
other binding substances (e.g., alpha1-acid glycoprotein),
intermediary metabolism, or endogenous substances are potential
areas of binding interactions (Sellers and Holloway 1978).
Before discussing any of these problems in any further detail,
some basic principles of pharmacokinetics require review.
One of the basic and most important concepts of clinical
pharmacokinetics is clearance. It is that pharmacokinetic
parameter that relates concentration to the rate of drug
elimination. It is expressed as volume per unit time and
indicates the volume of blood completely removed of drug per unit
time. Total systemic clearance (Cl) is the sum of hepatic
clearance (ClH) and extrahepatic clearance (ClEH) (Wilkinson and
Shand 1975).
Cl = ClH + ClEH (1)
When a drug is only eliminated through hepatic metabolism, which
is the case for a majority of the psychotropic drugs, then total
systemic clearance equals hepatic clearance.
Total systemic clearance can be calculated by one of the following
formulas:
(2)
(3)
V is the volume of distribution, and t½ is the half-life of
elimination determined from the elimination rate constant, Kel.
FD represents the fraction of the drug dose reaching the systemic
circulation and AUC is the area under the drug concentration-time
curve. Clearance may also represent loss of a drug across an
eliminating organ (i.e., liver) and the equation describing it can
be of value in understanding the effects of altered blood flow,
plasma protein binding, enzyme activity, and secretory activity
on drug clearance.
ClH = QH · EH (4)
Equation 4 demonstrates that hepatic clearance is a function of
hepatic blood flow (QH) and the hepatic extraction ratio (EH).
The extraction ratio relates the rate of drug extraction to the
rate at which a drug is presented to the liver. It can be
expressed as:
Clint
EH = QH + 
Clint (5)
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where Clint is the intrinsic clearance, defined as the maximum
ability of the eliminating organ (liver) to remove the drug from
the blood when there are no flow limitations. Substituting
equation 5 into equation 4 gives:
(6)
Since it is the unbound drug which is available for hepatic
elimination, the intrinsic clearance of unbound drug (equation 7)
can be substituted into equation 6 to give the hepatic clearance
of unbound drug:
(7)
where fB equals the unbound fraction in the blood.
(8)
For a drug with a high intrinsic clearance in the liver, the
extraction ratio is high and approaches unity, and hepatic
clearance approaches organ blood flow (equation 9).
(9)
These drugs are therefore flow-limited in their clearance. Some
psychotropics with high E (>0.7) include desipramine, morphine,
meperidine, propoxyphene, and propranolol (Williams and Benet
1982).
For drugs with intrinsic clearance much smaller than liver blood
flow, the extraction ratio is low (<O.3) and clearance is
considered capacity-limited (equation 10).
(10)
Low E drugs include amobarbital, phenobarbital, diazepam, chlor-
diazepoxide, and phenytoin (Williams and Benet 1982).
The effect that alterations in protein binding will have on
clearance is dependent on extraction ratio. hanges in protein
binding are most important in low E (<O.3) drugs since the
clearance of these drugs is dependent on unbound concentration
(equation 10). Changes in the protein binding of drugs with in
E>O.7 should have little to no effect on clearance since
clearance is dependent on blood flow (equation 9). For these
high intrinsic clearance drugs, the unbound drug is very
rapidly removed from the blood, but the instantaneous association/
dissociation of the drug from its binding sites provides a
constant source of unbound drug while passing through the liver.
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Displacement from binding sites in the blood
increases in the volume of distribution (V).
by the following relationship (Wilkinson and
can result in
This can be seen
Shand 1975).
(11)
Where VB equals the volume of the blood, VT equals the tissue
volume, fB is the fraction unbound in the blood, and fT is the
fraction unbound in the tissue. If the unbound fraction in the
blood increased, then the volume of distribution would
increase. For a drug with an E>0.7, this increase in the
volume of distribution will cause an increase in the half-life
for elimination of the drug, since:
(12)
This lengthens the time that the drug stays in the body as well
as the amount of time required for achievement of steady state,
although time averaged steady-state levels of total drug (bound
plus unbound) (Css) should be unchanged (Gibaldi and Koup 1981).
Average steady-state levels of unbound drug in blood (Cuss) will
be elevated, as can be seen by equation 13.
(13)
On single dosing, there will be a longer elimination half-life
with lower peak levels of total drug.
On the other hand, an increase in the volume of distribution for
a drug with an E<0.3 could be offset by the increase in clearance
and have no significant effect on elimination half-life. The
increase in volume of distribution and clearance will cause a
decrease in average steady-state blood levels of total drug.
The average steady-state levels of unbound drug will be unchanged,
although within a dose interval there will be fluctuations,
including an initial, transient, higher than normal unbound
concentration.
Diazepam can be used to illustrate these points. Diazepam has a
low E and is highly bound, and changes in protein binding affect
its systemic clearance as well as steady-state concentration of
total drug (bound plus unbound), but steady-state concentration
of unbound drug is relatively unaffected (Sellers et al. 1979;
Sandor et al. 1983). For a highly bound, low E drug, alterations
in unbound fraction have two important clinical implications
(Sandor et al. 1983). First, total drug concentration at steady
state may not correlate well with clinical effect. Second, an
increase in unbound drug in plasma is associated with a decrease
in total drug concentration in plasma as unbound drug enters
tissue. There is a transient rise in unbound concentration but
a more rapid distribution of drug. The clinical consequences are
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the possibility of increased therapeutic or toxic effects early
in the dosing interval and diminished therapeutic effect late in
the dosing interval. There is no change in the time averaged
unbound concentration over the dosing interval, although greater
fluctuations are seen.
An increase in the average steady-state concentrations of
unbound drug for a drug with E>0.7 could have a greater clinical
significance since larger concentrations of the unbound species
are available at sites of pharmacological action. Total drug
concentration in the blood could, once again, not correlate with
the observed clinical effect.
There are relatively few studies of protein binding changes with
acute and chronic ethanol administration. In vitro work has
shown that chronic ethanol administration can impair synthesis and
secretion of proteins and glycoproteins in the liver (Sorrell et
al. 1983). Acute ethanol administration in perfused rat liver
studies has demonstrated a depression of albumin production
(Rothschild et al. 1983). Malnutrition, often found in chronic
alcoholics, can also cause hypoalbuminemia (Rothschild et al.
1983). It is known that disease, stress, and trauma can increase
levels of alpha1-acid glycoprotein (AGP) (Edwards et al. 1982;
Piafsky 1980) which has a strong affinity for basic drugs, but
whether it increases with acute ethanol is not known, symptomatic
withdrawal from chronic ethanol administration may be stressful
enough to cause increases. In a recent study of 15 alcoholics
in withdrawal, the unbound fractions of diazepam and propranolol
were determined on each of the first 3 days of withdrawal and
again between 5 and 7 days postadmission (Sandor et al. 1983).
Unbound diazepam fraction was elevated and propranolol unbound
fraction was decreased relative to normal values during the first
day of withdrawal. Over the 7-day withdrawal period.the diazepam
unbound fraction decreased and the fraction of unbound propranolol
increased. The mechanism of diazepam binding changes is uncertain,
although altered liver metabolism and/or nutritional status may
be involved. Levels of free fatty acids, which increase during
chronic alcohol consumption (Shaw and Lieber 1976) and are known
to displace drugs from binding sites (Sellers et al. 1980b),
were only weakly associated with diazepam binding changes. There
was an elevation of AGP levels durinq the symptomatic phase of
withdrawal and this correlated well with a decreased unbound
fraction of the basic drug propranolol (pka = 9.45).
We have examined the protein binding of desipramine and imipramine,
two basic drugs that bind to albumin and alpha1-acid glycoprotein.
The decreased unbound fraction seen in alcoholics compared to
normal controls correlated with increased alpha1-acid glycoprotein
(table 1). We did not find hypoalbuminemia in our alcoholics,
although it has been observed in alcoholics with liver disease.
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TABLE 1
Comparison of Desipramine Protein Binding
in Alcoholics and Normal Controls
Alcoholics (n=4) Normals (n=4)
Free Fraction, % 14.07 1.62 17.15 1.29
Total Protein, g/dl 6.87 0.33 6.98 0.34
Albumin, g/dl 4.63 0.57 4.66 0.14
-Acid Glycoprotein, mg/dl 107.60 14.66 84.80 2.82
The acute effects of low-dose ethanol are to increase hepatic
blood flow by increasing cardiac output, vessel dilation, and
splanchnic blood flow (Stein et al. 19631, while acute high-dose
ethanol can lower hepatic blood flow by decreasing cardiac out-
put. The effects of chronic alcoholism on liver blood flow are
unknown. Although intrahepatic shunting of blood flow has been
found in cirrhosis (Groszman et al. 1972), the effects of chronic
alcoholism, short of alcoholic liver disease, has not been
documented. For drugs with E>0.7, increases in hepatic blood
flow result in increased hepatic clearance, while decreases in
hepatic blood flow decrease hepatic clearance. Acute low doses
of ethanol would be expected to increase hepatic clearance of
these drugs, while acute high doses might be expected to reduce
clearance. Blood flow changes should not have a significant
effect on the clearance of low E (<0.3) drugs.
Alcohol alters drug metabolism through its effects on hepatic
biotransformations. The purpose of drug metabolism by the liver
is to render lipid soluble (nonpolar) substances into water
soluble (polar) derivatives for renal excretion (Hoyumpa and
Schenker 1982). Acute alcohol intake usually decreases (by
inhibition or competition) drug metabolizing enzymes (i.e.,
decreases Cl int) (Rubin et al. 1970; Cinti et al. 1973).
Barbiturates, benzodiazepines, methadone, and meprobamate are so
affected (Hoyumpa and Schenker 1982; Williams and Benet 1982).
Chronic alcohol intake increases the activity of a variety of
microsomal enzymes, the content of cytochrome P-450, and the
activity of NADPH-cytochrome P-450 reductase (Ishii et al. 1973).
As a result, in the absence of severe liver damage, metabolism of
drugs (Clint) is usually enhanced. Without liver biopsies or
pharmacokinetic assessments, it is difficult to predict whether
enzyme induction or liver damage will predominate. Chronic.
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ethanol consumption enhances the metabolism of chlordiazepoxide,
diazepam, phenytoin, imipramine, meprobamate, barbiturates, and
others (Sellman et al. 1975; Sandor et al. 1981; Ciraulo et al.
1982; Misra et al. 1971). Chronic ethanol consumption may cause
an increase in glucuronidation by inducing glucuronyltransferase
(Ideo et al. 1971). On the other hand, acute ethanol consumption
was shown to decrease the clearance of lorazepam (a drug eliminat-
ed by glucuronidation) by inhibitin UDP-glucuronic acid
synthesis (Hoyumpa and Schenker 1982 , In general, cirrhosis
tends to impair oxidative metabolism, while it spares or only
slightly impairs glucuronidation (Williams and Benet 1982).
The concept of hepatic extraction ratio is important in predicting
the effects of metabolism interactions. For a drug with a high
extraction ratio, such as propranolol, induction does not affect
clearance or half-life, although oral availability is decreased,
due to a larger portion of drug being removed in the first pass
through the liver before it reaches the systemic circulation.
For a drug with a low extraction ratio (e.g., diazepam), enzyme
induction results in enhanced clearance and decreased half-life.
The extraction ratio of imipramine is intermediate (about 0.65).
Enzyme induction, as occurs with chronic alcoholism, enhances
metabolism of imipramine. Figures 1 and 2 show the semilogarithmic
plots of plasma concentration versus time in a representative
alcoholic and a normal control given single intravenous and oral
doses of imipramine (Ciraulo et al., unpublished data). Oral
availability was lower for the alcoholic subject. The alcoholic
had enhanced clearance and a shorter elimination half-life
(table 2).
TABLE 2
Pharmacokinetic Parameters for Imipramine in a
Representative Alcoholic and Normal Control
Parameters
Clearance, L/hr/kg
Elimination Half-life, hr-1
AUC, ng · hr/ml
Vol. of Distribution, L/kg
Free Fraction, %
Imipramine
50 mg P.O. 12.5 mg IV
Alcoholic Normal Alcoholic Normal
2.28 1.26 0.94 0.65
7.79 15.64 12.00 16.81
261.00 446.00 156.00 206.00
25.60 28.44 15.40 15.69
16.40 16.11 17.41 17.06
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FIGURE 1
Plot of imipramine plasma concentrations following an IV infusion of
a 12.5 mg dose. The solid line represents the computer generated
curve.
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FIGURE 2
Plot of imipramine plasma concentrations following a 50 mg oral
dose. The solid line represents the computer generated curve.
82
Chronic dosing studies show that steady-state levels of imipramine
and its metabolites are lower in depressed alcoholics compared to
nonalcoholic depressed patients (Ciraulo et al. 1982) (table 3).
A standard 150 mg dose of imipramine given to alcoholics yields
a mean steady-state concentration well below what many consider
to be a minimum effective therapeutic level (Ciraulo and Jaffe
1981). Clearance of desipramine is enhanced in alcoholics when
given intravenously (Ciraulo et al., unpublished data). Although
there is also a trend for enhanced clearance of oral and intravenous
desipramine (Ciraulo et al., unpublished data), there is such
great variability that differences are not statistically signif-
icant. The reasons for this are unclear, although such factors
as enterohepatic recycling and genetic variability in hydroxyla-
tion capacity may be involved.
Contrary to our findings with antidepressants, we have preliminary
evidence that hydroxylation of alprazolam, a triazolobenzodiaz-
epine, is inhibited in acute alcohol withdrawal. Figure 3
presents data from a multiple dose study in which panic disorder
patients, two of whom were alcoholics, received three different
dosing regimens of the drug. The alcoholic patients had impaired
clearance, higher steady-state plasma concentrations, and more
drug-related side effects as compared to nonalcoholics. The
TABLE 3
Plasma Levels (ng/ml) of Imipramine and Its
Metabolites 8 Hours After the Last Dosea
IMI % free DMI % free 2-OH-IMI 2-OH-DMI Total TricyclicSpecies
Alcoholics
Mean
SD
N
Controls
Mean
SD
N
IMI=imipramine; DMI=desipramine; 2-OH-IMI=2-hydroxyimipramine;
2-OH-DMI=2-hydroxydesipramine; SD=standard deviation. *p<O.O05,
**p<0.01, ***p<O.O5 (significance level using unpaired t test).
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FIGURE 3
Mean steady-state alprazolam plasma concentration versus daily dose
of alprazolam for six subjects. The two uppermost lines represent
data from two chronic alcoholics (nondrinking). The four lower lines
represent data from nonalcoholic subjects.
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number of subjects is too small for meaningful statistical
comparisons, but the clinical differences were dramatic. If
these findings are substantiated in a larger number of subjects,
it would suggest that not only are different oxidative processes
(e.g., demethylation, hydroxylation) altered differentially as a
result of chronic alcoholism, but also that drugs metabolized by
the same biotransformation reaction (i.e., hydroxylation) may be
affected differently by chronic ethanol consumption. Both
desipramine and alprazolam are hydroxylated, yet in chronic
alcoholics,clearance of the former drug is slightly enhanced or
unchanged while that of the latter is impaired.
For those drugs with an intermediate extraction ratio, there will
be a combination of effects caused by blood flow changes, intrinsic
clearance changes, and alterations in protein binding. Only
careful experimentation can show which change or combination of
changes will predominate.
SUMMARY
Acute and chronic ethanol consumption alters psychotropic drug
pharmacokinetics. An understanding of the processes of drug
absorption, distribution, biotransformation, and elimination
provide a rational basis for predicting and evaluating drug
interactions. Careful application of clinical pharmacokinetic
models describing these physiological processes are particularly
appropriate for the task of understanding drug and alcohol
interactions.
(1) Absorption. (a) Acute alcohol inhibits first-pass effect
increasing systemic bioavailability. (b) Ethanol inhibits
gastric emptying and may delay drug absorption (increase lag
time of absorption) and decrease the rate of absorption. (c) The
effects of chronic alcohol intake are unknown.
(2) Distribution. (a) Hypoalbuminemia may be present in alcoholics
with liver disease. (b) Fluctuations in free fractions of drugs
may occur in the alcohol withdrawal period. The clinical effects
of protein binding changes are dependent on degree of binding,
hepatic extraction ratio, and binding protein. (c) Acute low-dose
ethanoi increases hepatic blood flow while high doses decrease it.
The effects of chronic alcohol intake on liver blood flow are
unknown. Hepatic blood flow changes show the greatest effects on
drugs with high extraction ratios.
(3) Metabolism. (a) Acute alcohol ingestion usually inhibits
drug metabolism and chronic intake (in the absence of severe liver
disease) enhances metabolism. (b) Cirrhosis impairs oxidative
metabolism, but spares glucuronidation.
Although these generalizations may serve as useful guidelines for
predicting alcohol and psychotropic drug interactions, they should
be applied with caution as exceptions do exist.
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FOOTNOTE
1The terms alcohol and ethanol are used interchangeably.
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Complex Interactions Between
Drugs and Dietary Factors
Elliot S. Vesell, M.D.
Multiple dynamic interactions occur among host factors that affect
drug response (figure 1); these host factors and their
interactions are responsible for large interindividual variations
in drug disposition (Vesell 1982, 1984b). The critical role in
drug disposition played by host factors depicted in figure 1, and
by dynamic interactions among them, is insufficiently appreciated.
Too often, patients are incorrectly treated as being equivalent to
o n e  a n o t h e r  a n d  u n c h a n g i n g  w i t h  r e s p e c t  t o  t h e i r  d o s a g e
requirements. Too few physicians recognize that a particular
patient’s dosage requirements can change with an alteration in
even one of the host factors shown in figure 1. Thus, in a given
patient, a dose of a particular drug that is therapeutic at one
time may become either toxic or ineffective at another time. As
more active drugs with lower therapeutic indices are marketed,
physicians must individualize drug dosage according to the special
and changing requirements of each patient.
Diet is a multifaceted, complex host factor that can alter drug
response by changing several pharmaookinetic parameters (figure
1) . The human diet is highly heterogeneous in its preparation,
chemical composition, volume, and times of consumption (figure 2).
Accordingly, dietary ef fects  on drug kinetics  vary widely in
subjects  of  di f ferent age,  sex,  socioeconomic status,  ethnic
background, and geographic region. Indeed, these effects can vary
in the same subject over time and seasons as changes occur in his
or her dietary habits. Now, as a result of numerous studies on
food-drug interactions, several fundamental principles have
emerged, as well as certain problems whose resolution requires
more investigation and fresh insight. This review identifies
several of these problems and offers approaches to their solution.
MAGNITUDE OF INTERINDIVIDUAL VARIATION IN DRUG RESPONSE
Normal subjects  exhibit  large interindividual  variat ions in
pharmacokinetic values when the same drug in the same dose is
administered by the same route to different normal adult male or
8 9
female subjects under similar environmental conditions. Table 1
shows that the magnitude of these interindividual pharmacokinetic
variations commonly ranges from threefold to elevenfold, depending
both on the drug and the population studied. Figure 1 identifies
27 different host factors that can cause large variations among
subjects in rates of drug elimination. Since some of these host
fac to rs - - inc lud ing  genet i c  c ons t i tu t i on ,  d i e t ,  exposure  t o
numerous drugs, and other environmental chemicals--are broad in
scope, many additional specific items could be listed under each
factor. These and other host factors shown in figure 1 primarily
influence hepatic drug-metabolizing enzyme activity (HDMEA),
although effects on drug absorption, distribution, and excretion
can also occur. Since large interindividual pharmacokinetic
variations persist even when the other factors shown in the outer
circle of figure 1 are held constant, these large interindividual
variations, existing in normal subjects maintained under similar
environmental conditions, arise mainly from genetically controlled
differences in HDMEA (Vesell and Penno 1983).
FIGURE 1
This circular design suggests the multiplicity of either well-
established or suspected host factors that may influence drug
response in man. A line joins all such factors in the outer circle
to indicate their close interrelationship. Arrows from each
factor in the outer circle are wavy to indicate that effects of
each host factor on drug response may occur at multiple sites and
through different processes, including drug absorption, distribu-
tion, metabolism, excretion, receptor action, and combinations
thereof.
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DIETARY FACTORS THAT AFFECT DRUG RESPONSE
This review focuses on complex, multifaceted effects of dietary
factors on drug response. Most studies designed to identify the
influence of dietary factors have had to explore each dietary
factor in isolation from additional dietary factors and from other
host factors shown in figure 1. However, in the real world, many
of these dietary factors can and do interact with each other. The
extent and nature of such interactions among dietary factors and
also between dietary factors and other host factors need to be
explored and defined. Figure 2 suggests the extensive potential
for dynamic interactions among dietary factors.
FIGURE 2
This circular design suggests the possibility of dynamic
interactions among the several well-established or suspected
dietary factors that may influence drug response in humans.
Arrows from each factor in the outer circle are wavy to indicate
that effects of each dietary factor on drug response may occur at
multiple sites and through different processes. The inner circle
suggests that effects of dietary factors may be modified by many
other environmental factors, as well as by genetic factors.
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Table 1. lnterindividual variations in plasma half-lives of drugs
metabolised by hepatic detoxifying enzymes
Drug Plasma
half-life
(hours)
Factor of No. of individuals
variation investigated
Aminopynne 1.1-4.5 4 12
Amylobarbitone 1.4-6.4 5 14 pairs of twins
Antipyrine 5-35 7 33
Carbamazepine 18-55 3 6
Diazepam 9-53 6 22
Dicoumarol 7-74 11 14 pairs of twins
lndomethacin 4-12 3 15
Nonripryline 15-90 6 25
Phenylbutazone 1.2-7.3 days 6 14 pairs of twins
Phenytoin 10-42 4 86
Primidone 3.3-l6.2 5 46
Theophylline 4-l8 5 45
Tolbutamide 3-27 9 50
Wartarin 15-70 5 40
As documented abundantly for such drugs of abuse as alcohol,
marijuana, cocaine, and heroin (DuPont 1976), drugs of abuse are
r a r e l y  u s e d  s i n g l y ;  r a t h e r ,  t h e y  a r e  t a k e n  i n  v a r i o u s
combinations. Such multiple drug use by an individual enhances
oppor tun i t i e s  f o r  pharmacok ine t i c  and  pharmacodynamic
interactions between these drugs and numerous host factors shown
in figure 1 (Braude and Vesell 1976). The role of dietary factors
in  a f f e c t ing  po tent ia l  in te rac t i ons  among  drugs  o f  abuse
themselves and other host  factors  has been neither widely
recognized nor Investigated. Hopefully, this  review (Vesel l
1984b) will serve to focus attention on such interactions.
EFFECT OF FOOD ON ABSORPTION OF ORAL DRUGS
Figure 2 suggests not only that many dietary factors can interact
with each other to lnfluence drug disposition, but that each can
also affect drug disposition at several discrete sites, including
sites of drug absorption, distribution, metabolism, and excretion.
This section deals mainly with effects of food on absorption of
drugs taken by mouth. For decades, eating has been recognized to
of fact drug response, and patients have long been aware that
taking some medications with meals reduces gastrointestinal side
effects.
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The general outcome of taking medication with meals is a retarded
rate rather than an altered total amount of gastrointestinal drug
absorption. Retardation of the gastrointestinal absorption rate
of drugs occurs mainly because meals slow gastric emptying. Meals
can increase, decrease, or be without effect on the absolute
s y s t e m i c  a v a i l a b i l i t y  o f  a  d r u g  ( W e l l i n g  1 9 7 7 ) .  F o r  t h e
relatively few drugs whose gastrointestinal absorption increases
after meals--griseofulvin (Crounse 1961; Kabasakallan et al.
1970), lithium (Jeppson and Sjogren 1975), nitrofurantoin (Bates
et al. 1974; Reidenberg and Vesell 1975), diazepam (Korttila and
Kangas 1977; Korttila et al. 1976), and riboflavin (Jusko and Levy
1967; Levy and Jusko 1966)--explanation is offered “in terms of
delayed gastric emptying and gastrointestinal transit which allows
more complete dissolution or prolonged residence at a site in the
intestine from which absorption is optimum” (McLean et al. 1978).
Divergent effects of meals on drug disposition depend on the
pharmacologic  prof i le  of  the drug,  i ts  formulation,  and the
composition and size of the meal. Excellent reviews (Melander and
McLean 1983; Welling et al. 1975) of the effeots of meals on drug
absorption obviate detailed discussion here. Only the
pharmacologic principles that determine the results of these food-
drug interactions wil l  be described. Application of  these
principles requires recognition that food-drug interactions may be
markedly modified by numerous host factors, such as age and
general condition of the patient; cardiovascular, hepatic, and
renal function; intercurrent diseases; and whether the patient is
ambulatory or bedridden (Welling et al. 1975). The appreciable
influence of numerous host factors (rarely defined adequately in
i n d i v i d u a l  s t u d i e s  o n  t h i s  s u b j e c t )  m a y  e x p l a i n  f r e q u e n t
inconsistencies in the literature.
Two pharmacologic principles determine how food affects drug
absorption from the gut. Food enhances gastric blood flow but
retards gastric emptying. S ince  the  ra te  o f  d i f fus i on  o f  a
chemical across a capillary is a function of its concentration
gradient across the capillary membrane, meal-induced increases in
splanchnic blood flow should accelerate drug absorption from the
gut lumen to the capillary. Complexity in practical application
of this seemingly simple principle arises from the fact that the
effect  on blood f low depends greatly  on meal  content,  i .e . ,
chemical composition of the food. Blood flow can be doubled by a
high-protein liquid meal and slightly reduced by a liquid glucose
meal (Brandt et al. 1955). Effects of meal-induced enhancement of
splanchnic blood flow on drugs with high hepatic extraction are of
special significance and are discussed separately below.
The second fundamental principle is that meals slow the rate of
gastric emptying, thereby delaying rate of drug absorption from
the gastrointestinal tract. The influence of this factor on rate
of drug absorption is more complicated than might be suspected.
Changes in gastric emptying depend not only on the type of drug,
but also on the type of meal, as different foods have different
effects on gastric emptying. Delayed emptying is caused by hot
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meals (Davenport 1961), solutions of high viscosity (Levy and
Jusko  1965 ) ,  f a t ,  and ,  t o  l e s se r  ex tents ,  by  p ro te ins  and
carbohydrates (Bachrach 1959). Compared to liquid meals, solid
meals almost double emptying time of the stomach (Marcus and
Lengemann  1962).
Complexity is further increased because the nature of the drug
under consideration can modify this  ef fect . Pharmacologic
properties of drugs that influence absorption from the gut and,
thus ,  cause  var iab l e  e f f e c t s  on  gas t r i c  empty ing  inc lude
solubility and stability in the highly acidic gastric juices as
well as the llpophilic character of the dissolved drug molecules,
e.g., whether the drug is ionized (thus, relatively resistant to
passage) or not ionized (hence, readily traversing lipid mem-
branes) at gastric pH. The Important role of pH in drug absorption
is illustrated by the effect of antacids in altering rate but not
extent of diazepam absorption (Greenblatt et al. 1978).
After passage from the stomach to the small intestine, food
stimulates intestinal motility, thereby accelerating dissolution
of solid particles. Food also simultaneously decreases passage of
drugs from diffusion across intestinal mucosa by accelerating
their motion through the intestine. Further complication arises
from the fact that some foods, especially fat, stimulate bile flow
and secretion. As surface-active agents, bile salts enhance
dissolution of poorly soluble drugs, thereby accelerating drug
absorption (Gibaldi and Feldman 1970). On the other hand, bile
salts can impede absorption by forming insoluble complexes with
other drugs (Bates and Gibaldi 1970).
The pharmacologic character of the drug determines the precise
proportion absorbed in the stomach and in the small intestine. In
general, relatively little drug absorption occurs in the stomach
as compared to that in the small intestine, because of greater
surface area in the latter. By retarding stomach emptying, food
delays drug absorption, which takes place mainly in the small
intestine. Particular pharmacologic properties, such as weak
basicity or transportation by active carrier mechanisms, render
some drugs more likely than others to be absorbed in the small
intestine. Thus, complex characteristics of the patient, drug,
food, and physiologic mechanisms of gastrointestinal absorption
render difficult predictions and interpretations of how meals
ultimately influence drug absorption in a given patient at a given
time.
This  sect ion c o n c l u d e s  w i t h  a n  i l l u s t r a t i o n  o f  a  p r o b l e m
associated with literal interpretation of principles governing the
influence of enhanced gastric blood flow on drug absorption. Let
us consider model drugs with high intrinsic clearance. Several
investigators have reported that meals elevated plasma
concentrations of  such drugs subject  to  extensive f irst-pass
effect, including propranolol (McLean et al. 1981; Melander et al.
1977), metoprolol (Melander et al. 1977), and lidocaine (Elvin et
a l .  1 9 8 1 ) .  A f t e r  h i g h  p r o t e i n  m e a l s ,  t h e  i n c r e a s e  i n  o r a l
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bioavailability of drugs subject to large first-pass effect has
been attributed to the enhanced hepatic blood flow associated with
such meals. The area under the curve (AUC) after intravenous
(i.v.) dosing is decreased for such drugs, while it is increased
after oral dosing; the kinetic basis for this difference has been
reported (Elvin et al. 1981).
Enhanced blood flow presumably serves to allow such high-
extraction drugs to  pass rapidly through the l iver ,  thereby
escaping hepatic removal and causing higher drug concentrations in
s y s t e m i c  c i r c u l a t i o n .  L i d o c a i n e  k i n e t i c s  w e r e  e v a l u a t e d
t h o r o u g h l y  b e f o r e  a n d  a f t e r  a  m e a l ;  e n h a n c e d  s y s t e m i c
bioavailability of oral lidocaine after a meal was attributed
entirely to transient food-induced elevations in rate of perfusion
of the splanchnic vascular bed (Elvin et al. 1981). Whereas
alterations in rates of hepatic lidocalne metabolism or of protein
binding of lidocaine could hypothetically have induced similar
results, Investigation of these possibilities indicated that these
measures did not ohange after meals. Thus, alteration in hepatic
blood flow was induced by food alone (Elvin et al. 1981). Several
recent studies, however, offered a different view. A  thorough
computerized simulation performed to predict the magnitude of
change that meals produce in apparent oral bioavallability of
propranolol revealed that the meal-induced increase in hepatic
blood flow was of too short a duration to explain the extent to
which the bioavailability of an oral dose of propranolol rose
(Svensson et al. 1983). The authors concluded that “the effect of
food on drug metabolism appears to be a complex and time-dependent
p r o c e s s  r e q u i r i n g  f u r t h e r  i n v e s t i g a t i o n . ”  I n  a n o t h e r
investigation, they tested their conclusion by measuring clearance
o f  i n d o c y a n i n e  g r e e n  g i v e n  i . v . b e f o r e  a n d  a f t e r  a  h i g h
carbohydrate meal in six normal subjects (Svensson et al. 1984).
Again, they concluded that the meal-induced Increase In hepatic
blood flow probably made only a very small aontribution to the
increase in propranolol bioavailability (Svensson et al. 1984).
Related observations on altered aminopyrine disposition after
meals have been reported by Shively et al. (1981). In normal men,
aminopyrine t 1/2 was 34% longer acting and apparent volume of
disposition was 33% larger 3 hours after meals than during
fasting. Plasma protein binding of aminopyrine was reduced by
meals, explaining in part the meal-induced increase in aminopyrine
apparent volume of disposition. Melander and McLean (1983)
thoroughly and critically reviewed the influence of food on the
presystemic c learance of  drugs.  Meals  commonly accelerate
presystemic clearance of lipophilic bases (such as propranolol and
amitriptyline), but rarely alter that of lipophylic acids (such as
sal lcyl lc  acid and penici l l in) , although esters of such acids
(acetylsallcylic acid and pivampicillin) are subject to this meal-
induced effect (Melander and McLean 1983). See Helling (1984) for
the most recent review on effects of meals on gastrointestinal
absorption of drugs.
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DIETARY FACTORS THAT AFFECT DRUG METABOLISM
Pioneering experiments demonstrated that several discrete dietary
factors could alter the rate of drug metabolism and produce clear
results that have frequently been reviewed (Anderson et al. 1982;
Conney et al. 1977, 1980; Kappas et al. 1977; Vesell 1980). They
n e e d  o n l y  b e  s u m m a r i z e d  h e r e .  A n t i p y r i n e ,  t h e o p h y l l i n e ,
phenacetin, and acetaminophen served as model drugs in these
studies. Carefully selected normal subjects received an oral dose
of one of these drugs before, during, and after a single dietary
manipulation lasting 3 to 14 days. All other environmental
factors during the studies were controlled as rigidly as possible.
The present inquiry will focus on the question of how much these
and related dietary factors contribute to large interindividual
variations in rates of drug metabolism.
Results of these studies showed that: 1) On a dally diet of 2,500
calories, a high ratio of protein (44%) to carbohydrate (35%)
content enhanced antipyrine and theophylline metabolism, whereas a
high ratio of carbohydrate (70%) to protein (10%) content retarded
their biotransformation (Kappas et al. 1976). Substitution of fat
for  carbohydrate did not  s ignif icantly change these results
(Anderson et al. 1979), which recently were extended from an
entirely oral route of dietary intake to a completely i.v. one
(Vesell 1984a). 2) Ingestion of charcoal-broiled beef increased
the rate of antipyrine and theophylline metabolism (Kappas et al.
1978), but not that of acetaminophen (Anderson et al. 1983). The
rate of biotransformation of phenacetln was not changed, although
charcoal-broiled beef induced a large first-pass effect, thereby
appreciably reducing plasma phenacetin concentrations (Conney et
al. 1976). 3) Cruciferous vegetables in large amounts induced the
metabolism of antipyrine and theophylline (Pantuck et al. 1979)
and the glucuronidation of acetamlnophen (Pantuck et al. 1984a).
4), Theobromine acetate in high concentrations retarded its rate of
biotransformation (Drouillard et al. 1978). Theobromine is a
major constituent of chocolate, and the same dose of theobromine
taken in chocolate rather than as the salt did not alter its
metabolism, presumably because of its reduced bioavailability In
chocolate. 5) Starvation of obese subjects for 10 days did not
alter antipyrine or tolbutamlde disposition (Reidenberg and Vesell
1975), but antipyrine metabolism was impaired in Indian (Narang et
al. 1977) and Sudanese (Homeida et al. 1979) children with protein
malnutrition. Nutrit ional  rehabi l i tat ion of  these chi ldren
restored antipyrine kinetics to normal. A few of the factors shown
in the outer circle of figure 2 have not been studied in man; but
in laboratory animals, they have been shown to affect drug
metabolism and disposition.
TO WHAT EXTENT DO DIETARY FACTORS CONTRIBUTE TO INTERINDIVIDUAL
VARIATIONS IN DRUG METABOLISM?
The preceding studies, each performed on a different dietary
factor, were carefully controlled: only a single dietary variable
was altered independently of all others. Furthermore, subjects
were selected so that their hepatic cytochrome P-450-dependent
monooxygenases would be under stable, near-basal conditions
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(neither markedly induced nor Inhibited through the potential
influence of numerous environmental perturbations) (Anderson et
a l . 1982; Conney et al. 1977, 1980; Kappas et al. 1977; Vesell
1980, 1982). None of the subjects took any drug regularly, smoked
cigarettes, or drank alcohol chronically. A single  dietary
manipulation could be Introduced under these well-defined, uniform
environmental conditions. Any alteration in rate of metabolism of
a model drug (such as antipyrine) or the theophylline aould serve
as  a  re l iable , sensit ive index of  the ef fect  of  that  speci f ic
nutritional change on the subject’s hepatic drug-metabolizing
capacity. Use of each carefully selected subject as his or her own
control eliminated not only all genetia but also most extraneous
environmental sources of variation in drug metabolism. Therefore,
alteration o b s e r v e d  i n  d i s p o s i t i o n  o f  a  m o d e l  d r u g  a f t e r
imposition of a single dietary manipulation could reasonably be
ascribed to that nutritional change alone. Furthermore, this
experimental design permitted results to be verified in several
ways. The effect could be reproduoed in the same or in other
subjects. Dose-response relationships could be generated between
the particular dietary factor investigated and subsequent change
in model drug metabolism.
How far can these well-established, verified results on dietary
faators in normal subjects under near-basal aonditlons be extended
to other more complicated dynamic ciraumstanaes, such as those
prevailing among patients whose environments may be rapidly
changing in complex ways? What portion of total interindividual
variation among such patients, and among normal subjects with
unrestricted l i festyles, can be attributed to dietary factors?
These difficult questions cannot be answered simply. Complex
interactions between numerous factors probably explain the
totality of interindividual variation that occurs in rates of drug
metabolism among all subjects. In some individuals, dietary
considerations may play a major role, as as can smoking, age, and
genetic factors; or, several factors may share equally or interact
with these and additional factors to account for variability.
This discussion emphasizes the complexity of interactions that may
occur when all subjects are included. Interactions can take place
not only among different types of environmental factors, but also
among dietary factors themselves (figure 2). Therefore, the
magnitude of alteration in drug metabolism lnduaed by manipulation
o f  o n l y  s i n g l e  d i e t a r y  f a o t o r s  i n subjects under carefully
controlled environmental conditions needs to be compared to the
m a g n i t u d e  o f  t o t a l  i n t e r i n d i v i d u a l  v a r i a t i o n  i n  r a t e s  o f
metabolism of the same model drugs before imposition of any
dietary change. Since several dietary alterations can ahange a
subject’s rate of drug metabolism, It might be expected that these
dietary factors account for a large proportion of the extensive
variation among normal subjects. The latter, however, does not
necessarily follow from the former well-established observations,
and It remains to be determined whether such extrapolations are
valid.
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With respect, to changes in antipyrine and theophylline metabolism
after  imposit ion of  diets  high in cruci ferous vegetables  and
charcoal-broiled beef, relatively small alterations (10% to 20% of
basal) are caused by these dietary manipulations. Such changes
are an order of magnitude less than those observed among normal,
carefully selected subjects of the same age and sex, who use no
drugs, are nonsmokers, and are not excessive users of alcohol
(Penno et al. 1981; Penno and Vesell 1983). Alvan (1978) doauments
600% interindividual  variat ion in antipyrine c learance in a
representative number of  subjects .  Hence,  these particular
dietary factors might initially appear to play only a very small
role in accounting for the 600% interindividual variation in
antipyrine metabol ism among normal  subjects  under basal
environmental conditions. Although each factor may play a small
role by itself, a much larger synergistic effect could emerge in
combination with other factors. Figure 2 was designed to suggest
this  possibi l i ty  and shows each dietary factor  in dynamic
interaction with other dietary as well as environmental and
genetic factors.
While the magnitude of metabolic change contributed by large
shifts in the proportion of protein to carbohydrate content on an
isocaloric diet is larger than that of diets high In cruciferous
vegetables, It is still considerably less than the 600% interin-
dividual variation that is common when antipyrine kinetics are
compared in at least 12 normal subjects (Alvan 1978; Penno et al.
1981; Penno and Vasell 1983). Here again, It might initially
appear that even a very marked manipulation in the ratio of protein
to carbohydrate content might be insuff ic ient  to  contribute
substantially to the much larger interindividual variations among
normal subjects in rates of drug metabolism. Superficially, such
a conclusion might seem to be supported by the observation of no
change in antipyrine clearance after starvation of obese subjects.
Studies on starvation, however, are compatible with a major effect
of changing the proportion of the macromolecular constituents of
isocalorlc  diets . This reconciliation of seemingly contradictory
results offers an opportunity to stress the complex effects of
several dietary factors and the possibility for interactions among
them. Why doesn’t starvation change antipyrine metabolism, when
switching the proportion of carbohydrate to protein aontent alters
antipyrine metabolism profoundly? Possibly, the body is more
sensitive to the former dietary manipulation than to the latter.
Through detection of the gross diet change from starvation for a
limited time, the body can compensate by providing the amino acids
required for protein synthesis from another source. In contrast,
the body may not be able to detect and, hence, compensate for a
much more subtle switch in the proportion of calories supplied as
either carbohydrate or protein. If this change is uncompensated,
depletion of protein could reduce rates of synthesis of hepatic
drug-metabolizing enzymes, which, in turn, could induce retention
of antipyrine and theophylline.
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Although fasting greatly alters hepatlc metabolism of some drugs
in rodents (Dixon et al. 1960; Furner and Feller 1971; Kato and
Gillette 1965), no change in drug metabolism occurred in obese,
but otherwise healthy, human subjects after 7 to 10 days on a diet
i n  w h i c h  t o t a l  d a i l y  c a r b o h y d r a t e  i n t a k e  w a s  u n d e r  1 5  g
(Reidenberg and Vesell 1975). This diet induced ketoaaldosls and
weight loss ranging from 4 to 15 kg. When uncorrected for body
weight, the apparent volume of distribution of both antipyrine and
tolbutamlde was lower after fasting than before, presumably
because, during fasting, the early loss of body weight is mainly
from body water rather than from fat stores or muscle mass
(Reidenberg and Vesell 1975). In each subject, the extent of
decrease in the apparent volume of distribution was proportional
to loss of body weight; and when correction was made for body
weight, fasting had no effect on apparent volume of distribution
of either antipyrine or tolbutamide. These results, extended to
o ther  hepat i c  mi c rosomal  ox ida t i ons ,  Inc lud ing  those  f o r
s u l f i s o x a z o l e ,  i s o n i a z i d ,  a n d  p r o c a i n e  ( R e i d e n b e r g  1 9 7 7 ) ,
disclosed that, when allowance was made for body weight, neither
half-life values nor rates of hepatia metabolism of these drugs
changed in otherwise normal obese subjects who fasted 7 to 10 days.
Severa l  r ev i ews  that  desc r ibe  e f f e c t s  o f  obes i ty  on  drug
disposition suggest that volumes of distribution of certain drugs
are increased in obesity. The extent of this increase appears to
correlate with the lipid-solubllity of the drug (Abernathy and
Greenblatt 1982; Abernethy et al. 1984).
General conclusions on the failure of absolute fasting to alter
hepatlc drug metabolism in normal subjects or in subjects without
liver dysfunction were extended by a study of seven female
subjects, which confirmed classic anorexia nervosa (Bakke et al.
1978) .  In these subjects ,  prolonged refusal  to  eat  induced
differing degrees of dehydration, hyponatremia, hypoahloremia,
hypokalemia, and anemia. When compared with age- and sex-matched
normal nurses who served as aontrols and when values were
corrected for body weight, the subjects with anorexia had normal
antipyrine kinetics.
A study on Asian Indian subjects (Krishnaswamy and Naidu 1977)
revealed that in 15 men suffering from nutritional edema--a severe
manifestation of protein deficiency and resultant hypoalbumlnemia
--the mean plasma antipyrine half-life of 12.8 hours did not
differ from that of age- and sex-matched nonsmoking controls (11.2
hours), but it was higher than that of age- and sex-matched smoking
controls (8.9 hours). In the same study, another group of 13
undernourished, underweight men without edema had a short mean
antipyrine half-life of 8.6 hours (same range as that of smoking
controls); this could be because some of these 13 subjects smoked,
some drank alcohol, and some were agricultural laborers exposed to
pesticides known to induce hepatic drug-metabolizing enzymes.
Thus, in this study, severe malnutrition did not alter antipyrine
disposition, supporting observations a l ready  desc r ibed  f o r
subjects with anorexia nervosa and for obese, but otherwise
normal, subjects after a fast of 7 to 10 days. Several problems,
however, including chronic exposure of some subjects to inducing
chemicals, render the results inconclusive.
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In a s ignif icant  contribution,  phenylbutazone kinetics  were
measured in four normal male Asian Indian controls (mean age, 30
years) and in five undernourished male Asian Indian subjects with
hypoalbuminemia (mean age, 36 years), none of whom smoked
cigarettes or consumed alcohol for prolonged periods (Adithan et
al. 1978). The malnourished group had shorter mean plasma
phenylbutazone half-lives, but larger mean phenylbutazone apparent
volume of distribution and metabolic clearance, than did the
controls .  These deviat ions in phenylbutazone disposit ion in
undernutrition presumably arose as a result of reduced binding of
phenylbutazone to albumin, with a corresponding increase in drug
availability for metabolism and elimination.
A STATISTICAL APPROACH TO DETERMINE CAUSES OF LARGE INTER-
INDIVIDUAL VARIATIONS IN DRUG METABOLISM RATES
I s o l a t i o n  a n d  i n v e s t i g a t i o n  o f  e a c h  e n v i r o n m e n t a l  f a c t o r
Independent of all others and under rigidly controlled conditions
offer advantages enumerated above. Nevertheless, as we have also
seen,  this  method does not  permit  easy extrapolation to  a
different circumstance and a different question: How much of
total extensive interindividual variation in drug metabolism in a
large population under nonbasal conditions oan be accounted for by
each dietary factor alone?
Statistical approaches to this question have been attempted. In
g a t h e r i n g  1 2 8  f a c t o r y  w o r k e r s  i n  L o n d o n ,  i n v e s t i g a t o r s
deliberately chose subjects with different environments (Fraser et
al .  1979) .  Antipyrine was then given onoe to  each of  these
subjects. A computerized program based on multiple regression
analysis was used to relate antipyrine clearance of each subject
to numerous anthropometric and biochemical indices of nutritional
status. Five variables correlated independently with antipyrine
c l earance :  race ,  c ont racept ive  p i l l  usage ,  smok ing  s ta tus ,
ponderal index (weight/height2), and serum albumin concentration
(Fraser et al. 1979). Because coefficients for race and diet were
virtual ly  identical , the investigators concluded that it was
impossible to analyze the role of one factor independently of the
other. Most of their Asian Indian subjects were vegetarians,
whereas almost all of their population of white Londoners ate
meat; furthermore, many were subject to such additional
environmental  perturbations as  c igarette  smoking and oral
contraceptives.
Recognizing that  rel iable  conclusions regarding the role  of
dietary factors in large interindividual variations in antipyrine
kinetics were impossible in this mixed and, hence, hopelessly
confounded experimental situation, the investigators decided to
apply their statistical method to another group of less confounded
subjects. The second group was considered more amenable to
investigation by multiple regression analysis because it was
racially homogeneous. Subjects in the second study were 36
healthy adult Indo-Pakistani immigrants to Britain. Among these
subjects ,  antipyrine c learance was much slower in the 16
lactovegetarians (0.54 ± 0.06 ml min-1 kg-1) than in the 20 regular
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meat eaters (0.91 ± 0.07 ml min-1 kg-1) (Mucklow et al. 1982).
Since absence of  meat from the diet  was associated with a
significantly smaller daily intake of dietary protein (which, in
the 16 lactovegetarians, was abnormally low by Western standards),
Mucklow and coworkers concluded that this difference in daily
pro te in  in take  was  the  pr inc ipa l  cause  o f  d i f f e rences  in
antipyrine clearance,
The investigators recognized, however, that their methods are open
t o  c r i t i c i s m .  F o r  e x a m p l e ,  M u c k l o w  e t  a l .  ( 1 9 8 2 )  s t a t e :
“Retrospective dietary assessments made at a single interview,
even when this is conducted by an experienced dietician, are open
to criticism since they rely heavily upon the memory of the subject
interviewed, the estimates of quantity made by the dietician, and
subsequent expression of those quantities in mass units. The
opportunity for error is clearly increased when the interview is
conducted through an interpreter.” The 16 lactovegetarians had
high standard deviations in mean antipyrine clearance. This
extensive interindividual variation in antipyrine kinetics within
a population uniform with respect to low protein intake clearly
must arise from other factors. The investigators also attempted
to identify some alternative sources for these interindividual
variations: “significant correlations occurred between antipyrine
c l e a r a n c e  a n d  a g e ,  s e x ,  r e l i g i o n ,  s m o k i n g ,  h e m o g l o b i n ,
kilocalories, carbohydrate, and fat. No significant correlation
was observed between antipyrine clearance and weight, coffee/tea
index, alcohol intake or plasma albumin.” But, they did not
attempt to  relate  the socioeconomic or  educational  level  of
subjects to their dietary habits, particularly protein intake.
This and additional confounding factors might have influenced
results.
Even for this limited group of 36 Indo-Pakistanis, the methodology
left the major conclusion open to question because, as Mucklow and
coworkers (1962)  state ,  “when non-vegetarians alone were
cons idered ,  there  was  no  s i gn i f i cant  c o r re la t i on  be tween
a n t i p y r i n e  c l e a r a n c e  a n d  d a i l y  m e a t  i n t a k e ,  r a i s i n g  t h e
possibility that one or more other dietary factors might be of
greater importance. Moreover, many of the variables correlated
significantly with each other as well as with clearance. Stepwise
multiple  regression analysis  was therefore performed and
identified smoking, age and fat intake as independent correlates
with clearance.” Other discrepancies merit attention. Again,
according to the investigators, since “daily protein intake was
significantly lower amongst vegetarians, while daily fat intake
was similar  in the two subgroups, i t  was  surpr i s ing  that
regression analysis identified fat intake as the only independent
dietary correlate with antipyrine clearance.” This anomaly should
be considered in light of the carefully controlled dietary studies
by Anderson et al. (1979) that assigned a small role to fat in
antipyrine kinetics, and in connection with the inconsistency of
these results on albumin with those of a previous study by Fraser
et al. (1979). Collectively, these difficulties suggest that the
statistical approach used here and elsewhere (Fraser et al, 1976)
may yield irreproducible, erroneous results.
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In an earlier study with multiple regression analysis to determine
the basis of interindividual variations in antipyrine clearance
among 49 Gambians (Fraser et al. 1976), the principal causative
factor identified was another nutritional factor, the number of
cola nuts chewed per day (r = 0.4). In a prospective study on an
e n t i r e l y  d i f f e r e n t  p o p u l a t i o n  o f  c a r e f u l l y  c o n t r o l l e d ,
environmental ly  stable  normal  men l iv ing in south-central
Pennsylvania, chewing cola nuts did not alter antipyrine clearance
(Vasell et al. 1979). Because of multiple genetic and environ-
mental  di f ferences between the groups investigated,  these
apparently conflicting results are not necessarily contradictory.
Nevertheless, their divergence emphasizes the crucial role played
by the criteria used to select methods to analyze data and subjects
to receive drugs. This group has extensively applied their
statistical method to determine causation of large interindividual
kinetic variations without describing strengths and weaknesses;
therefore, o thers  have  a t t empted  t o  c r i t i ca l l y  assess  th i s
application of multiple regression analysis (Vasell 1984a; Vesell
and Penno 1983). While  this  statist ical  method has great
potential, i t  requires  considerable  modif ication beyond its
init ial  appl icat ions in this  area (Fraser  et  al .  1976,  1979;
Mucklow et al. 1982) if that potential is to be realized (Vesell
1984a; Vesell and Penno 1983). Thus far, its applications in
kinetics (Fraser et al. 1976, 1979; Mucklow et al. 1982) have been
disappointing, as those who have used it neither formulated nor
addressed,  much less  demonstrated ful f i l lment of ,  several
fundamental assumptions inherent in its use (Vasell and Penno
1983 ) .  As  no ted  above ,  c on t rad i c t o ry  f ind ings  emerged  in
different applications (Fraser et al. 1976, 1979; Mucklow et al.
1982; Vesell and Penno 1983).
Four fundamental assumptions of the particular statistical model
used are dubious when applied to investigations of sources of
in te r ind iv idua l  d i f f e rences  in  ant ipyr ine  k ine t i c s  and  are
described in detail elsewhere (Vesell 1982, 1984a; Vesell and
Penno 1983). Briefly, too few subjects are used to be
representative of the population from which they are derived; the
m e t h o d  h a s ,  t h u s  f a r ,  f a i l e d  t o  a c c o u n t  f o r  m o s t  o f  t h e
intersubject variability; the results are conflicting and they
d i f f e r  f r o m  m u c h  e a r l i e r  w o r k  o n  a g e ,  s e x ,  a n d  g e n e t i c
constitution (Vesell and Penno 1983). The potential of multiple
regression analysis to resolve sources of kinetic variations is
much greater than has been realized by the particular model used.
The technique itself is both sensitive and powerful. For multiple
regression analysis to be used appropriately, however, a model
must be developed that encompasses nonlinear as well as linear
relationships (Cohen and Cohen 1975). With antipyrine, only a
linear model has, thus far, been used. Error terms especially need
to be appropriately modeled, rather than treated in a simply
addit ive manner as in past  applications of  this  method.  In
contrast to the use of this statistical approach in the assessment
of variations in antipyrine kinetics, investigators who applied
this model in the assessment of factors that cause large interin-
dividual variations in theophylline clearance clearly recognized
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its limitations and the requirement that the conclusions be
considered only tentative until tested by a prospective controlled
experiment (Jusko et al. 1979). The investigators state that:
“The factors  identi f ied as important in theophyll ine body
clearances are associations found by retrospective statistical
analysis which need not imply a cause-and-effect relationship,
especial ly  where a pathophysiological  or  drug interact ion
rationale  does not  exist . Often these factors need further
confirmation by prospective examination of cohorts of subjects
with the disease or history in question.”
A THIRD APPROACH TO ASSESSMENT OF DIETARY CONTRIBUTIONS TO
INTERINDIVIDUAL VARIATIONS IN DRUG DISPOSITION.
The magnitude of interindividual variation shown in table 1 for
some drugs can depend on the drug selected for study, the number of
subjects  studied,  the particular population from which the
subjects are drawn, and the "condition" of the subjects, including
their present and past health, genetic constitution, age, sex,
diet , and exposure to environmental chemicals and drugs that
induce or inhibit hepatic mixed-function oxidases. Also, the
e x t e n t  o f  i n t e r i n d i v i d u a l  v a r i a t i o n  c a n  r e f l e c t  c o m p l e x
interactions among these and other sources (figures 1 and 2). Even
in the same subject ,  however,  kinetic  values can f luctuate
markedly from one study to another if any of these factors change.
As already suggested, results of previously published reports also
reflect the specific method used and the degree to which the
assumptions underlying each method are fulfilled. Accordingly,
this review stresses the characteristics of each method and the
assumptions upon which it is based.
It should be emphasized that when subjects are under basal
environmental conditions with respect to the many factors that can
affect hepatic drug oxidation and when, accordingly, their hepatic
drug-metabolizing enzymes are relatively uninduced and uninhib-
ited, large interindividual variations still remain (table 1).
Although well established, this important fact is often ignored.
Thus, under near-basal conditions, large interindividual kinetic
variations cannot  be attr ibuted convincingly to  any speci f ic
environmental factor. Twin and family studies have indicated that
these large interindividual kinetic variations in subjects under
near-basal environmental conditions arise from genetic factors
(Penno et al. 1981; Penno and Vesell 1983; Vesell 1982, 1984a;
Vesell and Penno 1983). Nevertheless, under other conditions in
which environmental factors are permitted to exert a differential
(unequal) influence, this pattern of genetic transmission can be
concealed. The major portion of  interindividual  variat ion
observed can then be attributed solely to environmental sources,
because underlying genetic factors that are also operative become
unrecognizable by conventional methods of detection. Accordingly,
the answer to the difficult question of what role nutritional
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f a c t o r s  p l a y  i n  m a i n t a i n i n g  l a r g e  i n t e r i n d i v i d u a l  k i n e t i c
variations in normal  subjects  l iving unrestricted l i festyles
depends on the specific characteristics of the subjects selected,
the extent of environmental perturbation, and the particular
combination of environmental factors that exert effects on these
subjects at any given time. Results obtained in such studies will
often reflect, in large measure, the methods used.
To elucidate these precise relationships, a slightly different
approach from those thus far undertaken is recommended. This
approach incorporates parts of the several methodologies described
above. Selection of normal subjects with unrestricted lifestyles
is adopted from studies that used multiple regression analysis.
The part adopted from carefully controlled studies on subjects
under uniform near-basal environmental conditions is manipulation
of  s ingle  nutrit ional  factors  independent of  al l  others with
repeated use of the model drug to obtain kinetic measurements
before, during, and after this single dietary change. Such an
experimental design should permit assessment of the influence of a
single dietary change (generally, withdrawal of a particular
dietary factor) on model drug kinetics. For example, in normal
sub je c t s  l i v ing  an  unres t r i c t ed  l i f e s ty l e ,  subs t i tu t i on  f o r
several weeks of a vegetarian diet for one in which meat plays a
principal  part  could be assessed with respect  to  antipyrine
kinetics. All other dietary and environmental conditions of the
subjects in such a study should remain as constant as possible. In
separate experiments,  ef fects  of  cruci ferous vegetables and
charcoal-brolled beef could be estimated by removing each from the
diet for several weeks and comparing the kinetics of a model drug
before, during, and after such withdrawal.
The influence of such variables as age, sex, smoking, alcohol,
o ra l  c on t racept ives ,  t o ta l  ca l o r i e s ,  r e la t i ve  propor t i on  o f
m a c r o m o l e c u l a r  c o n s t i t u t e n t s  o f  t h e  d i e t ,  e x e r c i s e ,  a n d
environmental exposure to certain prevalent chemicals would
eventually need to be recognized and, to some extent, tested
before the generality of any conclusions drawn in one group of
s u b j e c t s  c o u l d  b e  e x t e n d e d  t o  o t h e r  g r o u p s .  A s  a l r e a d y
emphasized,  on repetit ion under perturbed environmental
conditions, normal subjects are more variable in thin kinetic
v a l u e s  t h a n  a r e  s u b j e c t s  u n d e r  n e a r - b a s a l  e n v i r o n m e n t a l
conditions. Therefore, the suggested experimental design needs to
establish the extent of intraindividual variation in each subject;
that is, kinetic values should be measured in each subject several
t imes  be f o re  d i e tary  man ipu la t i on .  In  s ome  sub j e c t s ,  the
magnitude of intraindividual variation may possibly reach or,
perhaps,  exceed that  obtained after  imposit ion of  a  speci f ic
dietary change. Such studies are laborious, time-consuming; and
technically difficult to undertake, but they may represent the
next step in the extension of conclusions on dietary factors from
normal subjects under near-basal environmental conditions to
subjects under environmentally perturbed conditions.
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In this connection, a study revealed markedly altered therapeutic
responses secondary to a change in drug kinetics produced by
switching the proportion of macromolecular constituents in the
diet . In 14 children with asthma, theophylline kinetics were
accelerated by a diet high in protein content and retarded by a
diet high in carbohydrate content (Feldman et al. 1980). Of
particular interest  with respect  to  this  discussion was the
observation that, within each of the three dietary groups, the
extent of interindividual variation was in the same range (300%)
(Feldman et al. 1980). Therefore, under none of these three
d i f f e r e n t  d i e t a r y  c o n d i t i o n s  d i d  t h e  p r o p o r t i o n  o f  t h e
macromolecular constituents of the diet appear to account for the
300% interindividual variations in theophylline clearance. More
studies of this kind should be performed to assess the proportion
of total interindividual pharmacokinetic variation ascribable to
dietary factors.
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Interactions of Cannabis With
Other Drugs in Man
Leo E. Hollister, M.D.
Interactions of cannabis constituents with other drugs are of
interest because cannabis is often used in the context of other
drugs. Of the many constituents present in cannabis, or in
marijuana smote, only a few can be studied in any systematic way.
These are the cannabinoids, such as the major active component,
delta-9-tetrahydrocannabinol (THC), as well as those without
psychoactivity, such as cannabinol (CBN) and cannabidiol (CBD).
Many possible interactions of cannabinoids might be studied.
Pharmacodynanic interactions would mainly involve THC, as the
other cannabinoids have little direct evidence of pharmacological
activity in man. Pharmacokinetic interactions might involve any
of the cannabinoids, as well as possibly still unstudied or
unidentified materials in marijuana. Interactions might be
tested between THC and drugs that might be used as probes for
investigating the mechanism of action of THC. Finally, some
interactions may depend on characteristics of the users, such as
their idiosyncratic metabolism of the drug, or the psychological
effects of the setting in which the drug is taken as well as the
expectations of individual subjects.
PHARMACODYNAMIC INTERACTIONS
Ethanol
This drug is commonly taken concomitantly with the use of
marijuana, with the idea that it will augment the effects of the
latter drug. Such an assumption is well based, as both drugs
have similar actions. At low doses they tend to produce euphoria
and stimulation; at higher doses, sedation. Comparison between
ethanol and THC confirmed the similarities, the major distinction
being the more distorted time sense and hallucinogenic action of
THC (Hollister and Gillespie 1970). One might guess that their
effects would be additive. Adding ethanol to both high and low
doses of THC increased impairment on several measures, as well as
adding to subjective experiences (Manno et al. 1971).
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Sedatives
A situation similar to that of ethanol should prevail with
sedatives, but studies in man are few. Numerous studies in
animals support an additive effect. In man, THC given after
pentobarbital pretreatment induced hallucinations and anxiety in
five of seven volunteers, to the extent that four did not
complete the course of five doses of THC because of the severe
psychologic effects (Johnstone et al. 1975). The same
investigators found that in man THC potentiated the sedative and
respiratory depressant effects of the opioid oxymorphone.
Cardiovascular effects of THC seemed to be unaltered by the
presence of either drug. A second study in man confirmed an
additive effect when THC was combined with 150 mg secobarbital/70
Kg. No such interaction was found with CBD (Lemberger et al.
1976).
Stimulants
Stimulants combined with THC have relatively little effect in
man, seeming to act in a mildly additive fashion. A dose of 15
mg of dextroamphetamine in man followed by smoking an equivalent
of 15 mg THC from marijuana cigarettes revealed separate effects
from both drugs: marijuana caused tachycardia and conjunctival
injection; dextroamphetamine increased blood pressure and
respiratory rate. The impairment of performance on cognitive
tests produced by marijuana may have been overcome by dextro-
amphetamine, which improved performance when given alone (Zalcman
et al. 1973). Similar additive effects were seen in subjects
given 10 mg/70 Kg doses of dextroamphetamine and 50 ug/Kg doses
of THC by smoking. In this case, dextroamphetamine did not
counter the adverse effects of marijuana on motor performance
(Evans et al. 1974). Instances of combined use of amphetamines
and marijuana are infrequent in social practice. One would guess
that when they occurred, doses of amphetamine would be
considerably higher than those given experimentally. No studies
have examined an interaction with cocaine in man.
Other Cannabinoids
Two other major cannabinoids, CBN and CBD, are inevitably taken
with THC when marijuana is smoked. Their proportions may vary
considerably from one marijuana batch to another. Experiments
have been contradictory both in animals and man. Doses of from
15 to 60 mg of CBD orally were said to block the effects of 30 mg
oral doses of THC (Karniol et al. 1974). A similar finding was
reported from another study which showed attenuation of the
psychic “high” (Lemberger et al. 1976). CBD had no effect on the
action of barbiturates. On the other hand, smoked marijuana was
said to produce greater subjective , congitive, and physiological
effects than smoked THC in equivalent doses. Thus, the miniscule
amounts of CBN and CBD in marijuana seemed to enhance rather than
block effects (Galanter et al. 1973). A slight effect was seen
from 40 mg oral doses of CBD combined with 20 mg oral doses of
THC. Onset of THC effects was delayed, slightly prolonged, and
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slightly more intense. Quite possibly some of these differences
might be due to the known proclivity of CBD to impair metabolism
of other drugs, but the overall effect was of no clinical
consequence. Similar doses of CBN produced no appreciable
alterations of THC effects (Hollister and Gillespie 1975a). In
rhesus monkeys CBD decreased operant behavior produced by THC
(Brady and Balster 1980).
Other Drugs
Virtually no studies of interactions with other drugs have been
done-possibly because few others, as well as the sedatives and
stimulants mentioned above, are used directly in combination with
marijuana. A single case report of marked sinus tachycardia when
marijuana was used by a patient taking nortriptyline would be
expected as an additive effect (Hillard and Vieweg 1983).
Alcohol is commonly used in such combination and its use for
augmenting marijuana effects seems to be based on good evidence.
No antidote for THC effects is known. Tamarind, reported to be
such, was not found to be active in our unpublished studies.
Such has also been the case with phenitrone, which revealed no
antagonism when tested in a number of animal species (Spaulding
et al. 1972).
PHARMACOKINETIC INTERACTIONS
Alterations of Absorption and Distribution
When given in a lipid vehicle, THC is much better absorbed than
it is in a hydroalcoholic vehicle; possibly the lipid matrix also
accounts for social use of the drug in the form of a cookie.
Alimentary lipemia does not seem to bind IHC in blood; clinical
actions were unchanged in our studies.
Alterations of Metabolism
No changes in the kinetics of THC were observed when 20 mg oral
doses were given together with 40 mg oral doses of CBN and CBD
(Agurell et al. 1981). Even a 1500 mg oral dose of CBD failed to
alter the kinetics of an intravenous dose of THC; a minimal
effect on the formation and excretion of metabolites was noted
(Hunt et al. 1981). CBD decreased the metabolism of
hexobarbital; maximum concentrations and bioavailability were
increased; and plasma half-life and volume of distribution were
decreased (Benowitz et al. 1980). No change in the disposition of
cocaine was produced by THC in rats (Vadlamani et al. 1984).
EXPLORATIONS OF MECHANISM OF ACTION
Alphamethylparatyrosine (AMPT) blocks tyrosine hydroxylase and
inhibits formation of new catecholamines. Its interaction with
THC was not associated with any qualitative or quantitative
changes in THC action (Hollister 1974). There may have been a
slight additive effect due to the sedative effects produced by
AMPT. Propranolol blocked the tachycardia produced by THC but
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had no effect on the cognitive chanses (Drew et al. 1972).
 THC as decreased tachycardia and conjunctival injection.
Physostigmine amplified the lethargy and somnolence produced by
In many respects, physostigmine acts both similarly-to THC
(lethargy and somnolence) and different from THC (bradycardia).
The interactions were undoubtedly additive (Freemon et al. 1975).
INTERACTICINS BETWEEN CANNABIS AND CHARACTERISTICS OF SUBJECTS
Metabolism
Variable responses to the same dose of THC are seen not only
between subjects,but in the same subject as well. (One possible
explanation for between-subject variability would be different
rates of hydroxylation of drugs. An active metabolite of THC is
11-hydroxy-THC; subjects with a rapid rate of hydroxylation might
be expected to have a more precipitous onset and greater
intensity of  THC effect than slow hydroxylators. Both metabolism
of antipyrine and phenylbutatone were used as indices of
hydroxylation rate. It was impossible to correlate either the
speed of onset, total intensity, or duration of effects with
speed of hydroxylation of drugs (Hollister and Gillespie 1975b).
Thus, it seems unlikely that differing rates of drug metabolism
account for the widely variable responses between individuals
exposed to THC.
Personality
It has become axiomatic that the setting in which psychoactive
drugs are taken is a strong determinant in the effects they
produce. The axiom is seldom tested. A study of marijuana and
placebo cigarettes smoked under “favorable” and “unfavorable”
conditions found no appreciable contribution of the extreme
settings in which the drug was taken (Hollister et al. 1975).
Quite possibly, the psychological expectations or “set” of
subjects are the major determinant of interindividual
differences. This factor has not yet been adequately studied in
the case of THC (Hollister and  Overall 1976).
SUMMARY
Only THC, of all cannabinoids, has a significant pharmacodynamic
interaction with ethanol. Effects in man are additive as
expected. THC. but not CBD. showed a similar interaction with
barbiturates. Interactions with stimulants were weakly additive,
but the former drugs do not reverse impairments from THC. Inter-
actions between cannabinoids are controversial. Some evidence
consistently suggests that CBD may block actions of THC, while
other evidence could not show a clinically significant
interaction. CBD did not alter the kinetics of THC, but it
decreased metabolism of hexobarbital. Preliminary studies of
interactions between THC and drugs affecting activity of
neurotransmitters have not provided good tests of the mechanism
of action of the drug, showing, at best, subtle effects of
questionable clinical significance. The variable responses of
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subjects to THC is neither explained by differences in metabolism
of drugs nor by differences in the setting in which the drug is
taken.
FURTHER STRATEGIES
The paucity of recent studies of interactions of cannabis with
other drugs probably means that investigators no longer construe
these as very important. Adverse consequences of combined use of
cannabis with other drugs have been rarely reported. Of all
drugs, ethanol is the only one consistently used contempo-
raneously. Althogh studies of this interaction are sparse, and
by no means elegant, the conclusion of an additive effect seems
reasonable. Whether or not this interaction needs more
documentation is questionable.
One must realize that the clinical effects of smoking cannabis
are rather brief. The whole course is generally run within 3
hours, as judged both by assessment of subjective responses and
by measurement of plasma concentrations of THC. Thus, even
though cannabis users may also use other social drugs, unless
they were to use them concurrently with cannabis, significant
interactions would not be expected. Thus far, no such patterns
of combined use have emerged, other than for ethanol.
While it seems likely that many smokers of cannabis also use
tobacco, surprisingly little study of these interactions has been
done. As the potential for both a pharmacokinetic as well as a
pharmacodynamic interaction exists, it might be of some interest
to test these hypotheses. The clinical effects of cannabis, as
well as the kinetics of THC, might be studied in subjects who are
abstainers from tobacco and who are also heavy smokers. The
possibility that such studies would reveal any new important
interaction is remote, as this experiment has probably been done
many times in nature.
The number of interactions systematically studied to develop some
insight into the mechanism of action of THC have been sparse.
Work thus far in man has touched upon interactions involving
catecholamine neurotransmitters and acetylcholine. Clearly, more
work might be of interest, looking at specific alterations of THC
effect by modifying the actions of dopamine, serotonin, and
gamma-amincbutyric acid. In view of the fact that a possible
mode of action of THC might be one of disordering (fluidizing)
cell membranes, it might be well to study interactions between
THC and drugs that alter membrane lipids, such as chronic
exposure to alcohol, pretreatment with lithium, or other
techniques by which membranes may be made more or less rigid.
Such studies might very well be done on animals rather than in
man, however.
Factors influencing the variability of response to cannabis use
still remain relatively unexplored. More studies of the effects
of different rates of metabolism between subjects, as well as the
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effects of mind-set of subjects, would be of interest but are not
crucial.
Many of the concerns about the adverse effects on health
of cannabis use still remain to be explored. It does not appear,
at least now, that such adverse effects are likely to be
associated with unexpected interactions between the active
components of cannabis and other drugs.
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Alcohol and Marijuana: Concor-
dance of Use by Men and Women
Jack H. Mendelson, M.D.; Nancy K. Mello, Ph.D.; and
Barbara W. Lex, Ph.D., M.P.H.
INTRODUCTION
There is abundant evidence that many American men and women smoke
marijuana. To what extent does marijuana use enhance risk for alco-
hol abuse and does alcohol use increase probability for marijuana
abuse? There is evidence that use of substances which have abuse
liability potential (for example, opiates, alcohol, and tobacco)
increases probability of concurrent use and abuse of other drugs.
For example, cigarette smoking increases when men drink alcohol
or self-administer opiates (Mello and Mendelson, this volume).
While it is reasonable to postulate that marijuana cigarette smok-
ing may also contribute toward concurrent abuse of other substan-
ces, there are no empirical data available from controlled clinical
investigations which support this notion. The studies described
in this report were designed to examine the degree of covariance
between marijuana and alcohol use by men and women. We will first
describe our studies of alcohol and marijuana use by male subjects
who participated in controlled residential research ward investi-
gat ions. Next, we will review studies of marijuana and alcohol
use by female subject volunteers assessed in a prospective, conmmity-
based research paradigm.
MARIJUANA AND ALCOHOL USE BY MALES
This report describes the first attempt to examine the effects of
concurrent availability of marijuana and alcohol on drug use pat-
terns under clinical research ward conditions (Mello et al. 1978).
This study was designed to explore patterns of polydrug use invol-
ving marijuana and alcohol. The following behavioral questions
were examined in a situation where subjects could work at a simple
operant task to acquire marijuana, alcohol, or money.
1. Does the simultaneous availability of marijuana and alcohol
change the use of either or both drugs in comparison to conditions
where marijuana or alcohol is available alone?
2. When both alcohol and marijuana are available, is there a ten-
dency to use these separately or together?
NOTE: All figures and tables in this article and portions of the text
were originally published in Mello, N.K.; Mendelson, J.H.; Kuehnle,
J.C.; and Sellers, M.L. Human polydrug use: Marihuana and alcohol.
J Phamcol Exp Ther 207:922-935. Copyright 1978, William and Wilkins.
Reproduced by permission.
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3. Is the temporal pattern of drug acquisition behavior different
under conditions of single or simultaneous availability of alcohol
and marijuana?
Since most of our information about nonopiate polydrug use has been
derived from survey data andfromself-report information (Benvenuto
et al. 1975; Bourne 1975; Carlin and Post 1971; Fisher and Brickman
1973; Grupp 1972; Smart and Liban 1980; Wechsler et al. 1980;
Johnston 1980 and 1981; Kandel 1980 and 1984; Hochhauser 1977;
Einstein et al. 1975; Welte and Barnes 1982), direct observations
of multiple drug use patterns and its behavioral consequences are
useful for distinguishing the actual from the anecdotal.
Volunteer subjects were recruited through advertisements in local
periodicals and newspapers. All subjects selected were in good
health and showed no evidence of psychiatric or medical abnormali-
ties as determined by appropriate laboratory and clinical examina-
tions. These included a complete physical examination, mental
status examination, chest x-ray, electrocardiogram, timed vital
capacity, and the following laboratory assessments: lactic dehydro
genase, serum glutamic oxaloacetic transaminase, bilirubin total,
total protein, albumin, globulin, agglutination ratio, alkaline
phosphatase, uric acid, blood urea nitrogen, creatinine, glucose,
total lipids, white and red blood counts, hemoglobin, hematocrit,
and differential.
Sixteen adult male volunteers who reported concurrent use of mari-
juana and alcohol were selected. Each subject was fully informed
about the nature and duration of each phase of the study and was
told he could withdraw at any time. Subjects were closely matched
for age (mean = 25; range, 21-29), years of alcohol use (mean =
6.60 ± S.E. 0.77), and years of marijuana use (mean = 7.5 ± S.E.
0.61). Subjects were matched as closely as possible with regard
to socioeconomic background and general intelligence and had an
average of 13.2 years of formal education (range, 11-16). Sub-
ject characteristics and self-reports of the frequency of alcohol
and marijuana use are summarized in table 1.
Subjects were studied in groups of 4 and lived on a hospital re-
search ward for 34 days. The research ward contained 2 semiprivate
bedrooms, a nursing station, examining and testing rooms, kitchen
and lavatories, an operant equipment room, and a spacious, comfor-
table dayrooom with television, high fidelity equipment and other
recreational materials. Physicians, nursing personnel, and ward
assistants were present 24 hours each day.
Sequence of Procedures
The sequence of drug availability conditions is shown in table 2.
Each subject was used as his own control during a drug-free base-
line of 5 days; a 5-day exposure to either marijuana or alcohol
only; a 5-day exposure to the opposite drug only; a 10-day period
when both marijuana and alcohol were simultaneously’available;
followed by a 5-day drug-free control period. Each 5-day exposure
to alcohol only or to marijuana only was followed by 1 drug-free
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day to reduce the possibility that withdrawal from one drug would
influence initial acquisition of the second drug. The alcohol or
marijuana only periods provided a single drug use baseline against
which to compare drug use patterns during concurrent alcohol and
marijuana availability. Eight subjects were given marijuana first
and 8 subjects were given alcohol first during the single drug
availability periods. An alternating sequence of only alcohol or
only marijuana access was intended to control for the possible in-
fluence of the order of single drug conditions on concurrent drug
use during the lo-day access period.
A single acute drug administration day (marijuana plus alcohol)
preceded the first 5-day single drug period and followed the 10-
day period when both alcohol and marijuana were available. These
acute drug administration days were included to examine the effects
of acute alcohol and marijuana administration on a series of biolo-
gical and behavioral variables. Within a period of 1½ hours, sub-
jects smoked 3 marijuana cigarettes (1-g marijuana cigarette; 1.8-
2.3% tetrahydrocannabinol) and consumed a 43% alcohol solution in
a dose of 2.5 ml/kg in fruit juice which was sufficient to produce
a blood alcohol level between 100 and 120 mg/100dl.
Operant Behavioral Procedures
In order to earn purchase points for drugs or money, subjects
pressed the response button on a portable operant manipulandum.
Each response transmitted a discrete radiofrequency signal to the
programming and recording equipment. The manipulandum could be
easily held in one hand. It measured 4.5 x 9.4 x 1.6 cm and
weighed about 198g. Each manipulandum was color-coded and labeled
with the subject’s number to permit easy identification by the ward
staff and to discourage subjects from exchanging manipulanda.
Subjects worked for drugs or money on a second order fixed ratio
300, fixed interval 1 second schedule of reinforcement, an FR 300
(FI 1 sec:S). Only the first response after 1 sec elapsed was
recorded by the programming circuitry as an effective response.
Responses emitted at a faster rate had no programmed consequence.
This schedule of reinforcement was chosen to permit comparisons
with our previous studies of operant acquisition of marijuana
(Mendelson et al. 1976a).
Each purchase point required 300 effective responses on an FI 1
schedule. Thirty minutes of sustained performance resulted in 1800
effective responses or the accumulation of 6 purchase points. The
cost of 1 marijuana cigarette or 50 cents was 6 purchase points
(i.e., 30 min of work). This equation was made on the basis of pre-
vailing prices for marijuana in the Boston area. The cost for 1
ounce (30 ml) of alcohol was 3 purchase points (i.e., 15 min of
work). The price differential between marijuana and alcohol was
established after pilot studies showed that subjects did not buy
as much alcohol as they usually drank at the price of 6 purchase
points (Babor et al. 1978).
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Subjects could work at the operant task whenever they wished as
long as it did not interfere with other ward procedures or data
collection routines. Subjects could only work at the operant task
within the general confines of the clinical research ward.
Available Drugs
Marijuana
Cigarettes which contained approximately 1g of marijuana were ob-
tained from the National Institute on Drug Abuse (NIDA) in lot stan-
dard dosage form. Maximal standardization and equivalent dosage
“draw” characteristics of these cigarettes were ensured by machine
rol l ing. Each 1-g cigarette contained approximately 1.8 to 2.3%
tetrahydocannabinol (THC) as assayed by NIDA. Details of the Soxh-
let and modified Lerner extraction procedures and the gas chromato-
graphic assay procedure are available from NIDA. Content analysis
confirmed that the THC concentration of these cigarettes remains
stable over many months. Actual content analysis of the marijuana
indicated the following constituents (percent ± S.D.): cannabidiol =
0.18 ± 0.04%; 8-THC = 0.002 ± 0.002%; 9-THC = 2.06 ± 0.08%; can-
nabinol = 0.08 ± 0.12%.
Alcohol
Subjects could choose their preferred type of alcohol. Gin, vodka,
scotch, bourbon, beer, or wine and mixers were available. Prices
were established on the basis of the absolute alcohol ccmtent of
each beverage. One ounce (30 ml) of distilled spirits, one l2-
ounce (360 ml) can of beer, and one glass of fortified sweet wine
(2.5 ounces or 75 ml) cost 3 purchase points.
Reinforcement Choice
During the predrug baseline period, and the 2 drug-free control
days, subjects could work only for money. Money earned for oper-
ant work and for other performance and cooperation tasks was paid
upon completion of the study. During the two 5-day periods when
only marijuana or only alcohol were available, subjects could work
for the available drug or money. During the 10-day period when
both marijuana and alcohol were available, subjects could work for
marijuana, alcohol, or money.
Whenever a subject activated his operant instrument, he chose
whether to work for a drug or for money. When the subject pressed
the appropriate button on his control panel (i.e., money, alcohol,
or marijuana), this infonned the programning apparatus that points
earned should count towards the selected reinforcer. Once a sub-
ject chose to work for 1 reinforcer, he could not change to a sec-
ond reinforcer until an interval of 5 min elapsed. This change-
over delay contingency was included to prevent rapid alternation
between reinforcement conditions.
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Record of Earnings
A record of purchase points earned for money, alcohol, and mari-
juana was continuously available to each subject on his operant
control panel, located on one wall of the dayroom. When a drug pur-
chase was made, the number of points required for that purchase was
automatically deducted from the subject’s total points earned for
that drug. Subjects were not allowed to purchase for another sub-
ject or to earn points using another subject’s manipulandum.
Control of Drug Use
All alcohol consumption and/or marijuana smoking had to be done at
the time of drug purchase, under observation of a staff member.
Subjects were not allowed to share drugs. Unused portions of
smoked marijuana cigarettes were collected by staff so that
“roaches” were not accumulated and smoked without staff knowledge.
Bach roach was weighed to determine the amount of marijuana actual-
ly used by each subject. Since studies were carried out on an in-
patient clinical research ward, staff were able to ensure that sub-
jects did not use drugs other than marijuana and alcohol.
Measurement of Effective Drug Levels
Blood levels of marijuana and its metabolites were not measured
directly,and effective dosages were inferred from the number and
amount of cigarettes smoked.
Alcohol purchase data were supplemented by blood alcohol level
measurements. A breathalyzer device was used in order to avoid
multiple venipunctures. It has been repeatedly shown that about
95% of all breathalyzer readings are equivalent to simultaneous
blood alcohol determinations within 10% (Dubowski 1970). Subjects
were required to rinse out their mouths and refrain from smoking,
eating, or drinking for 10 min before each breathalyzer measure-
ment . Measurements were taken according to standard procedures.
Blood alcohol levels were measured at 8:30 a.m., 10:00 a.m., 2:00
p.m., 3:15 p.m., 8:00 p.m., 10:30 p.m., and every hour after 11:00
p.m. if subjects continued to drink. In addition, blood alcohol
levels were measured immediately before and 30 min after comple-
tion of the first and fourth drink of the day.
Medical and Neurological Assessments
Vital signs were taken 3 time each day and routine physical examin-
ations were conducted periodically throughout the study. Upon con-
clusion of each drug availability condition, neurological examina-
tions were conducted daily to ascertain the occurrence of withdrawal
signs and symptoms. A complete description of procedures used to
evaluate marijuana withdrawal appears in Mendelson et al. (1974).
A description of the alcohol withdrawal syndrome appears in Mello
and Mendelson (1977).
The pattern, rate, and duration ofoperantresponses for drug and
money acquisition were automatically recorded by the programming
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circuitry on electromechanical counters; interresponse time count-
ers; cumulative recorders; and running time meters. Data on indi-
vidual patterns of drug use are presented graphically. T tests
were used to evaluate the statistical significance of individual
changes in mean alcohol and marijuana intake during periods of
single and combined drug availability. Group data were evaluated
with an analysis of variance.
RESULTS
Individual Drug Use Patterns by Men
There was considerable variability between individual subjects in
the amount of marijuana and alcohol consumed during each drug
availability period. Consequently, individual drug use patterns
are described before consideration of group trends. All subjects
used alcohol or marijuana during each 5-day single drug availability
period. Fifteen of the 16 subjects studied used both alcohol and
marijuana during the 10-day period of concurrent drug availability.
The single exception (S3-MA5) used only alcohol when both marijuana
and alcohol were available.
Analysis of the weight of marijuana cigarette roaches per subject
per day indicated approximately 98% of each 1-g cigarette was
smoked. Subjects used roach clips and consistently smoked as much
as possible of each marijuana cigarette. Subjects appeared to
drink all alcohol purchased, and the effective dose of alcohol, in-
ferred from peak blood alcohol levels, was consistent with the
alcohol purchase pattern.
Average daily alcohol and marijuana use by individual subjects
during each drug availability period is shown in table 1. Sub-
jects are grouped according to the volume of alcohol actually con-
sumed during the alcohol only period, and are designated as heavy
(N=5) moderate (N=4) and light drinkers (N=7). Eleven subjects
were heavy marijuana users according to our previously established
criteria of 4 or more marijuana cigarettes per day (Mendelson et al.
1976a). The remaining 5 subjects could be classified as casual
users who smoked 3 or fewer cigarettes per day during the mari-
juana only period. During the single drug availability periods,
heavy drinking did not necessarily predict heavy smoking or the
converse. Heavy marijuana smokers accounted for 3 of the 5 heavy
drinkers, 3 of the 4 moderate drinkers, and 5 of the 7 light drinkers
(table 1, columns 2 + 5). No subject showed withdrawal signs or
symptoms after cessation of alcohol or marijuana use.
There was a marked lack of correspondence between actual marijuana
and alcohol consumption during the single drug availability per-
iods and retrospective self-report data shown in table 1. Only 1
of the 5 heavy drinkers reported daily alcohol use and the others
reported no more than 2 to 4 beers and 2 ounces of distilled spir-
its per week. In fact, these subjects drank between 12 and 19
drinks per day (table 1, column 2). Although 6 subjects reported
using fewer than 20 marijuana cigarettes per month, 4 of those sub-
jects smoked between 4 and 7.8 cigarettes per day (table 1, column
5). It is impossible to determine whether subjects do not remember
122
TABLE 1
or deliberately misinform to ensure selection for the study. How-
ever, an empirical classification based on actual drug use behavior
appears to be essential for analysis of these data.
Effects of Concurrent Marijuana and Alcohol Availability
Fourteen of the 16 subjects drank less alcohol during the period
of combined alcohol and marijuana availability, in comparison to
the 5-day alcohol only period (table 1, column 3). A reduction in
alcohol consumption by this number of subjects was significant
according to a nonparametric sign test (p<.01). Moreover, 7 sub-
jects drank significantly less alcohol when marijuana was avail-
able, as evaluated by t tests (table 1, column 4).
Twelve of the 16 subjects smoked more marijuana during the period
of concurrent alcohol and marijuana availability in comparison to
the 5-day marijuana only period (table 1, column 6). An increase
in marijuana use by this number of subjects was significant accord-
ing to a nonparametric sign test (p<.05). However only 2 subjects
smoked significantly more marijuana cigarettes (table 1, column 7).
Drug use was often quite variable within individuals over time.
Daily drug use and earning patterns for selected individual sub-
jects are presented in figures 1, 2, and 3. The most common pat-
tern observed, i.e., to increase marijuana use and decrease alcohol
use during the period of concurrent alcohol and marijuana avail-
ability, is shown in figure 1. This subject was a heavy marijuana
user who smoked an average of 7 cigarettes per day during the base-
line period of marijuana availability. He was also a heavy drinker
and consumed an average of 14 drinks per day during the baseline
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FIGURE 1
FIGURES 1, 2, and 3. Marijuana ad alcohol use and purchase points
for money and drugs earned  over 34 consecutive days. The succeesive
conditions of drug availability are show at the top of each figure.
The first row show the numbsr of marijuana cigarettes smoked
each day. The dotted line and cross-hatched area (± S.E.) denotes
the average number of marijuana cigarettes smoked during the entire
5 or 10 day period. The second row shows the number of alcohol
drinks consumed each day (0) and the 24-h ntean and range of blood
alcohol levels observed each day The average number of drinks
consumed during the 5 or 10 day period is shown as a dotted line
and cross-hatched area (mean ± S.E.). The third row shows the num-
ber of purchase points earned for money , marijuana and
alcohol  (0) . Consecutive  days of the study are shown on the abscis-
sa. The single day (D) inmediately following and preceding the pre-
and postdrug free baselines were days on which an acute combined-
dose of alcohol  and marijuana was given. The single day f o l -
lowing the 5-day period of marijuana and of alcohol availability
was a day on which no drugs were available.
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FIGURE 2 See legend under figure 1
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FIGURE 3 See legend under figure 1
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period of alcohol availability. Peak blood alcohol levels ranged
from 50 to 160 mg/100 ml during the hours of maximum drinking.
When both alcohol and marijuana were available concurrently, mari-
juana smoking increased slightly to an average of 10 cigarettes per
day Alcohol consumption decreased significantly to an average of
4 drinks per day (p<.001) and peak blood alcohol levels never ex-
ceeded 75 mg/100 ml.
A decrease in both marijuana and alcohol use during the periods of
marijuana and alcohol availability is shown in figure 2. This sub-
ject was also a heavy drinker who consumed an average of 19 drinks
per day during the baseline period of alcohol availability. Peak
blood levels ranged between 100 and 280 mg/100 ml. This subject
also showed a significant decrease in alcohol consumption during
the period of concurrent alcohol and marijuana availability, des-
pite a relatively low frequency of marijuana smoking (1.6-0.7
cigarettes per day).
Figure 3 shows data for 1 of the 2 subjects who increased both
marijuana and alcohol use during the period of concurrent alcohol
and marijuana availability. During the single drug baseline, this
subject was a moderate drinker and a heavy marijuana smoker. Dur-
ing the 10 days of concurrent alcohol + marijuana availability,
alcohol use increased slightly and marijuana smoking increased
significantly (p<.001) . This subject also smoked significantly
more marijuana during the final 5 days of the 10-day concurrent
drug access period than during the first 5 days as determined by
t  tes ts  (p< .05 ) .
Group Trends in Concurrent Drug Use Patterns
Analysis of variance for repeated measures across days was done
separately for alcohol and marijuana use during the 10-day period
of concurrent availability. There were no significant linear
trends in alcohol consumption through time. Rather, alcohol con-
sumption decreased when marijuana became available and remained
depressed in comparison to the alcohol-only baseline, throughout
the period of concurrent drug availability. In contrast, there
was a significant linear increase in marijuana smoking during
this 10-day period (p<.001). A trend analysis for the entire
15 days of marijuana availability also indicated a significant
progressive increase in marijuana smoking through time (p<.001).
The sequence of single drug conditions, alcohol, or marijuana
first, did not appear to determine drug use patterns during the
concurrent drug availability condition. There were no significant
differences between the 2 drug sequence groups in either alcohol
or marijuana consumption during the first 5 days of the concurrent
drug availability period. The 8 subjects exposed to marijuana
first also did not differ from the 8 subjects exposed to alcohol
first in baseline marijuana smoking. However, the alcohol-first
group drank significantly less alcohol than the alcohol-second
group during the alcohol only baseline (p<.001) as evaluated by
paired t tests.
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In order to examine the temporal concordance of alcohol and mari-
juana use, the number of occasions that each subject used each drug
during consecutive 4-h blocks was tabulated. Group drug use pat-
terns during the 10-day period of concurrent alcohol and marijuana
availability are compared with drug use patterns during the single
drug availability periods in figure 4.
During the period of concurrent availability, alcohol and marijuana
were usually used between noon and midnight (figure 4, row 1).
Although alcohol and marijuana were usually used together, there
were no instances of adverse reactions or other evidence of toxic
drug interaction. The temporal distribution of marijuana smoking
was similar during the marijuana only and concurrent drug availabil-
ity periods (figure 4, rows 1 and 2). There were no significant
differences in the nunber of marijuana cigarettes smoked during
each 4-h time period as a function of the availability of alcohol.
A comparison of the amount of alcohol consumed during each 4-h period
revealed a significant decrease in drinking between 4:00 and 8:00
p.m. and between 8:00 p.m. and midnight when marijuana was concur-
rently available (p<.01). The changes in alcohol consumption dur-
ing marijuana availability were not significant at any other 4-h
time period as evaluated by paired t tests.
Operant Work Patterns
Although only responses emitted at a rate of 1/sec counted toward
purchase points under the Fl 1 sec component of the schedule, all
subjects consistently responded at a faster rate. Usually response
rates were 2 or more per sec, and about 600 responses were emitted
for every 300 responses required. gates of 3 or more responses per
sec were not unusual. Subjects understood the schedule requirements
but preferred to respond at a comfortable rate.
The temporal pattern of operant work for purchase points for alco-
hol (0), marijuana and money by the entire group of sub-
jects during each drug condition is shown in figure 4. Subjects
usually began operant work in the morning between 8:00 a.m. and
12:00 noon. Subjects earned the most points for money between noon
and midnight in both the drug-free and drug access conditions.
Operant work for alcohol and marijuana points was more equally dis-
tributed between the hours of 8:00 a.m. and 12:00 midnight in both
the single and concurrent drug availability periods. Comparison
of figures 4 and 5 indicate that the periods of maximum operant
work usually corresponded to periods of maximum drug use.
Despite the difference in price for alcohol and marijuana (3 vs.
6 purchase points), work patterns for each drug were similar dur-
ing the alcohol or marijuana only periods. When both alcohol and
marijuana were available, subjects began to work for marijuana
earlier than for alcohol and earned consistently more marijuana
points through time. Purchase points earned for alcohol and mari-
juana were consistent with actual drug use. Subjects appeared to
earn about as many drug purchase points as were needed for daily
consumption. Subjects did not accumulate extra drug purchase
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FIGURE 4 Amount of alcohol and marijuana cigarettes used as a
function of time of day, across drug availabitity conditions.
Numbers of drinks or marijuana cigarettes used (mean ± S. E. ) are
shown on the ordinate and consecutive 4-h periods are shown on
the abscissa. The top rot) shows the nwnber of alcohol drinks con-
sumed (0) and marijuana cigarettes smoked during the 10-day
period of alcohol and marijuana availability. The second row
shows consumption of each drug during the 5-day period of single
drug availability.
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FIGURE 5 Purchase points earned as a function of time of day
across drug availability conditions. Purchase points earned
(mean ± S. E. ) are shown on the ordinate and consecutive 4-h
periods are shown on the abscissa. The top row shows points
earned for money marijuana and alcohol (0) during
the 10-day period of concurrent alcohol and marijuana avail-
ab i l i t y . The second row shows the purchase points earned for
money, alcohol, or marijuana during the two 5-day periods when
only alcohol or marijuana was available. The third row shows
points earned for money during the 5-day predrug baseline and
during the 5-day postdrug baseline.
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points or plan ahead for a period of work-free drug use as was
previously observed in alcohol addicts (Mello and Mendelson 1972).
It is apparent that subjects earned more points for money than
for either drug during both the single and combined drug avail-
ability periods (figure 3, rows 1 and 2). Subjects earned the
most points for money during the drug-free baseline periods when
marijuana and alcohol were not available as alternate reinforcers
(figure 3, row 3). Throughout the course of the study, subjects
earned an average of $257.68 (± S.E. $21.60).
The average number of total points earned per day across each
successive baseline and drug access condition is summarized in
table 2. The total number of points earned by the entire group
tended to decrease through time as determined by a trend analy-
s i s  (p< .025 ) . Subjects earned fewer points during the 3 drug
availability conditions than during the predrug baseline, and
fewer still during the final drug-free baseline period. Differ-
ences between the pre- and postdrug baseline periods were signifi-
cant as evaluated by matched pair t tests (p<.01).
Total points earned during the period when only alcohol was avail-
able and when alcohol and marijuana were available concurrently
did not differ significantly from the predrug baseline. However,
significantly fewer points were earned during the marijuana only
period than during the predrug baseline (p<.05).
The amount of operant work and total purchase points earned re-
mained quite consistent across the 3 drug availability conditions.
There were no significant differences in total points earned dur-
ing the alcohol, marijuana or concurrent drug availability periods.
Examination of total points earned as a function of alcohol con-
sumption revealed differences in total earnings. Heavy drinkers
earned significantly fewer total points than light drinkers
(p< .05 ) . Heavy drinkers also earned significantly less money
than light drinkers (p<.01). Light drinkers earned an average
of $8.92 per day or $303.45 for the study. Moderate drinkers
earned an average of $8.18 per day or $278.13 for the study.
Heavy drinkers earned an average of $5.21 per day or $177.25 for
the study.
Eleven of the 16 subjects were heavy marijuana users and 3 of
these were also heavy drinkers. However, if the effects of mari-
juana use are examined, independent of alcohol use, heavy mari-
juana users earned significantly more total points than light
users (p<.05) . Heavy marijuana users also earned more money
than light smokers, but this difference was not significant.
Heavy marijuana users earned an average of $8.13 per day or
$276.42 per study, whereas light marijuana users earned an aver-
age of $6.37 per day or $216.58 per study.
Translation of average points earned per day on an FR 300 (FI 1
sec) schedule reveals that subjects worked between 8.6 and
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and 10.1 h per day during the pre- and postdrug baseline periods.
When drugs were available, subjects worked an average of 9.7 h
per day during alcohol only, 9.1 h per day during marijuana only
and 9.3 h per day when both drugs were available.
DISCUSSION (Males)
Alcohol and Marijuana Use in Men
When alcohol and marijuana were concurrently available, marijuana
appeared to affect alcohol use far more dramatically than alcohol
influenced marijuana use. A significant nwnber of subjects
reduced alcohol use in comparison to a period when only alcohol
was available. The magnitude of the decrease in alcohol con-
sumption was also significant in half of those subjects. Al-
though marijuana smoking increased when alcohol was also avail-
able, this change cannot be attributed solely to the effects of
alcohol. Marijuana smoking began to increase during the mari-
juana only period and this trend continued throughout the period
of marijuana and alcohol availability. The progressive increase
in marijuana smoking during the 10 days of concurrent alcohol and
marijuana access was comparable to that previously observed dur-
ing 21 days of access to only marijuana (Mendelson et al. l976a,b).
These data may reflect an increased tolerance for marijuana. The
development of behavioral and physiological tolerance to mari-
juana during chronic use has been reported by several investiga-
tors (Mendelson et al. 1974; Babor et al. 1975; Jones and Benowitz
1976).
A marijuana-related suppression of drinking was unexpected and
the factors which account for this finding are unclear. There
were no progressive changes in alcohol consumption comparable to
changes in marijuana smoking over time. Rather, alcohol consump-
tion decreased abruptly when marijuana became available, and re-
mained suppressed in comparison to baseline throughout the period
of concurrent drug availability (cf. figure 1). Reanalysis of
drinking patterns in 18 control subjects from previous studies of
casual and heavy drinkers (Babor et al. 1978) also failed to re-
veal any significant linear trends in alcohol consumption through
time (J.H. Mendelson, unpublished observations). Therefore, it
is unlikely that the observed depression of alcohol consumption
reflects a time-related trend which is independent of marijuana
availability.
It could also be postulated that subjects drank less alcohol dur-
ing marijuana use because the level of intoxication produced was
either equivalent to a higher dose of alcohol or was aversive.
It is generally acknowledged that the combined effects of alcohol
and marijuana are “additive” in the sense that performance impair-
ments induced by the combined administration of both drugs are
greater than those observed with either drug alone (Burford et al.
1975; Franks et al. 1975; Manno et al. 1971; Smiley et al. 1975;
Smith 1976). Subjective aspects of marijuana intoxication have
also been reported to be enhanced by the concurrent use of alcohol
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(Hollister 1976; Manno et al. 1971). However, alcohol consumption
decreased even in subjects who smoked only 1 to 3 marijuana cig-
arettes per day (cf. table 3), so this explanation is not compel-
ling. The critical dose-response relationships between alcohol
and marijuana which influence drug use patterns remain to be
determined.
These subjects did not appear to be unusually intoxicated and did
not report that the combined effects of alcohol and marijuana
were aversive. We have seen no evidence for toxic interactions
between marijuana and alcohol in either the chronic self-adminis-
tration or the acute dose studies in which 3 marijuana cigarettes
were smoked in combination with a 2.5 ml/kg dose of alcohol over
a 1½-h period. Our findings are at variance with a report by
Sulkowski and Vachcm (1977) in which far lower doses of alcohol
(1 g/kg) and marijuana (1 cigarette containing 18 mg of 9-THC)
administered within a 1-h interval resulted in prolonged vomiting,
headaches, and severe intoxication in 4 of 7 healthy young men
with a history of alcohol and marijuana use. A lower dose of
alcohol (0.5 g/kg) did not result in comparable adverse effects.
Blood alcohol levels were not reported (Sulkowski and Vachon
1977).
These data indicate that the simultaneous availability of 2 recrea-
tional psychoactive drugs does not necessarily increase drug use,
as has been reported for alcohol and tobacco (Griffiths et al.
1976) Rather, the availability of marijuana modulated the use of
alcohol, even in heavy drinkers. Although marijuana has rarely
been considered a plausible addition to the armamentarium of drugs
arrayed against alcoholism, Rosenberg (1977) has proposed to use
marijuana to reinforce compliance with a disulfiram maintenance
program for alcoholics.
Operant Work Patterns by Men
Concurrent use of alcohol and marijuana did not change the amount
or temporal pattern of operant work in comparison to periods when
only alcohol. or only marijuana was available. Subjects continued
to work at the operant task during the periods of maximum drug use
in all 3 conditions of drug availability. Operant response rates
were consistently higher than required by an FI 1 sec schedule of
reinforcement. These data are consistent with our previous obser-
vations of sustained operant performance for marijuana and for
money during a 21-day period of marijuana availability (Mendelson
et al. 1976 a,b).
The sustained performance for drugs and money during intoxication
differs from that previously observed with alcoholic subjects
working at a simple operant task for alcohol or cigarettes. Alco-
holic subjects alternated 2- to 3-day periods of work with 2- to
3-day periods of drinking even though periods of abstinent working
resulted in alcohol withdrawal signs and symptoms (Mello and
Mendelson 1972). Differences in operant task requirements do not
appear to account for observed differences in drug acquisition
patterns between alcohol addicts and multiple drug users. However,
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the finding that heavy alcohol users earned fewer total points and
less money than light drinkers is consistent with our previous obser-
vations of alcohol-related decreases in operant work by alcohol ad-
dicts (Mello and Mendelson 1932).
The tendency to earn fewer total points as the study progressed is
consistent with our previous observations of both casual and heavy
marijuana smokers. The total number of points earned during the
postdrug baseline period were always fewer than during the predrug
baseline period (Mendelson et al. 1976a). Since there was no evi-
dence of withdrawal signs and symptoms in these 16 polydrug users,
or in the 47 marijuana smokers studied previously (Mendelson et al.
1974, 1976a), this decrement may reflect boredom with the operant
task.
MARIJUANA AND ALCOHOL USE BY FEMALES
We are aware of no studies with women similar to those previously
described for human males. While such studies are entirely feasible
for women, a number of preliminary investigations are essential pre-
requisites before utilizing a residential research ward design analo-
gous to that which has been described for studies with human males.
The major reason for the conduct of preliminary studies with women
is due to a possible influence of menstrual cycle function on mari-
juana use. Clinical studies have suggested that women may use alco-
hol or other psychoactive substances in greater or lesser amounts
as a consequence of menstrual cycle related phenomena (Belfer et al.
1971) . It has been postulated that women who experience premen-
strual or menstrual related tension and dysphoria may be at higher
risk for using or abusing substances when they are symptomatic
(Podolsky 1963). Therefore, we have carried out a study to deter-
mine if alcohol and marijuana use vary as a function of menstrual
cycle phase. This study is, to the best of our knowledge? the
first major prospective investigation designed to ascertain the
frequency and amount of daily alcohol and marijuana use by women
during 3 consecutive menstrual cycle phases.
Thirty adult female volunteers between the ages of 21 and 36 (mean
age 26.4) were recuited via newspaper advertisements and provided
informed consent for participation in the study. All subjects were
selected following complete physical and mental status examination
and laboratory studies. No subject was pregnant, had past or cur-
rent history of drug or alcohol abuse, or a recent history of amen-
orrhea or menstrual function disturbance. Findings reported in
this study were obtained within the context of an extensive multi-
disciplinary investigation of behavioral and biological concomitants
of marijuana use by women. Subjects were typically single women
with some college education and their experience with drugs other
than marijuana and alcohol was infrequent. Upon admission to the
study, subjects did not differ significantly on any background vari-
ables . Table 3 summarizes general background characteristics of
the subjects.
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Procedures
All subjects completed a detailed diary questionnaire each day.
The diary was designed to monitor use of marijuana, alcohol, tobacco
cigarettes, nonprescription drugs, recreational drugs (other than
marijuana), occurrence of unusual events, frequency of sexual acti-
vity, morning basal body temperature, menstrual cycle status, men-
strual distress symptoms, and mood states each day during 3 conse-
cutive menstrual cycles. Subjects began diary reporting on the
first day of menstruation following acceptance into the study and
continued to record daily responses for 3 consecutive menstrual
cycles. Subjects used an oral thermaneter to record morning basal
body temperature to the nearest tenth of a degree Fahrenheit each
morning before arising from bed. The remainder of diary data were
recorded each evening before retiring. Completed diaries were
mailed to the Harvard-McLean Alcohol and Drug Abuse Research Center
every day. This study reports patterns of marijuana and alcohol
consumption; mood state data and biological findings will be repor-
ted elsewhere.
During each 24-h period, subjects reported the total number of mari-
juana cigarettes (or other marijuana compounds) used and the 6 time
periods during the day (“early morning,” “late morning," “early
afternoon,” “late afternoon,” “early evening,” and “late evening”)
during which use occurred. Subjects also reported consumption
“al l  day,” which indicated that some amount of consumption had oc-
curred during each of the 6 successive time periods but did not
necessarily signify continuous consumption throughout the day.
Subjects similarly noted the total nwnber and specific types of
alcoholic beverages consumed (beer, wine, or spirits or mixed
drinks) and times of alcohol use. The number of tobacco cigarettes
smoked and the time of their use was recorded. Subjects further
noted the quantity of other recreational or nonprescription drugs
used. They also reported onset and cessation of menses and occur-
rence of sexual activity. Occurrence of unusual events was recor-
ded in response to the question: “Did anything unusually good or
bad happen?” during the daily reporting period.
Conclusions and Comments
Compliance of subjects for reporting daily diary events was excel-
lent in this study. Less than 1.5% of over 2,700 questionnaires
were not completed. There was a highly statistically significant
correlation (p<.0001) between concordant use of marijuana ciga-
rettes and alcoholic beverages during the 3 consecutive menstrual
cycles. In addition, subjects tended to consistently conswne alco-
hol, marijuana, marijuana and alcohol, or abstain from using either
substance in a similar manner across all 3 menstrual cycles.
The data obtained in this first prospective study designed to eval-
uate concordance of marijuana and alcohol use by women is in agree-
ment with findings which have been obtained in previous investiga-
tions of relationships between alcohol and marijuana use (Fisher
and Brickman 1973; Smart and Fejer 1973; Wechsler and Rohman 1981).
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However, studies of marijuana and alcohol use by women in controlled
research ward environments analogous to those described in the
initial portion of this paper for men have yet to be undertaken.
These studies should yield more precise information about acquisi-
tion and use patterns of marijuana and alcohol when both substances
are relatively freely available for women.
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Cocaine and Other Drug Interac-
tions: Strategy Considerations
Reese T. Jones, M.D.
THE STATE OF THINGS
Although cocaine is by most criteria an old, almost ancient drug
(Van Dyke and Byck 1976), there is relatively little data on
cocaine and other drug interactions collected from controlled
laboratory experiments in humans. Many clinical observations,
reports, and speculations about drug interactions based on uncon-
trolled clinical observations date back virtually to the first use
of cocaine. Clinically significant cocaine interactions in humans
with epinephrine and most other sympthomimetics (National Insti-
tute on Drug Abuse 1977). with opiates, and with various thera-
peutic drugs-lithium (Cronsow and Flemenbaum 1981), antidepres-
sants (Rowbotham et al. 1984), local anesthetics, and virtually
every class of psychoactive drug-indicate that interactions are
likely tut unpredictable and complicated as to mechanisms. A vast
amount of animal data illustrates numerous neurochemical, behavior-
al, and functional effects from cocaine’s interaction with other
drugs (Catravas and Waters 1981; Colpaert et al. 1978; Guinn
et al. 1980; Nigro and Enero 1981; Smith et al. 1981). However,
most of the published observations about humans consist of small
samples in not well-controlled case reports, in surveys of oper-
ating room fatalities, in self-reports from drug users, etc.
(National Institute on Drug Abuse 1977).
WHY STUDY COCAINE AND OTHER DRUG INTERACTIONS?
Information about drug interactions can be important when planning
therapeutic approaches. Host of the data supporting or refuting
current drug therapies for treating cocaine dependence (e.g.,
lithium or tricyclic antidepressants) come from patient reports and
clinical observations under conditions where the dose of cocaine,
the frequency of dose, the variety of adulterants that may have
been added, and the variation in route of administration are com-
pletely uncontrolled and, in the usual clinical situation, uncon-
trollable.
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Cocaine users, like most drug users, use a variety of other drugs
often concurrently with cocaine or before and after. Alcohol,
opiates, sedatives, anxiolytics, stimulants, cannabis, tobacco,
and coffee are commonly used along with the cocaine. In addition
to the drugs ingested along with the cocaine, cocaine users are
exposed to a variety of adulterants commonly added to illicit
cocaine Cunningham et al. 1984). Besides the usual lidocaine,
lactose, or mannitol, a variety of local anesthetics are likely to
be present.
I will discuss some reasons why cocaine and other drug inter-
action studies are so seldom done and speculate about consider-
ations leading to useful strategies for controlled human labora-
tory studies or more controlled clinical studies with cocaine.
The emphasis will be on considerations for human studies, even
though there is a large and growing body of literature from animal
studies with cocaine attempting to use drug interaction data to
get at mechanisms for various effects (e.g., Knapp and Mandell
1972; Nigro and  Enero 1981). This valuable literature will only
be mentioned in passing where it has some specific relevance to a
point being made about human psychopharmacologic studies with
cocaine.
Cocaine pharmacokinetics, particularly relationships between
routes of administration and relationships between kinetics and
various physiological and psychological effects, have been studied
in our laboratories for the past few years. In the course of
these studies, we have had an opportunity to measure, in a limited
way, drug interactions that may have clinical relevance, even
though they don’t provide much information on mechanisms of cocaine
effects. A better understanding of mechanisms, of course, is one
of the ideal outcomes of a drug interaction study. Our experience
will illustrate potential research strategy problems and suggest a
few useful considerations to partially overcome them.
WHAT NEEDS TO BE CONSIDERED IN THE PERFECT STUDY
In Adler’s chapter (this volume) on critical factors in studying
drug interactions, a number of basic pharmacokinetic and pharmaco-
dynamic principles are reviewed, Research with cocaine nicely
illustrates some of the problems in fully meeting those principles
in human studies. Table 1 lists a few relevant methodological
issues.
For example, a crucial and primary consideration is the ability of
cocaine to reach its sites of action; in the brain so far as the
user is concerned, but elsewhere in the body as well. The intense
vasoconstriction produced by cocaine (Brodsky and Goldwyn 1977) at
any but the weakest concentrations probably limits the rate of its
uptake with any route of administration except, perhaps. when
smoked. Thus, the time and magnitude of peak effects, duration,
and, perhaps, metabolites are altered as dose/drug concentration
increases.
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TABLE 1 
Some Methodologic Problems in Cocaine
and Other Drug Interaction Studies
1.
2.
3.
4.
5.
6.
7.
8.
9.
Intense vaso (venous and arterial) constriction limits
cocaine uptake.
Metabolism not well understood:
a) Both blood (pseudocholinesterase) and hepatic
metabolism;
b) Possible active metabolites--benzolecgonine and
norcocaine.
Brief duration of action and relatively rapid clearance.
Rapid tolerance to many effects after a few repeated doses.
Marked species differences in metabolism and effects;
genetic differences within species.
Why routes of administration in common use.
Extremely wide range of doses commonly used.
Extremely varied pattern of use, both frequency and other
concurrent drug use.
Adulterants very comnon in illicit cocaine.
After intravenous (iv.) administration in distal forearm or hand
veins, we find lower peak blood cocaine levels and decreased area
under the time-concentration curves, presumably because of veno-
constriction in smaller veins, and a relatively longer sojourn in
the venous return from the arm of injection Slower uptake and
distribution leads to longer exposure to pseudocholinssterase
metabolic activity when the cocaine is injected in small diameter,
more peripheral veins This characteristic not only affects
determination of time course of drug action, but pharmacokinetic
measures as well. Surprisingly, we find no greater variability
with nasal administration than with i.v., and less variability in
peak levels and area under the time-concentration curve with oral
administration The variability does not appear to be due to the
assay (Jacob et al. 1984). Presumably, the vasoconstrictive prop-
erties of cocaine alter and generally delay absorption even more
so in small animals where peripheral veins are smaller or where,
after intraperitoneal administration, absorption may be erratic.
Blood or tissue levels of the drug are seldom measured in animal
studies, so the degree of variability is unknown
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WHAT IS PROPER TIME FOR TESTING BEHAVIORAL OR PSYCHOLOGICAL
EFFECTS?
The time course of most cocaine effects is relatively short when
compared to a number of drugs (e.g., opiates, alcohol, some seda-
tive hypnotics) with which one might want to study the inter-
action. The great discrepancy in duration of effects poses design
problems when selecting the most appropriate time of testing,
particularly with pyschological or cognitive tests that do not
lend themselves to frequently repeated administration
Under usual laboratory conditions, the well-described euphoria or
stimulated state associated with cocaine is frequently, in fact
most often, followed by a sleepy, lethargic, and slightly depressed
state lasting for some hours. The problems associated with study-
ing the brief euphoria are different than the problems of studying
interactions at the later state, though it’s the euphoria most
people are interested in Usually, because of rapidly acquired
tolerance with repeated testing (Fischman and Schuster 1981;
Teeters et al. 1963), it is difficult to study both  phases of drug
effects in the same experiment
COCAINE METABOLISM
The metabolism of cocaine is not well understood for example,
most published human studies often involve only a small number of
subjects (Ambre et al. 1983: Fish and Wilson 1969; Holmstedt
et al. 1979; Inaba et al. 1978; Kogan et al. 1977; Javaid et al
1983; Stewart et al. 1979). Because of two major routes of metab-
olism-one involving pseudocholinesterase in blood and other
tissue, the other by hepatic microsomal enzyme systems-one might
expect relatively great variability in cocaine pharmacokinetics.
Thus, data from small samples of subjects can be misleading. The
question of active metabolites in humans has not been well explored.
There are some suggestions from animal studies that benzoylecgonine
(which is present in extremely high levels in cocaine users) and,
more likely, norcocaine have biological activity (Hawks et al.
1975). Levels and activity of other metabolites and shifts in
metabolic pathways when route, frequency of administration, and
other concurrent drug use are varied is not well worked out in
animals or in humans. Particularly in metabolic differences, the
limited evidence is for great species differences in cocaine
kinetics with good evidence for hepatotoxic metabolites in some
strains of mouse, for example; yet, very little evidence exists
for either the presence of such metabolites or hepatotoxicity in
humans or, for that matter, in other genetic strains of mice
(Freeman and Harbison 1981; Kloss et al. 1984).
DOSE EFFECT FUNCTIONS
Because of the very wide dose range used under illicit conditions,
a proper clinically relevant and full dose-response curve is diff-
icult to achieve with cocaine when research subject safety and
selection characteristics are kept in mind  as they should be
(Barnett et al. 1981). Probably because of acquired tolerance,
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the frequent cocaine user outside of the laboratory can achieve
astronomical blood levels of cocaine and its metabolites with only
minimal cardiovascular/respiratory or behavioral toxicity. Such
levels cannot be safely reproduced in the laboratory under single
dose conditions where subjects have been relatively drug-free just
prior to testing.
The most realistic conditions for studying cocaine and other drug
interactions are after repeated doses of both drugs of interest
The research design issues associated with acute single doses are
complex. The even more complex issues and potential research
design criticisms of multiple dose subchronic cocaine studies are
such that it appears difficult to convince peer reviewers that
such studies are worthy of funding. For example, a relatively
straightforward chronic cocaine administration project by our
group has been reviewed four times by seperate peer review groups,
revised each time, and still is judged to be too expensive and not
important enough to support (three approvals, one disapproval).
Thus, studies of full dose-response curves and of subchronic drug
administration are usually either done in animals, with the result-
ing questions about species differences, or they are done under
quite unnatural and nonrealistic ways in humans, usually with a
limited dose range.
ENVIRONMENT AND TESTING SCHEDULES
Although there is no reason to think that there should not be
circadian or, possibly, metaholic differences in cocaine effects,
most laboratories cannot take this easily into account Our
laboratory is typical in that it usually starts experiments at 8
o’clock in the morning. Many subjects comment that, in their
experience, that’s a rather unnatural time to be taking cocaine
and that 8 p.m. or 1 a.m. would be more appropriate.
Environment is another important variable if behavior and psycho-
logical/cognitive consequences are of major interest (Post et al.
1981). With volunteer subjects drawn from the San Francisco area
subject pool, it’s extremely unusual for someone to take cocaine
alone with no other users present As with many, if not all,
psychoactive drugs, one might expect quite a different sequence
of effects depending on dose and setting interactions, with inter-
personal aspects of the setting being most important.
ROUTE OF ADMINISTRATION
Route of drug administration is a particularly knotty problem with
cocaine, or at least one that makes for complicated designs when
both the demands of controlled scientific studies and relevance to
the real world are considered. Cocaine is taken  by a substantial
number of users via virtually every possible route--i,v., oral, and
nasal, and by smoking, chewing, and, occasionally, other applica-
tions, mainly to mucous membranes (Van Dyke and Byck 1976). Proper
quantitative dosimetry studies, particularly by the smoking route
and by the buccal or chewing route (if swallowing is to be prevent-
ed), are particularly methodologically demanding. Despite our
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laboratory’s experience with quantitative tobacco smoking and mari-
juana smoking studies, we find that the usual style of smoking
cocaine, the rapidity of onset, and the intensity of effects defy
proper measures of dose actually ingested.
I have already commented on the surprisingly similar and great
variability in peak blood levels and AUC when oral is compared to
nasal and i.v. routes (Van Dyke et al. 1978; Wilkinson et al.
1980). Bioavailability is similar when cocaine is taken orally or
nasally (about 30% to 35%). Oral administration offers many advan-
tages for drug interaction studies, yet it would raise questions
Of relevance in the minds of many. There is only a slight advan-
tage to the nasal route in initial uptake of cocaine, at least as
judged by venous blood levels. Perhaps, brain uptake is more
rapid by the nasal route, but we have no evidence for this as
judged by time of onset of various physiologic and subjective
effects. Without radioactive-labeled cocaine and suitable instru-
ments, brain uptake cannot be as easily measured in humans as in
animals (Misra et al. 1975).
The balance between scientific precision and relevance to the real
world of drug use is a tricky one to judge, particularly when
planning drug interaction studies. Rapidly acquired tolerance and
the likelihood of cross-tolerance to other drugs on certain (but
not all) systems complicates any design involving repeated admin-
istration of a drug or involving frequent and infrequent users in
a drug interaction study. Most laboratories investigating cocaine
in humans find markedly diminished cocaine-induced physiologic and
psychological effects after relatively few doses (Fischman and
Schuster 1981). In contrast, in a repeated dose paradigm lasting
more than a few days, the appearance of other and new signs and
symptoms should be expected; for example, irritability, perceptual
acuity increases, and, perhaps, paranoid and delusional thinking
(Lesko et al. 1982; Post and Cbntel 1981). These later signs and
symptoms represent cocaine effects which are just as important and
real (but usually not studied) as the more commonly considered
acute or early drug effects  To properly study tolerance, cross-
tolerance, and drug interactions with these later developing
cocaine effects in humans, relatively expensive experiments done
in rarely available test laboratories equipped for chronic human
studies are necessary. The history of Federal support for chronic
administration studies suggests that the peer review process is
not particularly sympathetic to the need for such studies with
cocaine, even though most individuals would agree that data asso-
ciated with chronic administration is at least as important as
acute, single dose administration studies.
MECHANISM OF ACTION
The ideal and, to some scientists, the major justification for
drug interaction studies is to try to clarify mechanims of one
or the other of the drugs involved. All indications from animal
studies are that neurotransmitter systems affected by cocaine are
multiple, interacting, possibly species dependent, dose dependent,
and frequency-of-dose dependent Simple explanations of mechanisms
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will not soon be forthcoming. Thus, if those who control research
funds believe that understanding mechanisms is a major criterion
or justification of interaction studies in humans, one might
assume fewer such studies will be undertaken.
ROUTE OF COCAINE ADMINISTRATION: AN EXAMPLE OF ITS SIGNIFICANCE
Route of administration has important consequences. For example,
we recently reported (Rowbotham et al. 1984) that a single 100 mg
dose of trazodone diminished a number of the physiologic and
subjective effects of a subsequent oral 2 mg/kg dose of cocaine.
Cocaine-induced increases in blood pressure and pupil size and
decrease in skin temperature were diminished by the trazodone
pretreatment. Trazodone did not alter cocaine-induced changes in
plasma epinephrine or norepinephrine levels and did not markedly
alter the subjective effects of the cocaine.
We repeated the exact protocol with eight subjects but used an
i.v. dose of cocaine, 0.2 mg/kg, which produced similar blood
levels to the oral cocaine dose. By neither the oral nor the i.v.
route was there a significant change in cocaine metabolism. As is
evident in table 2, there were no significant interactions between
the trazodone and the i.v. cocaine. Possible explanations include:
TABLE 2
Trazodone/Cocaine Interactions
Oral vs. Intravenous cocaine
Effect Cocaine cocaine
(Maximum Change Ran 2mg/kg Oral 0.2 mg/kg I.V.
Precocaine Levels)
Heart Rate (BPM)
Placebo
Trazodone
Systolic BP (mmHg)
Placebo
Trazodone
Skin Temperature (‘C)
Placebo
Trazodone
Pupil Size (mm)
Placebo
Trazodone
Subjective High (0-100)
Placebo
Trazodone
+27.1
+18.6
+26.5
+12.2
-7.3
-3.7
+1.02 0 .0001 +1.3 0.31
+0.80 +1.3
P P
0.14 +21.0 0.08
+17.0
0.01 +18.3 0.55
+2l.0
0 .0001 -4.2 0.05
-2.4
38
37
NS 33 0.24
29
Conclusion : No Change after 0.2 mg/kg i.v.
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a more rapid bolus of i.v. cocaine is less likely to be blocked in
the central nervous system (CNS) than is the more gradual rise in
CNS cocaine levels after oral cocaine, The slower absorption of
cocaine orally might allow a different CNS pattern of metabolism
than that reflected in the peripheral blood, A rapid change in
CNS drug levels or function after i.v. doses might trigger off
mechanisms which cannot be blocked or altered by the trazodone.
The point is that there are route differences. Possibly, nasal
administration would be different from either i.v. or oral.
In the trazodone-cocaine interaction study, our group, as often is
the case in human studies, picked doses of drugs which we thought
were in a reasonable range in terms of clinical use, and in some
intermediate range of dose effect function. It would have been
better to use two doses or three doses of both trazodone and
cocaine. The single trazodone dose compared to placebo took 16
test sessions with innumerable blood samples and measures. The
additional complexity from multiple doses was not practical given
the money available for the study. A more serious limitation when
generalizing to clinical situations is that only a single adminis-
tration of trazodone was used, which would not be the case for
most regular drug users
It would nave been more clinically relevant to examine not only
the single administration, but the events 2 or 3 weeks after
chronic trazodone and/or cocaine administration Such a study in
outpatient volunteers would not be possible and probably would be
viewed by the current research program peer review system as pro-
hibitively expensive with hospitalized volunteers. Hence, the
alternatives are either subchronic animal drug interaction studies
or none.
TABLE 3
Caffeine-Cocaine Interactions
(Cocaine 2 mg/kg p.o.)
Peak Effects
Post/Pre Cocaine
Heart Rate
(BPM)
Caffeine
600 mg p.o. Placebo
Before cocaine Before Cocaine P
42.2 28.2 0.01
Systolic BP 33.4 22.3 0.05
(mmHg)
Skin Temperature
(‘C)
-7.8 -6.3 0.10
Pupil Size 1.3 0.99 0.06
(mm)
Subjective High 48.6 36.2 0.01
(O-100)
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WHAT DRUG USE TO CONTROL? WHAT ABOUT COFFEE AND TOBACCO
A practical consideration facing any clinical investigator doing
drug interaction studies is the question of what should be done
about commonly used hugs like tobacco (nicotine) and coffee
(caffeine). It is unusall for a frequent cocaine user not to use
tobacco and coffee. It is even more common for other populations
of dependent individuals, for example, heroin- or alcohol-depen-
dent persons, to use those drugs frequently and at high dose
levels. when setting up protocols, the question always arises,
should such people be allowedtocontinue their tobacco use
through the period of the experiment? Should they be deprived of
tobacco for 12 hours prior to the experiment? Similar questions
arise about coffee.
In some of our earliest pilot studies with cocaine before we were
set up to measure blood levels and pharmacokinetic parameters, we
measured caffeine-cocaine interactions. Table 3 lists a number of
effects of a modest oral dose of cocaine, given an hour after a
substantial dose of caffeine or after a caffeine placebo. Ten
subjects were studied in a crossover design
The table shows peak effects after the cocaine as compared to pre-
cocaine/postcaffeine levels, with heart rate, blood pressure, skin
temperature, pupil size, and subjective effects all being enhanced
by the caffeine pretreatment.
FIGURE  1
Percent Heart Rate Increase After Oral Cocaine:
Tobacco Smokers vs. Nonsmokers
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Whether coffee drinkers, deprived or not, are different in cocaine
responses or drug interaction studies, of course, depends partially
on the importance of the multiple metabolic pathways of cocaine.
Since the significant metabolism of cocaine occurs in both blood
and liver (Foldes 1978; Yamamoto et al. 1953), the likely predic-
tions as contrasted with dealing with a drug that has primarily
hepatic metabolism are more uncertain Whether a particular
research study deprives coffee drinkers of their caffeine or not
is probably less important than reporting just how this issue was
handled so that future investigators can take account of it.
The problem of what to do with tobacco smokers is also relevant.
Because both cocaine and nicotine have similar effects on the
noradrenergic system, one might expect some degree of interaction,
probably cross-tolerance. In fact, when a small group of non-
smokers was contrasted to a group of smokers who regularly used at
least one pack a day of cigarettes, there was some evidence of
cocaine/nicotine cross-tolerance on heart rate (figure 1).
The plots of smoothed functions in figure 1 compare percent in-
crease in heart rate over precocaine levels with plasma levels of
cocaine on both the ascending and descending limbs of plasma
cocaine levels If there were no difference in cocaine effects at
a given plasma level on the ascending and ascending blood level
functions, there would be a relatively straight and narrow line.
Instead, the large, whale-shaped or balloon-shaped pattern in the
figure suggests that a certain degree of acute cocaine tolerance
develops even over the few hours after the single oral dose of
cocaine represented in that figure. Also, the peak increase in
heart rate at any given blood level was substantially greater for
nonsmokers than for smokers, suggesting cross-tolerance. Clear-
ance and t-1/2 did not vary in the two groups.
When subjects receive prolonged (2 to 3 hours) infusions of cocaine
and are allowed to smoke tobacco cigarettes, we have, on each
occasion, measured less cardiovascular  change blood pressure and
heart rate) from the tobacco cigarette smoked later in the cocaine
infusion than prior to it or at the beginning, again indicating
that as tolerance develops to the cocaine, there is cross-tolerance
with the tobacoo. Certainly, the study of interactions between
tobacco and cocaine are worthy and important in their own right
But, even if other drug interactions with cocaine are the primary
interest, both nicotine and caffeine consumption need to be taken
into account.
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Cigarette Smoking: Interactions
With Alcohol, Opiates, and
Marijuana
Nancy K. Mello, Ph.D., and Jack H. Mendelson, M.D.
A number of drugs from diverse pharmacological classes have been
shown to influence tobacco smoking. Alcohol, opiates, and certain
stimulants increase cigarette smoking, whereas marijuana has no
apparent effect on tobacco use. This chapter will describe some
clinical studies of the interactions of alcohol, opiates, and mari-
juana with cigarette smoking. Some factors that may influence cig-
arette and drug interactions will be discussed.
ALCOHOL EFFECTS ON CIGARETTE SMOKING
An association between smoking and drinking was first observed in
studies of alcoholics. Anecdotal observations that alcoholics
tended to be heavy smokers were conflrmed by survey data and self-
report studies (Dreher and Fraser 1967; Maletzky and Klotter 1974;
Walton 1972). Our clinical studies of alcoholic men working for
alcohol on a simple operant task (FR 1000) further strengthened the
impression of concordant alcohol consumption and cigarette smoking
(Mello and Mendelson 1972). Figure 1 shows the covariation between
cigarette smoking and alcohol consumption by a typical subject
(Subject E.S.) during 62 days of concurrent work-contingent ciga-
rette and alcohol acquisition. There was an alternation between
periods of drinking and working for alcohol and cigarettes at the
operant task, even though these self-imposed abstinence periods
were often associated with alcohol withdrawal signs. Cigarette
acquisition declined from baseline during the alcohol availability
phase but smoking was temporally correlated with episodes of drink-
ing. Periods of abstinent working for alcohol and for cigarettes
also covaried (Mello and Hendelson 1972).
The powerful association between cigarette smoking and drinking in
alcoholic men was demonstrated under clinical laboratory conditions
by Griffiths and coworkers (Griffiths et al. 1976). Smoking be-
havior of alcoholic men was measured during 6-hour sessions when
alcohol or a nonalcohol vehicle control solution was available.
Subjects could consume a total of 12 drinks (90 ml each containing
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FIGURE 1
Earning and spending pattern of an alcoholic man working for
cigarettes during a 10-day baseline period; for both cigarettes and
alcohol during a 62-day period of alcohol availability; and for
cigarettes during a 10-day withdrawal period. Tokens to purchase
alcohol and cigarettes were acquired by working at a simple operant
task on an FR 1000. Tokens earned for alcohol were not inter-
changeable with tokens earned for cigarettes. Patterns of earning
(closed circles, shaded area) and spending (open circles, dotted
line) for cigarettes and for alcohol are shown in the top two rows.
Subjects wre allowed to work for alcohol tokens during the last 24
hours of the 10-day baseline period end these tokens could be spent
after 8:00 a.m. on the first day of drinking. Tokens earned that
day are shown at the arrow as first day earnings. Average daily
blood alcohol levels are shown in the third row and the occurrence
of measurable withdrawal signs during drinking are indicated as
asterisks. The type and duration of  withdrawal signs and symptoms
after the subject stopped drinking are shown at the right of figure
1. Reprinted with permission from Mello and Mendelson 1972.
Copyright 1972, Elsevier Science Publishing Company, Inc.
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11.14 g of ethanol) at a rate of one drink every 30 minutes. Sub-
jects could smoke their preferred brand but all cigarettes were
cut to an equal length. Cigarettes were color coded for each
subject and dlscarded butts were collected and weighed. Access to
alcohol consistently induced an increase in cigarette smoking in
comparison to control sessions when no alcohol was available.
Measures of the number of cigarette puffs and butt weight indicated
that the effect was not due to smoking less of each cigarette
(Griffiths et al. 1976).
These findings in alcoholic men have been confirmed (Henningfield
et al. 1984) and extended to social drinkers (Mello et al. 1980a).
Tobacco cigarettes were freely available upon request in a study
designed to examine the covariance between alcohol consumption and
marijuana smoking (Mello et al. 1978), described more fully else-
where in this volume (Mendelson et al.). Figure 2 illustrates the
dramatic covariance between dally alcohol consumption and tobacco
smoking in a male social drinker. This subject (3-MA5) rejected
marijuana except on one occasion and used only alcohol during the
5-day period of alcohol availability and the 10-day period when
alcohol and marijuana were concurrently available. This subject
was a heavy smoker who averaged over a pack a day during the pre-
drug baseline period and the 5 days of marijuana availability.
When alcohol became available, he consumed 22 drinks to achieve a
peak blood alcohol level of 160 mg/100 dl, and almost doubled his
cigarette consumption. On the second day of alcohol availability,
he drank very little and cigarette consumption returned to baseline
levels. When alcohol consumption increased on the third day,
tobacco smoking also increased. This pattern of parallel
fluctuations in smoking and drinking continued throughout the 15
days of alcohol availability.
Pretreatment with a single dose of alcohol did not consistently in-
fluence smoking in social drinkers. Henningf ield and coworkers
(1984) compared the effects of a single alcohol dose (0.125 to 1.8
g/kg) on cigarette smoking in social drinkers and alcoholic men.
Alcohol given 30 minutes before smoking sessions had inconsistent
effects on smoking by social drinkers, Two subjects increased cig-
arette smoking, two subjects decreased cigarette smoking and smok-
ing was unchanged in a fifth subject. Differences in the usual
pattern of alcohol consumption may have contributed to these incon-
sistent results in social drinkers. Subjects who increased smoking
after alcohol reported consuming about one drink each day. The
subject whose smoking did not change reported drinking three to
four times per week whereas the subjects whose smoking decreased
after alcohol usually drank once a month. However, in the alco-
holic group, alcohol pretreatment was associated with significant
increases in cigarette smoking (Henningfield et al. 1984).
In summary, an association between cigarette smoking and alcohol
consmption by alcoholics has been shown consistently In clinical
studies with a variety of techniques (Mello and Mendelson 1971;
Griffiths et al. 1976; Henningfield et al. 1983, 1984). When
social drinkers were given unrestricted access to alcohol over
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FIGURE 2
Tobacco, alcohol, and marijuana use by a male subject over 30 days.
The successive drug free and drug availability conditions are shown
at the top of the figure. The first row shows the number of alco-
hol drinks (closed circle) and marijuana cigarettes (open square)
used each day. The dotted line denotes the average number of
alcohol drinks consumed or marijuana cigarettes smoked during the 5-
or 10-day period of drug availability. The number of tobacco
cigarettes smoked each day in each condition is shown in the second
row. Reprinted with permission from Mello et al. 1980a.
Copyright 1980, The C. V. Mosby Company.
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several days, there also was a striking covariation between alcohol
consumption and cigarette smoking (Mello et al. 1978).
The mechanisms by which alcohol influences tobacco use are unknown.
In a series of behavioral studies, Griffiths and coworkers (1976)
presented data showing that increased cigarette smoking by alco-
holic men was not adjunctively maintained by patterns of drinking
and socializing. Moreover, increased cigarette smoking could not
be accounted for by alterations in number of puffs per cigarette or
amount of cigarettes smoked. Since increased smoklng occurred both
during ethanol sessions and during the remainder of ethanol days
(but not vehicle control days), sequence effects or instructions
probably did not influence the phenomenon (Griffiths et al. 1976).
In social drinkers, daily alcohol consumption (Mello et al. 1980a)
or admfnfstratfon of a single dose of alcohol to individuals re-
porting a history of daily drinking (Henningfield et al. 1984)
appears to be an important determinant of the facilitatory effect of
alcohol on cigarette smoking. It is interesting that a history of
sedative abuse appeared necessary for acute pentobarbital adminis-
tratfon to increase cigarette smoking in alcoholic men
(Henningfield et al. 1983).
Metabolic hypotheses include the possfbflity that alcohol may
change the rate of nicotine metabolism. Since chronic alcohol con-
sumption stimulates the activity of mfcrosomal enzymes which regu-
late drug metabolism (Lieber and DeCarli 1968; Rubin et al. 1970),
and induction of hepatic mitochondrial activity is associated with
an increased rate of nicotine metabolism (Russell 1976), smoking
during drinking could be less reinforcing. However, an alcohol-
related change in nicotine metabolism could account for only one
dimension of the reinforcing properties of cigarettes since many
complex interacting factors, including expectancy, affect drug use.
OPIATE EFFECTS ON CIGARETTE SMOKING
The opiate agonists, heroin and methadone, also have been shown to
be associated with increased cigarette smoking by opiate addicts
during intoxication (Mello et al. 1980b; Chait and Griffiths 1984).
It appears that heroin addicts, like alcoholics, are often heavy
cigarette smokers (Gritz 1980). There has been recent speculation
that endogenous opioids may mediate the reinforcing effects of cig-
arette smoking (Karras and Kane 1980; Chernick 1983; Tobin et al.
1983; Pomerleau et al. 1983). Studies of the interactions between
cigarette smoking, opioid agonists, opioid antagonists, and an
opioid mixed agonist-antagonist, buprenorphine, will be reviewed in
this section.
Opioid Agonist Interactions with Cigarette Smoking
The effects of heroin self-administration on cigarette smoking were
studied in 12 adult male volunteers with a history of heroin addic-
tion and cigarette smoking (Mello et al. 1980b). Each volunteer
gave informed consent for participation in studies of the effects
of new pharmacotherapies on heroin self-administration in a
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clinical research ward setting . Naltrexone (50 mg/day p.o.), a
long-acting narcotic antagonist, was compared with naltrexone pla-
cebo under double-blind conditions. Nine of the subjects in the
nal trexone study were cigarette smokers. Three other subjects were
involved in studies of buprenorphine, a new partial-agonist antag-
onist (cf. Jaslnski et al. 1978; Lewis et al. 1983). The effects
of buprenorphfne and buprenorphine placebo on heroin self-adminis-
tration also were compared under double-blind conditions. Naltrex-
one and buprenorphine each significantly suppressed heroin self-
administration by heroin addicts under research ward conditions
(Mello et al. 1981, 1982; Mello and Mendelson 1980; Meyer and Mirin
1979). The effects of heroin and methadone on cigarette smoking by
eight subjects assigned to the placebo naltrexone condition, one
subject assigned to active naltrexone, and three subjects assigned
in the placebo buprenorphine conditions are described below.
Buprenorphine- and naltrexone-maintained subjects were closely
matched in age (X = 27 years, range 22 to31) and social and educa-
tional background. Subjects were fully informed about the nature
and duration of each phase of the study, and vere free to withdraw
at any time. All subjects were in good health and showed no evi-
dence of psychiatric or medical abnormalities as determined by ap-
propriate clinical and laboratory examinations. Subjects lived on
a clinical research ward throughout the study. Each subject served
as his own control during a drug-free baseline and each successive
drug condition. Consequently, it was possible to compare the ef-
fect of heroin, methadone, and control conditions on cigarette
smoking by each subject.
Naltrexone subjects were studied over 34 consecutive days in groups
of  four. The sequence of conditions was as follows: A 9-day drug-
free baseline, a 10-day period of heroin availability during which
naltrexone or naltrexone placebo was given; a 5-day detoxification
phase during which methadone was given to subjects on naltrexone
placebo; 7 drug-free days, followed by 3 days of inpatient main-
tenance on nal trexone. Subjects given naltrexone during heroin
availability continued to receive naltrexone throughout the study.
The eight cigarette smokers assigned to naltrexone placebo condi-
tions each self-administered heroin. The one cigarette smoker who
was given active naltrexone did not self-administer heroin.
Buprenorphine subjects were studied over 39 consecutive days. The
sequence of conditions for the buprenorhine subjects was as fol-
lows : A 5-day drug-free baseline; a 14-day period during which
buprenorphine (or buprenorphfne placebo) vas administered in as-
cending doses; 10 days of maintenance with buprenorphine (8 mg/
day) or placebo when heroin was also available; 5 days during which
methadone was given to subjects on buprenorphine placebo and bupre-
norphine in decreasing doses was continued for subjects given
active buprenorphine; 3 drug-free days were followed by 2 days on
nal trexone prior to discharge. Three cigarette smokers were
assigned to the buprenorphine placebo condition and each
self-administered heroin.
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Tobacco and Heroin Acquisition. Tobacco cigarettes were available
during all phases of the study. Each subject purchased his pre-
ferred brand of cigarettes. However, the nursing staff retained
the cigarettes and distributed them upon request. The time of each
cigarette request was recorded. Cigarette puff volume and puff
duration were not measured In these ambulatory subjects (cf. Jarvik
et al. 1977).
Subjects worked for heroin or for money at a simple operant task on
a second order fixed ratio 300, fixed interval 1-second schedule of
reinforcement FR 300 (FI 1-sec:S). Only the first response after a
1-second interval had elapsed counted as an effective response and
300 responses were required to earn one purchase point. Approxi-
mately 90 minutes of sustained performance on an PI 1-sec schedule
earned 18 purchase points which could be used to buy one dose of
heroin or exchanged for $1.50 in cash upon completion of the study.
Subjects could work for money throughout the study but points
earned for money could not be exchanged for points for heroin.
When both heroin and money mere available, subjects chose to work
for one or the other each time they activated the operant
instrument. Details of the operant apparatus and procedures are
presented elsewhere (Hello et al. 1981).
Subjects self-administered a fixed dose of heroin intravenously
under the supervision of a physician. Subjects could omit any
heroin injection but could not receive doses larger or smaller than
specified in the protocol. Medical considerations preclude un-
limited access to heroin. Naltrexone subjects could take a maximum
of 40 mg of heroin each day in four 10 mg doses (at 8:00 a.m., 1:00
p.m., 8:00 p.m., and 2:00 a.m.). Buprenorphine subjects could take
a maximum of 21 mg of heroin in three doses during the first 5 days
of buprenorphine (or placebo) maintenance (7 mg at 9:00 a.m., 5:00
p.m., and 1:00 a.m.); and a maximum of 41.5 mg of heroin (13.5 mg
per dose at the same times) during the second 5 days of buprenor-
phine maintenance.
Effect of Drug Conditions on Smoking. Ten of the twelve heroin
addicts were heavy smokers. One subject smoked 1 1/2 packs of
cigarettes or more per day and nine subjects smoked one pack or
more a day during the drug-free baseline period. The other two
subjects smoked less than a pack per day. The naltrexone placebo
group smoked significantly (p< .01) more cigarettes per day during
the 10 days of heroin self-administration than during the drug-free
baseline as evaluated by t tests. Average cigarette smoking during
the period of heroin availability was also significantly greater
than during methadone detoxification (p< .001). There were no
significant differences in cigarette smoking during the drug-free
baseline periods which preceded and followed heroin and methadone.
Cigarette smoking during methadone detoxification also did not
differ from the drug-free baseline periods. Consequently, the
significant increase in cigarette smoking appeared to be specific
to the heroin condition.
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The one subject given naltrexone, rather than naltrexone placebo,
did not self-administer heroin since naltrexone effectively blocked
heroin’s subjective and physiological effects. Although this sub-
ject lived on the research ward with other subjects who were taking
heroin and smoking more, there were no significant differences in
his smoking behavior across conditions. This subject smoked an
average of 25 cigarettes per day over the entire study. This sug-
gests that heroin, rather than any nonspecific social interaction
factors, accounted for the increase in cigarette smoking seen in
the nal trexone placebo group.
Illustrative data for six individual naltrexone placebo subjects
are shown in figures 3 and 4. Heavy smokers who smoked an average
of over one pack of cigarettes per day during baseline are shown in
figure 3. Moderate smokers who smoked a pack a day or less during
baseline are shown in figure 4.
Each of the heavy smokers smoked significantly more cigarettes
during heroin use than during the drug-free baseline (p< .01).
 Two subjects (4-HG-1, 1-HT-1) took all or almost all of the four
heroin doses available each day. Therefore, variations in ciga-
rette smoking observed during heroin self-administration were not
related to the specific daily dose of heroin. Although subject
2-HA-1 tended to smoke least on the days that he took the fewest
heroin doses, the fluctuations in cigarette smoking did not appear
to vary consistently with the heroin dose. An increase in smoking
to three packs a day during the final naltrexone period immediately
before discharge was unusual and has not been observed in other
heroin addicts studied under these conditions. Since the subject
who was maintained on active naltrexone throughout the study did
not show comparable elevations in smoking, it is difficult to
attribute this finding to the effect of naltrexone per se.
Among the moderate smokers shown in figure 4, the subject (3-HT-1)
who smoked least during baseline (an average of 15 cigarettes per
day), increased smoking most dramatically when heroin became avail-
able, to an average of 32 cigarettes per day (p< .001). This sub-
ject took all the available doses of heroin. Subject 1-HG-1 smoked
an average of 20 cigarettes per day during baseline. During the
period of heroin availability, he took most of the heroin available
and increased smoking by an average of seven cigarettes per day (p
< .01). Subject 4-HA-2 smoked an average of four cigarettes more
per day during the period of heroin availabillty (p< .05) and also
took most of the heroin available.
The number of cigarettes smoked per day across the successive con-
ditions of the study by the three buprenorphine placebo subjects
is shown In figure 5. Since there were only three cigarette
smokers in the buprenorphine placebo group, changes in cigarette
smoking as a function of drug conditions were analyzed for Indi-
vidual subjects with t tests. The introduction of buprenorphine
placebo did not result in significant changes in cigarette smoking
by any subject in comparison with baseline. Heroin self-administra-
tion was associated with an abrupt increase in cigarette smoking by
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FIGURE  3
Cigarette smoking across successive drug conditions. Cigarette
smoking over 34 consecutive days is shown for three individuals who
were heavy tobacco smokers. Each subject was given naltrexone
placebo durlng heroin availability. The successive drug conditions
(drug free baseline, heroin plus naltrexone placebo, methadone
detoxification, drug free baseline, and naltrexone availability)
are shown across the top of the figure. Consecutive days in each
condition are shown on the abscissa. The number of heroin doses
taken each day by each subject is shown at the top of each row.
The number of cigarettes smoked each day is shown on the ordinate.
Reprinted with permission from Mello et al. 1980b.
Copyright 1980, Springer-Verlag, Heidelberg.
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FIGURE 4
Cigarette smoking across successive drug conditions. Cigarette
smoking over 34 consecutive days is shown for three individuals who
were moderate tobacco smokers. Each subject was given naltrexone
placebo during heroin availability. The successive drug conditions
(drug free baseline, heroin plus naltrexone placebo, methadone
detoxification, drug-free baseline, and naltrexone availability)
are shown across the top of the figure. Consecutive days in each
condition are shown on the abscissa. The number of heroin doses
taken each day by each subject is shown at the top of each row.
The number of cigarettes smoked each day is shown on the ordinate.
Reprinted with permission from Mello et al. 1980b.
Copyright 1980, Springer-Verlag, Heidelberg.
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FIGURE 5
Cigarette smoking across successive drug conditions. Cigarette
smoking by three individual subjects is shown over 39 consecutive
days. Each subject was given buprenorphine placebo prior to and
during heroin availability. The succcssive drug conditions (drug-
free baseline, buprenorphine placebo, heroin plus buprenorphine
placebo, and methadone detoxification) are shown at the top of the
figure. Consecutive days in each condition are shown on the
abscissa. The number of heroin injections taken each day by each
subject is shown at the top of each row. The number of cigarettes
smoked each day are shown on the ordinate. Missing data are indi-
cated by an asterisk. The day on which each subject left the study
is indicated by  a star. Reprinted with permission from Mello et
al. 1980b. Copyright 1980, Springer-Verlag, Heidelberg.
all subjects. Each subject smoked more cigarettes on the average
during heroin self-administration than during the drug-free base-
line or during buprenorphine placebo. However, only one subject
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(1-HB-1) smoked significantly more during heroin use than during
the immediately preceding buprenorphine placebo conditions (p <
.001). Two subjects (1-HB-1, 2-HB-1) smoked significantly more
cigarettes (p< .01)  during the period of heroin self-administra-
tion than during the subsequent methadone detoxification period.
The other subject (4-HB-1) left the study before the methadone
detoxification period.
Temporal Patterns of Cigarette Smoking as a Function of Heroin Use.
In an effort to determine if the significant increases in cigarette
smoking by the naltrexone placebo subjects during heroin avail-
ability were generalized increases or were temporally associated
with each heroin injection, two types of analyses were done. The
number of cigarettes smoked before and after each heroin injection
was compared and the temporal distribution of cigarette smoking
during bastline, heroin, and methadone conditions was examined.
The number of cigarettes smoked during the hour preceding and the
hour following each heroin injection was tabulated and the differ-
ences in cigarette smoking before and after heroin were evaluated
for individual subjects. An analysis of variance showed that the
time of day of the heroin injection did not result in significant
differences in cigarette smoking. Therefore, it was possible to
pool all pre- and post-heroin injection cigarette smoking data for
each subject for matched t test analysis.
Five of the eight subjects smoked significantly more cigarettes
during the hour immediately following heroin injection than during
the hour preceding heroin self-administration (p< .01 to .001).
The other three subjects smoked fewer cigarettes immediately
following a heroin injection and this decrease in smoking was
significant for two subjects (p< .05).
The average number of cigarettes smoked by the naltrexone placebo
group during consecutive 6-hour periods was tabulated for each of
three conditions: drug-free baseline, heroin availability, and
methadone detoxification. The temporal distribution of group
cigarette smoking during each of these conditions is shown in
figure 6. There were no significant differences in number of cig-
arettes smoked as a function of the drug condition during the morn-
ing to early afternoon (8:00 a.m. to 2:00 p.m.) and during the af-
ternoon to early evening (2:00 p.m. to 8:00 p.m.) periods. How-
ever, significantly more cigarettes (p< .01) were smoked in the
evening and at night (8:00 p.m. to 2:00 a.m. and 2:00 a.m. to 8:00
a.m.) during heroin use than during baseline. Subjects smoked
significantly more cigarettes in the morning (p< .05) and at night
(p< .01) during heroin self-administration than during methadone
detoxification. Since heroin was given once every 6 hours (at 8:00
a.m., 1:00 p.m., 8:00 p.m., and 2:00 a.m.), this shift in the
temporal distribution of smoking could reflect the fact that sub-
jects were awake longer and therefore smoked more. However,
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FIGURE 6
Cigarettes smoked as a function of time of day. The number of
cigarettes smoked ( + S.E.) are shown on the ordinate and
consecutive 6-hour periods are shown on the abscissa. The top row
shows the number of cigarettes smoked by the naltrexone placebo
group (N=8) during the drug-free baseline (open circle), the 10
days of heroin availability (closed square), and the methadone
detoxification period (open triangle). The second row shows the
number of cigarettes smoked by the buprenorphine placebo subjects
(N=3) during the drug-free baseline (open circle), heroin
availability (closed square), and methadone detoxification (open
triangle). Reprinted with permission from Mello et al. 1980b.
Copyright 1980, Springer-Verlag, Heidelberg.
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comparison of hours slept during baseline, heroin self-administra-
tion, and methadone detoxification revealed no significant differ-
ences by t test analysis. Consequently, there were equivalent
waking hours available for smoking during each condition.
The temporal distribution of smoking by the buprenorphine placebo
group was also analyzed as a function of consecutive 6-hour periods
during the drug-free baseline, buprenorphine placebo, and heroin
availability conditions. These data are shown in the lower panel
of figure 6. Heroin injections occurred three times a day, at 9:00
a.m., 5:00 p.m., and 1:00 a.m. Although more cigarettes were
smoked during heroin use in the evening and at night than during
the drug-free baseline, these differences were not statistically
signif icant. There were also no significant differences in hours
of sleep during baseline and heroin self-administration. However,
these subjects did sleep significantly more during methadone detox-
ification than during heroin self-administration (p< .05).
Intercigarette Interval Analysis. In order to determine if there
were marked changes in the overall rate of cigarette smoking as a
function of heroin self-administration, the distribution of inter-
vals between successive cigarette requests was examined for three
representative placebo naltrexone subjects. The number of ciga-
rette requests occurring at intervals of less than 15 minutes, 16
to 30 minutes, 31 to 45 minutes, and so on were tabulated for the
drug-free baseline condition and for the period of heroin self-
administration for individual subjects. The percent of the total
number of cigarettes smoked during each condition at each inter-
cigarette interval was calculated. The distributions of inter-
smoking intervals are shown in figure 7.
Subject 3-HT-1 increased cigarette smoking during heroin self-
administration by an average of 17 cigarettes per day or 113% (cf.
figure 3). The peak intercigarette Interval distribution fell
between 16 and 30 minutes during both baseline and heroin condi-
tions. However, during baseline, he smoked 19% more of the total
number of cigarettes at intervals of 46 to 60 minutes, 61 to 75
minutes, and 76 to 90 minutes than during heroin self-adminis-
tration. When heroin became available, this subject smoked more
cigarettes more frequently,  i.e., 72% of all cigarettes were smoked
at intervals between zero and 45 minutes. During baseline, he only
smoked 50% of his total cigarettes at this rate and 6% of the
cigarettes were smoked at intervals of 6 or more hours.
Subject 1-HA-1 smoked an average of 10 more cigarettes per day
during heroin self-admlnistration than during baseline and averaged
45 cigarettes per day (cf. figure 3). The peak and form of the
distribution of intercigarette intervals during baseline and heroin
conditions were very similar. However, he smoked 12% more ciga-
rettes at 0- to 30-minute intervals during heroin self-adminis-
tration than during baseline.
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FIGURE 7
Distribution of intercigarette intervals during baseline and heroin
use. The interval between successive cigarette requests is shown
on the abscissa. The percent of the total cigarettes smoked during
the 9-day baseline period and 10 days of heroin availability is
shown on the ordinate. Intersmoking interval data are presented
for three naltrexone placebo subjects who were moderate or heavy
smokers. Reprinted with permission from Mello et al. 1980b.
Copyright 1980, Springer-Verlag, Heidelberg.
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Subject 4-HG-1 also smoked an average of 10 more cigarettes per day
during heroin self-administration than during baseline and averaged
39 cigarettes per day during that period (cf. figure 3). However,
there was no appreciable change in the distribution of interciga-
rette intervals, except that he smoked fewer cigarettes at
intervals of 3 to 6 hours during heroin self-administration than
during baseline.
These distributions of intercigarette intervals suggest that the
increased smoking during heroin self-administration reflects a more
rapid rate of smoking, rather than smoking more cigarettes at long
intervals of 3 hours or more. The consistency of the peak of the
distribution of intersmoking intervals within and across subjects
and across conditions indicates that these moderate to heavy
smokers usually smoke a cigarette every 15 or 30 minutes (Mello et
al. 1980b).
Methadone Effects on Cigarette Smoking. These observations that
intravenous heroin self-administration is associated with increased
cigarette smoking have recently been extended to oral administra-
tion of another opioid agonist, methadone (Chait and Griffiths
1984). Five male volunteers with a history of opiate drug abuse,
and maintained in a methadone maintenance treatment program, were
studied. Dally 120-minute sessions were held five times each week.
Ninety minutes before the smoking session, subjects were given the
pretreatment drug (methadone, dextromethorphan, or placebo) and
then allowed to smoke ad libitum for 60 minutes. A 30-minute
period of cigarette deprivation preceded each smoking session.
These subjects were maintained on 40 to 60 mg of oral methadone.
The methadone pretreatment dose was 0.5, 1.0, or 2.0 times each
individual subject’s maintenance methadone dose (Chait and
Griffiths 1984).
Figure 8 shows that methadone pretreatment resulted in dose de-
pendent increases in cigarette smoking in four of the five sub-
jects studied. Group data shows that the mean number of cigarettes
smoked during the two-hour session increased twofold after the high
dose methadone in comparison to placebo. Pretreatment with placebo
or dextromethorphan had no consistent appreciable effect on
cigarette smoking. A number of other smoking related measures also
increased with increasing methadone doses. Subjects changed their
smoking behavior to increase their smoke intake, i.e., both the
number and duration of puffs per session increased at higher metha-
done doses. Moreover, the total time spent puffing during the
session increased 2.8-fold after the high dose of methadone in
comparison to placebo. Correlated increases in expired air CO
levels indicated that subjects were actually inhaling more smoke
during the high methadone dose smoking sessions. Similarly, there
was a decrease in the latency to the first puff of the session as
well as the mean intercigarette interval with increasing methadone
doses (Chait and Griffiths 1984).
these findings that methadone pretreatment can produce substantial
increases in cigarette smoking are concordant with previous
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FIGURE 8
The number of cigarettes smoked per session as a function of drug
pretreatment for individual subjects and for the group (bottom
right panel). Bars show ±1 S.E.; P, placebo; D, dextromethorphan;
M, methadone. Reprinted with permission from Chait and Griffiths,
1984. Copyright 1984, American Society for Pharmacology and
Experimental Therapeutics.
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observations of the effects of methadone detoxification. As the
daily methadone maintenance dose was decreased, the number of
cigarettes per day also gradually decreased (Bigelow et al. 1981).
One possible implication of the association between opioid agonist
administration and increased cigarette smoking is that endogenous
opioids may contribute to the reinforcing effects of cigarette
smoking . Pomerleau and coworkers (1983) have reported that after
cigarette smoking, increased plasma nicotine levels were signifi-
cantly correlated with increased beta-endorphin levels, with no
change in ACTH levels. These findings suggest the importance of
examining the effects of opioid antagonists on cigarette smoking.
Opiate Antagonist Effects on Cigarette Smoking
Unfortunately, studies of the effects of opioid antagonists on
cigarette smoking have yielded inconsistent and contradictory find-
ings. Nal trexone, a long acting opioid antagonist, did not change
cigarette smoking in one heroin addict subject (Mello et al.
1980b). The naltrexone-maintained (50 mg/day p.o.) subject smoked
an average of 25 cigarettes per day during a 9-day drug free base-
line and a 10-day period of naltrexone maintenance (Mello et al.)
The effects of administration of a short acting opioid antagonist,
naloxone (10 mg s.c.), on cigarette smoking was studied in three
men and four women under ordinary working conditions (Karras and
Kane 1980). Subjects were offered a cigarette every 30 minutes for
3 hours following naloxone administration and asked to report their
desire for a cigarette, their mood, and their satisfaction with the
cigarette (if smoked). Subjects were allowed to smoke a cigarette
only for 2 minutes and were requested to abstain from cigarettes
except during the smoking trials. The experimenters recorded the
number of puffs taken and weighed the butts of the cigarettes.
Subjects took 32% fewer puffs and smoked 30% less often after
naloxone administration than after placebo administration. The
amount of each cigarette smoked, inferred from the weight of the
remaining cigarette butt, was also reduced by 33%. Karras and Kane
(1980) interpreted these data as consistent with the hypothesis
that beta-endorphin is released during smoking and may be partially
responsible for smoking maintenance.
These findings were not replicated under laboratory conditions in
subjects given a range of naloxone doses (0.625, 0.25, 1.0, and 4.0
mg/kg i.m.) when a number of smoking related measures including
expired carbon monoxide levels were also examined (R.R. Grifflths,
Personal Communication, 1984). Naloxone or placebo was adminis-
tered 60 minutes before the 120-minute smoking sessions in seven
normal subjects. Each subject was used as his own control in three
treatment conditions with at least 48 hours between smoking
sessions. Naloxone administration had no effect on any smoking
related measures including carbon monoxide levels in expired air
across the naloxone dose range studied.
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At present, most of the evidence suggests that narcotic antagonists
do not significantly alter cigarette smoking under both acute and
chronic administration conditions. However, the effects of opiate
antagonists have been studied in a total of 15 smokers in three
different laboratories and findings have been inconsistent. Addi-
tional studies should provide a more definitive answer to this
question.
Opioid Mixed Agonist-Antagonist Effects on Cigarette Smoking
Since opioid agonists consistently increase cigarette smoking
(Mello et al. 1980b; Chait and Griffiths 1984) and opiate antagon-
ists either have no effect or decrease smoking behavior, it is
interesting to consider the effects of an opioid that has both
agonist and antagonist properties. Buprenorphine is a potent
opioid agonist with respect to analgesia, physiological, and
subjective reactions in man and is also a long acting opiate
antagonist like naltrexone (Houde 1979; Jasinski et al. 1978; Levis
et al. 1983). Buprenorphine has been shown to produce opiate
agonist-like subjective effects comparable to morphine and
methadone. A comparison of the effects of single doses of bu-
prenorphine (0.2 to 2.0 mg), morphine (15 to 40 mg), and methadone
(30 mg) showed similar euphoria and liking scores on several self-
report measures. An 8 mg/day dose of buprenorphine produced sub-
jective effects and euphoria equivalent to that produced by 120
mg/day of morphine (30 mg q.i.d.) or 40 to 60 mg of methadone
(Jasinski et al. 1978).
The agonist and antagonist components of buprenorphine appear to
have different durations of action (Lewis et al. 1983). Bupre-
norphine can antagonize high doses of morphine (60 to 120 mg) for
almost 30 hours (Jasinski et al. 1978), whereas an analgesic dose
of buprenorphine effectively relieves pain for about 6 hours (Houde
1979).
The effects of huprenorphine on heroin self-administration and
cigarette smoking were evaluated under clinical research ward con-
ditions (Mello and Mendelson 1980; Mello et al. 1982). Nine heroin
addict subjects were cigarette smokers. Three were sssigned to
buprenorphine treatment and two to buprenorphine placebo treatment.
Four subjects participated in two separate studies and received
both buprenorphine and placebo in a counterbalanced order; i.e.,
two received buprenorphine first and two received placebo first.
Consequently, final data are reported for seven subjects assigned
to buprenorphine and six subjects assigned to placebo under double
blind conditions.
After a 5-day drug free baseline, subjects were given ascending
doses of buprenorphine or its placebo for 14 days at 8 a.m. each
day. An initial subcutaneous buprenorphine dose of 0.5 mg/day was
gradually increased by 0.5 mg per day for 12 days and by 1 mg per
day for 2 days to a final dose of 8 mg/day s.c. The volume of
placebo and buprenorphine injections was equivalent at each dose
level. Subjects were maintained on 8 mg/day of buprenorphine (or
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placebo) for 10 days during which they could work for i.v. heroin
at a simple operant task. They were then gradually withdrawn from
buprenorphine over 5 days in a dose reduction schedule of 7, 6, 5,
3, and 1 mg/day. All subjects assigned to placebo buprenorphine
used heroin and were detoxified with methadone in progressively
decreasing doses (25 to 5 mg/day p.o.) over 5 days.
Heroin self-administration was significantly suppressed by bupre
norphine treatment, whereas placebo maintained subjects self-admin-
istered 93% to 100% of all the heroin available (Mello and
Mendelson 1980; Mello et al. 1982). Placebo maintained subjects
increased cigarette smoking significantly during heroin self-
administration (Mello et al. 1980b).
Buprenorphine treatment was associated with a significant increase
in tobacco smoking in comparison to the drug free baseline. During
the 14-day ascending dose phase, buprenorphine doses of 2.0 mg/day
s.c. and above were associated with significant increases in ciga-
rette smoking (p< .01). During the 10-day period of buprenorphine
maintenance at 8 mg/day, the significant increase in smoking ob-
served during buprenorphine induction was sustained. Subjects
smoked significantly more cigarettes during the period of high dose
buprenorphine maintenance than during the buprenorphine induction
phase (p < .01). As the daily buprenorphine dose was decreased
from 7 to 1 mg/day, cigarette smoking also decreased and returned
to baseline levels during the postbuprenorphine drug free period.
Subjects in the buprenorphine treatment group and the placebo
treatment group smoked an equivalent number of cigarettes during
the predrug and postdrug free baseline periods (Mello et al. 1985).
These data suggest that the agonist properties of buprenorphine
remained salient in terms of its effects on cigarette smoking over
29 days of chronic administration. These findings are interesting
in view of the fact that the antagonist component of buprenorphine
appears to last for almost 30 hours (Jasinski et al. 1978), whereas
the agonist analgesic effects persist for about 6 hours (Houde
1979). Tolerance to most of the opioid agonist-like side effects
developed within 21 days of chronic buprenorphine maintenance in
most subjects (Mello et al. 1982).
Buprenorphine appears to act primarily like an opioid agonist in
its effects on cigarette smoking (Mello et al. 1985). Bupre-
norphine also acts primarily like an agonist rather than an an-
tagonist on male pituitary hormones (Mendelson et al. 1980).
chronic buprenorphine maintenance was associated with the sup-
pression of luteinizing hormone (LH) and prolactin (PRL) levels, a
finding comparable to that previously observed in heroin users and
heroin addicts treated with methadone and with LAAM (Mendelson and
Mello 1975, 1982; Mendelson et al. 1974, 1975 a,b,c). In contrast,
opioid antagonists such as naltrexone have been shown to be as-
sociated with an increase in LH in normal adult males (Mendelson et
al. 1980; Ellingboe et al. 1982), and naloxone is frequently used
to stimulate LB for endocrine studies in the males of several
species (Moult et al. 1981; Mirin et al. 1976; Cicero et al. 1979,
1982).
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In summary, the facilitatory effects of opiofd agonists on ciga-
rette smoking appears to be a robust finding consistently observed
under different experimental conditions (Mello et al. 1980b; Chait
and Griffiths 1984). The decrease in cigarette smoking associated
with gradual decreases In daily methadone maintenance doses
(Bigelow et al. 1981) was also seen during both buprenorphine and
methadone detoxification (Hello et al. 1985). However , despite
these converging findings, it is difffcult to account for the
apparent effects of opioid agonists on smoking. It is not clear if
more cigarettes were smoked during opioid use because they were
more reinforcing, or because their effects were attenuated by
opioid intoxication and more cigarettes were required (cf. Hello et
a l . 1980b). Chait and Griffiths (1984) suggested that methadone
might block or attenuate the aversive effects of cigarette smoking
such as throat irritation which could limit smoking under drug free
conditions.
The possible contribution of endogenous opioids to cigarette smok-
ing is a provocative hypothesis, but still quite speculative. The
notion that an opiofd antagonist such as naloxone or naltrexone
might lower cigarette smoking by antagonizing smoking related in-
creases in plasma beta-endorphin levels (cf. Karras and Kane 1980;
Pomerleau et    al  . 1983) has been challenged by studies showing that
opioid antagonists have no effects on cigarette smoking (Mello et
al . 1980b; R.H. Griffiths, Personal Communication, 1984). The fact
that the opioid mixed agonist-antagonist buprenorphine significant-
ly increased cigarette smoking is also inconsistent with the hy-
pothesis that opioid antagonists might antagonize cigarette smoking
through related changes in endogenous opioids. Since buprenorphine
effectively antagonized both the subjective and physiological ef-
fects of heroin and decreased heroin self-administration by heroin
addicts over  10 days (Mello and Mendelson 1980; Hello et al. 1982),
it is likely that buprenorphine antagonized endogenous opioid
levels as well . Alternatively, if increases in beta-endorphin
levels associated with increased nicotine levels following smoking
(Pomerleau et al. 1983) are important for the reinforcing proper-
ties of cigarette smoking, it could be argued that more cigarettes
were smoked during buprenorphine treatment because they were less
reinforcing.
MARIJUANA EFFECTS ON CIGARETTE SMOKlNG
In contrast to alcohol, opiates, and certain stimulants, marijuana
does not appear to alter tobacco smoking in any systematic way
(Hello et al. 1980a; Hello and Mendelson, in press). Examination of
cigarette smoking in a study of the covariation between alcohol and
marijuana use (see Hendelson et al., this volume) showed that there
were no dose related changes in cigarette smoking during marijuana
availability. The introduction of marijuana did not change average
cigarette smoking in comparison to the drug free baseline, except
in one occasional tobacco smoker who smoked more during both
alcohol and marijuana availability (Hello et al. 1980a).
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Recently, we have examined cigarette smoking during marijuana
smoking in women (Mello and Mendelson, in press). Sixteen of 21
women studied were cigarette smokers. Cigarettes were freely
available upon request. Women could earn one 1-gram marijuana
cigarette or 50¢ in 30 minutes of performance at a simple operant
task on a second order FR 300 (FI 1 sec:S) schedule of reinforce-
ment. A 7-day drug free baseline was followed by 21 days of
marijuana availability and a postmarijuana drug free period of
7 days. The amount and temporal pattern of tobacco cigarette
smoking observed during drug free conditions were not changed
during concurrent marijuana use by either heavy or moderate
marijuana smokers (Mello and Mendelson, in press).
Although it might be expected that smoking marijuana and tobacco
would be antithetical, in fact, these drugs usually were smoked in
close temporal contiguity by both men and women (Mello et al.
1980a, Mello and Mendelson,in press). These data have unfortunate
implications for one medical consequence of marijuana and tobacco
smoking, impaired pulmonary function. Adverse effects of marijuana
smoking on pulmonary function have been consistently demonstrated
in numerous studies with men (Tashkin et al. 1973, 1976, 1980;
Vachon et al. 1973; Bernstein et al. 1976). Studies of pulmonary
function in these female marijuana users have shown that single
breath carbon monoxide diffusion capacity was signifcantly lower
than in tobacco cigarette smokers and nonsmoker control subjects
(Tlllea et aL,in press). These data were interpreted to suggest that
marfjuana smoking may cause significant impairment of pulmonary
function associated with the gas exchange surface of the lungs.
TOBACCO SMOKING AND DRUG INTERACTIONS
Alcohol, opioid agonists, and mixed agonist-antagonists as well as
certain stimulants (Schuster et al. 1979; Henningfield and
Griffiths 1981) have been shown to be associated with increased
cigarette smoking. Since these drugs have a broad spectrum of
actions, it is difficult to construct a plausible hypothesis con-
cerning specific pharmacological effects on cigarette smoking.
Nicotine appears to be the primary pharmacological reinforcer in
cigarette smoking (Jaffe and Jarvik 1978; Russell 1976; Gritz
1980), but it has been difficult to separate the effects of nico-
tine from other constituents of tobacco smoke. The  pharmaco-
kinetics of nicotine make it an almost ideal drug reinforcer.
Nicotine inhaled from cigarettes reaches the CNS within seconds and
appears to produce rapid behavioral effects which diminish over 30
to 40 minutes (Jaffe and Jarvik 1978). There is increasing
evidence that subjects adjust their smoking behavior to maintain
constant nicotine levels when low nicotine content or short ciga-
rettes are provided (Benowitz and Jacob 1984; Herning et al. 1981;
Gritz 1980; Chait and Griffiths 1982; Robinson et al. 1983). But,
analysis of several aspects of the microtopography of smoking
behavior, such as puff duration (Nemeth-Coslett and Griffiths 1984)
and puff frequency (Griffiths et al. 1982), has not shown
significant effects of nicotine dose. Consequently, the role of
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nicotine in maintaining cigarette smoking is continually under
evaluation (Jarvik et al. 1977; Kumar et al. 1977).
In experimental animal studies, intravenous nicotine can be a
positive or a negative reinforcer depending upon the schedule of
nicotine reinforcement and the behavioral history of the animal
(cf. Goldberg et al. 1983 for review). Similar results have been
obtained in human studies of the reinforcing properties of intra-
venous nicotine (Henningfield and Goldberg 1983). These studies
Illustrate the complexity of analyzing the reinforcing properties
of nicotine alone.
The interactions between cigarette smoking and other drugs from
various classes presents an even greater challenge. This problem
illustrates aome as yet unresolved questions concerning the nature
of the reinforcer in polydrug use. The simultaneous use of drugs
which appear to have contradictory pharmacological effects is
especially puzzling. We have suggested elsewhere that polydrug use
may have less to do with the pharmacological properties of the
drugs or the anticipated effects than with the capacity to produce
some change in subjective states (Mello 1977, 1978, 1983). Change,
rather than any particular direction of change, may be the goal of
the polydrug user. It appears that any drug or drug combination
that has definite stimulus properties and behavioral effects for
the user may have abuse potential. Since multiple drug use appears
to be an increasingly common pattern, the way in which drugs inter-
act to modulate use patterns is an important area for further
study.
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Drug Combinations in Pleasure and
Pain
Conan Kornetsky, Ph.D.
The use of more than one drug simultaneously is not new. Drugs
are combined for both medical and nonmedical use, e.g., codeine and
aspirin for the relief of pain, heroin and cocaine for the
enhancement of euphoria. In this essay, I will describe a series
of experiments from my laboratory on the effects of various
combinations of drugs on the threshold for brain-stimulation reward
(pleasure) and brain-stimulation escape (pain).
We, as well as others (e.g., Kelly and Reid 1977; Wise 1980), have
suggested that many abuse substances increase the sensitivity of
animals to rewarding brain stimulation and, by inference, these
substances cause an activation of those areas of the brain that are
involved in brain-stimulation reward. Olds and Milner (1954) were
the first to report that animals would work in order to receive
electrical stirmlation to various areas of the brain. Although
animals will work for stimulation to many midbrain and cortical
sites, the most reliable site commonly used for eliciting self-
stimulation behavior is the medial forebrain bundle/lateral hypo-
thalamic area. The phenomenon has been called intracranial self-
stimulation (ICSS) as well as brain-stimulation reward. For the
most part, but not exclusively, the former term has been used when
the animals are in an operant paradigm and the dependent variable
is rate of lever pressing for the rewarding stimulation. We have
used the term brain-stimulation reward to designate threshold
determinations.
We (Marcus and Kornetsky 1974) first demonstrated that morphine
will lower the threshold for brain-stimulation reward and raise the
threshold for brain-stimulation escape. The dose-effect curve for
the brain-stirmlation reward is U-shaped, while it is a monotonic
positive dose-effect curve for escape from aversive brain stimula-
tion. For a review of this work see Kornetsky and wheeling (1982)
and Kornetsky (1985).
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REWARDING BRAIN STIMULATION
METHOD
Bipolar stainless steel electrodes (0.013cm in diameter and
insulated except at the tips) are stereotaxically implanted
bilaterally in the lateral hypothalamic region of the medial
forebrain bundle of male rats (300 g, CDF, Charles River
Laboratories, Wilmington, MA). Surgical anesthesia is produced by
systemic administration of Equi-Thesin (0.3 ml/100 g of
body weight). After surgery, animals are given at least 1 week for
postoperative recovery before behavioral testing is instituted.
Animals are maintained on a 12-hour light/dark cycle, housed in
standard steel cages, and have ad libitum access to food and water.
During the initial phase of animal training, each electrode is
tested to determine the current intensity needed to produce
appetitive behavior with little or no motor artifact. The
electrode which produces appetitive behavior at the lowest current
intensity and has the least or no motor artifact is used in the
subsequent study. Animals are trained and tested on a rate
independent threshold procedure in a plastic chamber (20 by 20 by
35 cm) A wheel manipulandum is located within one wall of the
test chamber. Four equally spaced cams on one endplate of the
wheel manipulandum operate a microswitch which results in immediate
delivery of a stimulation when the wheel is rotated one-quarter of
a turn. A constant current stimulator (Sunrise System, Pembroke,
MA) is used to deliver the biphasic symmetrical pulses. Each
stimulus consists of a 500 milliseconds (msec) train with a pulse
width of 0.2 msec and a delay of 0.2 msec between the positive and
negative pulses at a frequency of 160 Hz.
Thresholds are determined by a procedure involving the use of
discrete trials systematically presented over a range of stimulus
intensities. A trial begins with the delivery of a non-contingent
stimulus. A response of one-quarter wheel turn within 7.5 seconds
(sec) of this stimulus results in the delivery of a contingent
stimulus, identical in all parameters to the non-contingent
stimulus, and terminates the trial. Failure to respond has no
scheduled consequences and the trial is terminated after 7.5 sec.
The interval between trials varies around an average of 15 sec, and
responses made during the intertrial interval (error responses)
result in a 15 sec delay before the start of the next trial.
Stimulus intensities are varied using a modification of the
classical psychophysical method of limits. Stimuli are presentd
in an alternating descending and ascending series with a step size
of 5 or 10µA (depending on the sensitivity of the individual
animal) with five trials presented at each intensity level before
the next lower or higher intensity is presented. Subjects complete
four series (i.e., descending, ascending, descending and
ascending) prior to injection, then four or eight series postinjec-
tion, with the entire pre-, post-session lasting 2.5 to 3 hours.
All experimental data are collected and stored by an on-line micro-
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computer. Each series’ threshold value is defined as the midpoint
in microamperes between the level at which the animal makes three
or more correct responses out of the five stimulus presentations (a
plus score) and the level where less than three correct responses
(a minus score) were made. The pre- and post-injection thresholds
are defined by the respective series means.
Animals require approximately six 1-hour training sessions to
learn the task and approximately four additional sessions for the
establishment of a stable threshold level whereupon saline injec-
tions are begun. Animals are tested with saline injections for
five days before drug administration is initiated. Also, saline
days are interspersed with drug treatment day so that animals
receive a drug only twice weekly.
Threshold values are calculated for both the preinjection and the
postinjection sessions, with the difference between the two scores
taken as the dependent measure. These difference scores are
transformed to standard scores (Z-scores) based on the mean and
standard deviation of the difference scores for all saline days. A
Z-score of ±2.0 or greater (95% confidence limits) is preselected
as the level for significance.
TRIPELENNAMINE AND PENTAZOCINE
Because of the street use of this combination, called “T’s and
Blues,” we determined the effect of these drugs alone and in
combination on the threshold for rewarding brain stimulation. In
previous studies, we had already found that pentazocine would lower
the threshold by itself (Kometsky et al. 1979) and, to our
surprise, we found that tripelennamine would also lower the thres-
hold by itself (Unterwald et al. 1984). This finding is in
agreement with those of Jasinski (personal communication), who
found that tripelennamine causes an increase in euphoria as
measured by the Addiction Research Center Inventory. Although both
tripelennamine and pentazocine significantly lower the threshold
for reward, the effect is minimal and considerably less than that
seen after morphine.
Figure 1 (top) shows the mean effect (in Z-soorss) of five animals
after various doses of tripelennamine. The bottom panel of the
figure shows the effects of 2.5 mg/kg of tripelennamine adminis-
tered simultaneously with various doses of pentaxocine (Unterwald
and Kometsky 1984). As can be seen, the 2.5  mg dose of tripelen-
namine has no significant effect by itself, but when combined with
ineffective doses of pentazocine, the effect is clearly and marked-
ly significant. It is important to note that the results suggest
a real synergistic effect, for were the effect only due to
increasing the amount of pentazocine available at receptor sites,
then the dose/response curve simply would have moved to the left.
By combining the two drugs, however, the mamximum effect, or
efficacy, is clearly enhanced.
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FIGURE 1
Mean Z-score Effects of
Various Doses of Tripelen-
namine (top panel) and
Pentazocine (bottom panel).
TheBottom Panel also shows
the Effects of 2.5mg/kg
of Tripelennamine with
Various Doses of Pentazo-
cine. Error Bars Indicate
the Standard Error of the
x Z-score. A Z-score of
±2 Indicates the 95%
Confidence Limits.
(Adapted from Unterwald
and Kometsky 1984)
Copyright 1984, ANKHO
International, Inc.
NALBUPHINE AND TRIPEPENNAMINE
In order to further examine the effects of tripelennamine with a
mixed agonist-antagonist, we studied the simultaneous administration
of tripelennamine with nalbuphine. Nalbuphine is currently avail-
able in injectable form for clinical use as an analgesic. Jasinski
and Mansky (1971) reported that it has significantly less abuse
potential than morphine, although it does increase the euphoria
score on the Addiction Research Center Inventory. Also, animals
will self-administer nalbuphine (Steinfels et al. 1982). Figure 2
Shows the results obtained with an ineffective dose of tripelen-
nanine combined with various doses of nalbuphine in the rat. As
can be seen, although nalbuphine alone will significantly lower the
threshold for rewarding brain stimulation, the addition of
tripelennamine causes a highly significant increase in efficacy, and
moves the We-effect curve to the left.
Figure 3 presents sane idea of the relative effects of these
tripelennamine mixtures as compared to morphine, cocaine, or
amphetamine.As can be seen,the combinations put tripelennamine,
with pentazocine and nalbuphine, in the same class with the latter
highly favored and abused substances.
MORPHINE AND D-AMPHETAMINE ON REWARD
Two experiments with morphine and d-amphetamine were carried out by
Hubner et al (1983). In the first one, a minimally effective dose
of morphine was given simultaneously with various doses of d-
amphetamine. In the second experiment, the procedure was reversed;
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FIGURE 2
Mean Effect of Various Doses of Nalbuphine Alone and
in Combination with 2.5 mg/kg of Tripelennamine
FIGURE 3
Mean Maximal Lowering Effect on Rewarding Stimulation
for Several Drugs. As in Previous Figures, Data are
Presented in Z-scores with Error Bars. (Data from
Unterwald and Kometsky 1984)
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an ineffective dose of d-amphetanine was given simultaneously with
various doses of morphine. The procedure used in these experiments
was similar to that used in the previously described studies. In
both cases, there was clearly a greater effect of these two drugs
when given together than when given separately. However, it is not
clear whether the effect was simply additive or synergistic. A
summary of the effects of the combination in the three animals
used in the second experiment is shown in figure 4. The figure
shows doses of morphine from 0.25 to 2.0 mg/kg alone and with a
nonsignificant threshold-lowering dose of d-amphetamine. The dose
of d-amphetamine used varied between animals. In each case, a non-
significant dose was selected. The doses were 0.063, 0.125, and
0.5 mg/kg, respectively. Although the effect of morphine alone, as
represented in the figure, indicates no significant effect at the
2.0 mg/kg dose, doses up to 1.0 mg/kg rarely show a significant
lowering of the threshold in an individual animal.
FIGURE 4
Mean Effects of Morphine Sulfate Alone (N=3) and in
Combination with d-Amphetanine. (Data from Hubner
et al. 1983)
AVERSIVE BRAIN STIMULATION
METHOD
The experimental chamber, the manipulandum, and the characteristics
of the electrical stimulation are identical to those we use in
determining the threshold for brain-stimulation reward. However,
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in these experiments, the electrodes are stereotaxically implanted
into a brain site that, when stimulated, is only aversive. The
brain site that we use is the mesecephalic reticular formation
(MRF). The rat quickly learns to escape from such stimulation by
rotating the manipulandum a quarter turn. A trial is initiated by
the onset of the electrical stimulation. A response within 7.5 sec
immediately terminates the shock and the trial. If no response
occurs within 7.5 sec, the stimulus is automatically terminated.
Stimulus intensities are varied according to a modification of the
classical psychophysical method of limits. Stimuli are presented
in an alternating ascending and descending series with a step size
of 1 or 2µA, depending on the sensitivity of the animal. An
ascending series is initiated at a previously determined sub-
threshold intensity. Three trials are given in succession at each
intensity.  Two or more escape responses at a particular intensity
are scored as a plus, while less than two responses are scored as a
minus. An ascending series is conducted until plus scores are
achieved in two successive steps. A descending series is then
initiated at one step size lower and current intensity continuous-
ly decreased until two successive minus scores are achieved. The
threshold for a particular ascending or descending series is
defined as the midpoint between those intensities which delimited
the transition from plus to minus scores.
Four series, two ascending and two descending, comprised a session.
A session threshold is computed as the mean of the four series
thresholds. Immediately after the first session is completed,
animals are injected subcutaneously with the test drug or saline,
and a second session of four series is conducted.
Threshold differences between pre- and post-injection sessions on a
drug test day are expressed as a Z-score based on the standard
deviation of the mean threshold differences for all saline test
days. As in the case of brain-stimulation reward, a Z-score of ±2.0
or greater (95% confidence limits) is preselected as the level for
significance.
Using this method, we have found that morphine (Wheeling et al.
1981), cyclazocine and pentazocine (Sasson and Kometsky 1986) and
ethylketocyclazocine (Sasson and Kometsky 1984) all raise the
escape threshold. Naloxone lowers the threshold (Sasson and
Kometsky 1983), and amphetanine either lowers it or has no effect
(Sasson et al. 1983).
AMPHETAMINE AND MORPHINE
It has been previously demonstrated that amphetamine combined with
morphine results in a greater degree of analgesia in man than
morphine alone (Forrest et al. 1977). In order to test whether our
model would also show a potentiation of the analgesic effect of
morphine by amphetamnine, we tested various doses of amphetamine in
combination with a dose of morphine that was ineffective in raising
the escape threshold (Sasson et al. 1983).
Four animals were tested. As in previous experiments, we found
that morphine alone in doses from 1.0 to 16.0 mg/kg (i.p.) caused
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a dose-related increase in the escape threshold d-Amphetamine at
doses from 0.06 to 4.0 mg/kg (i.p.) either had no effect or lowered
the escape threshold. Figure 5 show the interaction of a minimal-
ly effective or ineffective dose of morphine in combination with
various doses of d-amphetamine in two of the four animals tested.
Similar results were obtained in the other two animals As shown,
the d-amphetam
the morphine
ine clearly potentiated the antinociceptive effect of
FIGURE 5
Effects of Morphine Alone and in combination with d-
Amphetamine in   Two Separate Animals, Left and and Right
Two charts, Respectively. As in Previous Work, Data is
Expressed as Z-score charges. (Data from Sasson et al.
1983)
DISCUSSION
These experiments show that combinations of drugs often lead to
effects that exceed the simple algebraic sum of the actions of the
individual drugs. This complex interaction seems to exceed what
might be seen if one drug simply increased the amount of the other
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drug’s availability at the receptor. These synergistic or
potentiation effects are manifested not only in the euphoriant
action of drugs, but also in their analgesic action.
The combining of the antihistmine tripelennamine with the mixed
agonist-antagonist raises sane interesting questions regarding the
role of histamine in the effects of these opiate drugs. The effect
is not confined to the euphoriant action, for Tagashira et al. (1982)
reported that tripelennamine enhanced the analgesic response of
pentaxocine in the mouse using the hot/plate method. Also, Shannon
and Su (1982) found that tripelennamine enhanced the morphinelike
discriminative stimulus effects of pentaxocine in rats trained to
discriminate morphine from saline.
Shannon and Su (1982) argued that the interaction seen at the
behavioral level is not due to a molecular interaction at the
opiate receptor. This conclusion is based on their finding that
tripelennamine did not alter the response of the stimulated guinea
pig ileum to pentazocine, did not modify the Ke for naloxone in
antagonizing pentaxocine, and did not change the inhibition of
specific (3H)-naloxone binding by pentazocine. However, other
evidence suggests that a central histamine system may account for
the interaction Mazurkiewicz-Kwilecki and Henwood (1976) found
that, in the rat, chronic treatment with morphine causes a decrease
in histamnine in the CNS. Also, Eroglu (1979) reported that
naloxone can reverse or block these effects of chronic morphine
treatment on brain histamine. Fran the above mentioned studies,
the mechanism involved in the synergistic effect of tripelennamine
with the mixed agonist-antqonist is not clear. It is clear,
however, that the role of histamine in the response of opiates is
still not understood.
The mechanisms involved in the enhancement of a putative analgesic
response of morphine by d-amphetamine and the drugs’ combined
increaesd effect on brain-stimulation reward are certainly not
apparent. It is highly possible that different mechanisms are
involved since, in the case of rewarding brain stimulation, each
drug independently will increase the animal's sensitivity.
However, in the case of brain-stimulation escape, there is clearly
no similarity in the effects of these two compounds.
Despite a great deal of evidence that dopaminergic pathways are
involved in the reward system (Fibiger 1978), some recent data
suggest that there may not be a close correspondence between the
boundaries of the reward system and those of the dopamine terminal
fields (Prado-Alcala and Wise 1984; Prado-Alcala et al. 1984).
However, the finding that naloxone will attenuate the threshold
lowering effect of d-amphetamine on brain-stimulation reward
(Esposito et al. 1980) suggests an interaction between the
dopaminergic and an endogenous opiate system. This is supported by
the finding that opiate receptors have been localized on
dopaminergic presynaptic neurons in the mesolimbic system and the
striatum (Pollard et al. 1977a, 1977b). However, the role that
these endogencus opiates play in the behavior of the dopamine
neuron is not clear. Some investigators have proposed that opiates
189
facilitate (Chesselet et al. 1981) the release of dopamine, while
other suggest inhibition (Pollard et al.).
Clearly, these experiments suggest that the neuronal mechanisms of
drug interactions require understanding of a greater magnitude than
does the action of either drug alone. There is, however, sane
advantage to studying drug combinations. First,of course, the
abuse liability of new drug combinations may be predicted,based on
animal models. Equally important, the study of combinations may be
helpful in understading the underlying mechmisms involved in the
action of each of the drugs alone. For example, the use of the
combination of the antihistamine with opiates has helped to
elucidate the role of histamine in the action of the opiate drugs.
Thus, while gathering information to understand more fully the
synergistic effects of drug combinations, we gain information
valuable in its own right.
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Drug Interactions With Methadone
in Humans
Mary Jeanne Kreek, M.D.
In a rigorous consideration of the desirable
strategies for research on the interactions of drug
abuse, and also interactions with drugs used to treat
drug abuse, it becomes evident that despite the use-
fulness of animal models and in vitro models, both
for delineation of mechanisms of observed inter-
actions and for screening for possible interactions,
ultimately, controlled studies must be carried out in
normal human volunteer subjects, or patient volunteer
subjects, because of the profound dispositional,
pharmacokinetic, and pharmacodynamic differences with
respect to drug fate and action in humans as con-
trasted to other species. Also, because of the enor-
mous number of theoretically possible drug interactions
of various kinds which might occur, it is essential
first to explore what kinds of drugs are being used
and/or abused in combination by humans using both
wide-scale epidemiological techniques as well as
small-scale, careful clinical observational
techniques. These findings could then direct both
clinical research, animal model and in vitro model
research. By this approach, priorities with respect
to which potential drug interactions should be
studied first can be more logically established.
Research on potential drug interactions should
include not only studies of the possible interactions
between drugs or chemical agents which are documented
to be used (or abused) concomitantly, but also
interactions between similar new drugs or chemical
agents which might be, in the near future, so used in
combination. Studies of model compounds which might
elucidate mechanisms of drug interactions -- such as
compounds known to alter drug disposition by specific
mechanisms, compounds known to alter receptor site
actions by antagonism or which may effect augment-
ation of action, and, finally, drugs which may
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have dynamic actions that either compliment or
counteract some of the diverse actions of the primary
drug of interest -- should also be encouraged,
both in animal models and, when appropriate and
possible from both a regulatory and ethical
standpoint, in humans. For legal, ethical, and
scientific reasons, studies of many model compounds,
of combinations of new drugs,and of combinations of
new and old drugs probably should be carried out
initially in animal model; and/or in vitro systems.
However, studies of possible interacts of those
drugs of use and/or abuse which are already known by
clinical observations to be used in combination by
active drug-abusing, or former drug-abusing humans,
in treatment, and studies of drugs which must be used
together in the treatment of former drug-abusing
humans, should be carried out in controlled human
studies at the earliest possible time.
The use of human subjects, both volunteer subjects
and patient subjects, for studies of interactions of
drugs of use and/or abuse presents many diverse types
of ethical, feasibility-related, and methodological
problems. Studies of drugs of abuse in normal
volunteer subjects are frequently not acceptable on
ethical grounds. Similarly, the administration of
large doses of drugs of abuse, such as the amounts
actually taken in street drug abuse situations, may
not be easily accepted by ethical review committees,
even when studies are to be carried out in subjects
who themselves are substance abusers using those very
drugs in large amounts. However, as in other
scientific-clinical-ethical considerations,
thoughtful development of risk/benefit factor
analysis will undoubtedly facilitate the approval
for performance of needed research.
Feasibility is a second extremely important issue
when clinical studies are to be carried out for any
purpose. Although problems of feasibility will not
be discussed in detail here, it should be made clear
that the most ideal, scientifically and method-
ologically rigorous type of drug interaction studies,
such as the most desirable types of studies using
animal models designed to determine the time course
of action and pharmacokinetics of each drug alone and
in combination, as well as the full dose response
curve of each drug alone and in combination, are not
feasible in humans. Also, diverse factors which may
influence drug interactions--such as circadian
variations of drug disposition, sex and age of
subject, environment, route of drug administration--
and the various diverse pharmacodynamic effects of
each drug alone and in combination--such as the
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effects on neurotransmitter or neuroendocrine
systems--obviously cannot be fully considered in even
the most basic clinical research. From a purely
scientific standpoint, however, it is not absolutely
clear that it would be desirable to carry out such
rigorous testing in humans since a relatively narrow
range of doses of each drug is used and abused in
humans and careful clinical observational studies may
promptly identify these dose ranges for each drug
when used alone and in combination. Similarly, the
approximate time course of action of most drugs used
or abused can be established by careful clinical
observations with respect to time of maximal clinical
effect. Also, the time of peak drug levels in plasma
may be determined and, therefore, the possible time
of maximum action at receptor sites predicted.
On the other hand, many of the criteria demanded for
excellent animal model research in drug interaction
studies certainly can and should be demanded of human
research as well. Perhaps the most important issue
to be addressed in appropriate rigorous clinical re-
search is patient selection and characterization,
coupled with appropriate subset analyses when a
heterogeneous population of subjects is to be
included in the study. Many factors, including
circadian factors, effects of food and other drugs,
and effects of environment, can be controlled by the
environment selected for the clinical research
studies. For instance, in-patient clinical research
in a formal Clinical Research Center setting is far
preferable for such work than outpatient studies
conducted in outpatient clinics, which in turn are
preferable to studies carried out in a nonresearch
clinical setting. In human studies, when feasibility
must be a major consideration (despite the views of
many pharmacologists and pharmacokineticists), it is
most appropriate to study drugs by the routes of
administration which are used both in clinical
medicine and in abuse settings, rather than to
demand, purely for study purposes, one specific route
of administration (e.g., intravenous route with the
misconception that this is essential for pharm-
acokinetic studies), or to demand studies following
drug administration by all possible routes of
administration which is clearly the most desirable
way to carry out the studies in an animal model, but
is not necessarily feasible or desirable to be done
in human subjects. Increasingly, it is being
appreciated that the route of administration used
may significantly alter drug disposition,
pharmacokinetics, and pharmacodynamics; and, again,
careful consideration of possible species differences
in each of these parameters is extraordinarily
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important in interpretation of data. In human
studies, appropriate statistical analysis of data
should be demanded, and the end-point to be studied
should be chosen in advance of controlled studies.
The technological methods to be used in human re-
search will be addressed to some extent in this
report by giving examples of those methadologies
which have been used in studies of methadone
interaction with other drugs, which have allowed
scrutiny of such indices as dispositional
pharmacokinetics of both racemic methadone and each
of the enantiomers of methadone following oral dosing
in the setting of chronic drug administration.
Methadone is an orally effective opioid agonist
which, because of its long-acting properties in
humans (but not in any animal model, where it is
always a short-acting drug with rapid clearance), can
be effectively used to treat narcotic addiction in
humans. Methadone may also be used effectively in
the management of chronic pain, either by providing
analgesia for which the dosages used must exceed the
degree of tolerance developed by the individual, or
by preventing signs and symptoms of narcotic
withdrawal (effects similar to one of the effects
desired in the treatment of narcotic addiction) for
which the doses used should be less than the degree
of tolerance developed by the individual. In the
case of chronic pain patients, additional use of
short-acting narcotics is required to provide the
desired analgesic effects per se.
Methadone has been used in chronic maintenance treat-
ment of addiction of several hundreds of thousands of
patients in the United States as well as an in-
creasing number abroad. To a limited extent, meth-
adone has remained a minor drug of abuse on the
street, just as it was prior to the introduction of
methadone maintenance treatment in 1964. Because of
the wide-spread clinical use and dramatic efficacy of
methadone in the maintenance treatment of addiction,
it has been essential to determine any significant
interactions between other drugs of use, and of
abuse, with methadone, since it is the steady state
of plasma levels and effects of methadone in
chronically treated individuals which allows
normalization of physiological functions, including
neuroendocrine functions, which are significantly
perturbed by chronic abuse of short-acting narcotics,
such as heroin.
Two general types of interactions between any two
drugs or chemical agents may occur: first, disposi-
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tional or pharmacokinetic interactions, which either
increase or decrease the actual amount of drug avail-
able at sites of action; and, secondly, interactions
which alter the pharmacodynamics of either or both
drugs by competition at sites of action, such as at
specific receptor sites, or by a variety of actions
of each drug which may augment or counteract the
primary desired actions of each. Appropriate studies
of the first kind of interactions should include as
"end-points" the determination of the disposition of
one drug alone, and then with the addition of a
second drug. Observations should be made of clinical
symptoms of increased or decreased action of the
first drug, which may occur as a result of dis-
positional interactions when the second drug is
added. The end-points for study with respect to the
second type of drug interactions could be of a wide
variety of types depending upon the primary and
secondary actions of each drug.
Most studies of drug interactions with methadone in
humans have dealt with dispositional drug inter-
actions. The most obvious, though not always fully
recognized, interaction of the second type, which
will be considered briefly, is the interaction of
methadone with a specific opioid antagonist, nal-
oxone. Studies were carried out to determine whether
the addition of naloxone to a methadone formulation
had any significant effect on methadone disposition
(Kreek 1973B). In these studies, naloxone was admin-
istered orally along with methadone in a 1 to 10 dose
ratio. Naloxone has very limited oral bioavail-
ability; thus any dispositional interactions would
have to occur at the intestinal wall sites of
binding, absorption, or metabolism prior to the sites
of hepatic uptake, biotransformation, and clearance
of naloxone as its major glucuronide metabolite.
Naloxone's poor oral bioavailability is due not to
failure to absorb the drug but rather to extensive
metabolism to the inactive naloxone glucuronide after
initial up-take by the liver, or the classical "first
pass" effect. The studies which we carried out to
determine whether any dispositional interactions
occurred showed that naloxone, added to the oral
formulation of methadone, did not alter either plasma
levels of methadone or urinary excretion of methadone
in its major pyrrolidine metabolite. However, when
oral naloxone was given with the oral methadone
formulation to narcotic-tolerant and -dependent
individuals, profound gastrointestinal signs and
symptoms of narcotic withdrawal were observed,
presumably due to antagonist effects of naloxone at
opiate receptor sites within the intestinal wall
(Kreek 1973B). These gastrointestinal signs and
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symptoms were associated with only minimal systematic
signs and symtoms of narcotic withdrawal, reflecting
the very small percentage of naloxone administered
which reached the systemic circulation in a
chemically active unmetabolized form (Kreek 1973B;
Kreek et al. 1976B, 1983B). In this case, there was
no dispositional interaction between the opiate
agonist methadone and the opiate antagonist naloxone,
but rather a profound pharmacodynamic interaction --
i.e.,precipitation of gastrointestinal narcotic
abstinence syndrome--was observed, probably due to
interaction at the opiate receptor sites within the
intestinal wall.
Studies of factors which may significantly alter
methadone disposition in humans have been carried out
to address hypotheses which we have developed
concerning the action of methadone in the treatment
of addiction. Our hypotheses state that a narcotic
drug must be available to critical receptor sites (or
binding sites) for finite and definable periods of
time for tolerance and physical dependence to
develop: that drug-seeking behavior follows as a
natural consequence when the symptoms resulting from
narcotic drug withdrawal in a tolerant and physically
dependent individual (the abstinence syndrome) are
identified by that individual as being related to
drug withdrawal and are observed by that individual
to be relieved when a narcotic drug is readministered;
that constant availability of a narcotic drug (in
this case, methadone) to critical receptor sites is
essential for the steady-state maintenance of a
tolerant and dependent stage; and, finally, that
availability of drugs to critical receptor sites
depends in part on various factors which may affect
overall drug disposition, pharmacokinetics and
excretion. We have shown that three types of factors
may significantly alter methadone disposition in
humans: 1) altered drug disposition in a setting of
chronic disease, including liver and renal disease:
2) altered drug disposition in a setting of the
altered physiological state of pregnancy; and 3)
altered drug disposition due to interaction with
other drugs or hormones (Kreek, Gutjahr, Garfield et
al. 1976B).
When methadone is administered orally on a chronic
basis, a steady state is achieved with relatively
steady plasma levels over a 24-hour dosing interval.
A small increment of methadone plasma levels is found
after oral dosing, with a peak reached in 2 to 4
hours (Kreek 1973B; Kreek, Gutjahr et al. 1976B).
After oral dosing, the peak plasma levels of methadone
rarely exceed a doubling of the nadir or steady-state
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plasma levels and then these slowly decline to a
steady-state plateau level over the remainder of the
24-hour dosing interval (see figure 1). Using a
conventional model of analysis, the specific and
sensitive technique of gas liquid chromatography, it
has been shown that the apparent plasma terminal
half-life of methadone in humans receiving methadone
orally on a chronic basis ranges from around 18 to 28
hours (Kreek 1973B; Kreek et al. 1979).
One of the major problems encountered when animal
models are used in attempts to study methadone
disposition or methadone interactions with other
agents is that the pharmacokinetics of methadone in
amimal models is entirely different from that in
humans. Using gas chromatographic techniques, we
have determined that the apparent plasma terminal
half-life of racemic methadone in the rat is 90
minutes after chronic oral administration of drug and
70 minutes after chronic parenteral subcutaneous
(s.c.) administration of drug. The clearance of
methadone in the mouse is similarly very rapid: 112
minutes after chronic parenteral S.C. administration.
Therefore, the most commonly used rodent models are
very poor models to use for studies of methadone
interactions unless either a constant infusion of
methadone is given or, more realistically, the
profound differences in pharmacokinetics are
Figure 1
Plasma Levels of Methadone Over a 24-Hour Dosing
Interval in an Individual Maintained on 100mg/day
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appreciated and drug interactions are studied only
during the first 1 hour following methadone
administration (Burstein et al. 1980; Kreek 1979) (see
figure 2).
To be able to rigorously determine the dispositional
fate and pharmacokinetics of a single dose of orally
administered methadone against a background of
chronic methadone dosage, a new technology has been
developed and used in basic clinical research
studies. For this purpose, various stable isotope-
labeled species of methadone have been specially
synthesized. These include: dl(SR)- pentadeutero-
methadone, d(S)-trideuteromethadone, l(R)-pentadeu-
teromethadone, and dl(SR)-octadeuteromethadone
(Hachey et al. 1977; Kreek et al. 1979; Nakamura et al,
1982) (see figures 3 and 4).
Figure 2
Plasma Levels of Methadone in the Rat During Chronic
Treatment Using the Oral or Subcutaneous Routes of
Administration. Copyright 1979, Phar Biochem
Behav, ANKHO Int. Inc. Kreek 1979.
200
Figure 3
Structure of Pentadeuteromethadone (Methadone-
d5,i.e., 
2H5-Methadone). Copyright 1979, Life Sci,
Pergamon Press, Ltd. Kreek et al. 1979.
Figure 4
Four Different Species of Stable Isotope Labeled
Methadone. Copyright 1982, J of Pharm Sci,
American Pharmaceutical Association. Nakamura
et al. 1982.
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In some studies, the entire daily dose of methadone
has been administered to chronic methadone-maintained
patients as the racemic dl(SR)-pentadeuteromethadone.
Using gas chromatography-chemical ionization mass
spectrometry with selected ion monitoring, the en-
richment of the labeled over the unlabeled species of
methadone has been determined over a period of sever-
al days following administration of the single,
stable isotope-labeled oral dose. In other studies,
a single, stable isotope-labeled species of one enan-
tiomer of methadone has been administered along with
equal amounts of the other enantiomer in unlabeled
form and the fate of the single-labeled enantiomer
was determined, again using gas chromatography-
chemical ionization mass spectrometry, with selected
ion monitoring to determine the amounts of the
single-labeled species against a background of
unlabeled methadone. Finally, and most recently, the
technique has been significantly modified so that
each of the two enantiomers of methadone may be given
simultaneously as separate, stable isotope-labeled
species. Thus, the full daily dose of methadone can
then be given as racemic methadone, but with each
enantiomer labeled separately so that the fate of
each enantiomer may be determined simultaneously in a
single study. For these studies, dl(SR)-octadeutero-
methadone is used as an internal standard in the gas
chromatography-chemical ionization mass spectrometry
measurements, so that the absolute amounts, as well
as the ratios of labeled to unlabeled species, of
methadone may be determined in a single analytical
procedure (Hachey et al.1977; Kreek et al. 1979;
Nakamura et al. 1982) (see figures 5 and 6).
Radioisotope-labeled species of methadone could not
be used in such studies because of the very wide dis-
tribution and tissue binding of methadone in the
body; the resultant low plasma levels of methadone
which ensue; and the appropriate ethical limits on
amounts of radioisotope-labeled compound which can be
given to human subjects. The ethically acceptable
amounts would be insufficient to obtain a sufficient-
ly high specific activity of labeled methadone in
plasma for pharmacokinetic studies. Using the stable
isotope technology, it has been determined that the
plasma apparent terminal half-life of methadone
ranges from 19 to 38 hours and that the plasma
apparent terminal half-life of the active l(R)-enan-
tiomex is significantly greater than that of the in-
active d(S)-enantiomer. Using this stable isotope
technique, it has been shown that mean half-times for
disappearance of the two enantiomers of methadone in
urine are 34 hours for the inactive d(S) and 57 hours
for the active l(R)-enantiomers, respectively.
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If studies of drug interactions between drugs of
abuse, or drugs for treatment of drug abuse and other
agents of use or abuse are to be carried out in human
subjects, appropriate subject selection, characteri-
zation of the health status of each subject, and
appropriate sub-group analysis are essential. The
very high prevalence of liver disease in substance
abusers, in general, necessitates a consideration of
the effects of liver disease on the disposition of
each drug to be studied, as well as on the effects of
drugs ox agents used concomitantly. We have carried
out extensive studies of the effects of liver disease
of various types and degrees of severity on the
disposition of methadone in humans. This was
absolutely essential because of the very high
prevalence of liver disease in both heroin addicts
and former heroin addicts in methadone maintenance
treatment. Several prospective studies by our group,
as well as similar studies by others (Beverly et al.
1980; Hartman et al. 1983; Kreek et al. 1972; Kreek
1973A; Kreek 1978A; Kreek 1981,; Novick et al. 1985A;
Figure 5
Urine Disappearance Curves
of d - and 1 - Methadone
in 3 Patients (After
Separate Oral Administra-
tion of Pentadeuterometha-
done: Time in Hours).
Copyright 1979, Life Sci,
Pergamon Press, Ltd.
Kreek et al. 1979.
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Novick et al. 1985B), have shown that over 60% of all
heroin addicts have biochemical, with or without
clinical, evidence of chronic liver disease and that
approximately the same percentage of patients
continue to have biochemical with or without
clinical evidence of chronic liver disease during
chronic long-term methadone maintenance treatment.
It has been shown that chronic liver disease in
former heroin addicts and in methadone maintenance
treatment patients is due to: 1) chronic sequelae of
hepatitis B virus infection, delta agent infection,
and, undoubtedly, also sequelae of non-A/non-B
hepatitis virus infection: and 2) alcohol-induced
hepatotoxicity, with alcohol-induced liver disease
(Kreek et al. 1972). In many patients, liver disease
has been documented to be of a mixed type, due both
to viral sequelae of hepatitis virus infection and to
alcohol-induced injury (Beverly et al. 1980; Hartman
Figure 6
Plasma Disappearance Curves of the Separate d - and 1
- Enantiomers of Stable and Plasma Levels of dl -
Methadone (After Simultaneous Oral Administration of
Separate Stable-Labeled Species). Copyright 1982,
J of Pharm Sci, American Pharmaceutical Association.
Nakamura et al. 1982.
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et al. 1983; Kreek 1978A; Kreek 1978B; Kreek 1984;
Novick et al. 1985A; Novick et al. 1985B).
In one prospective study, it was shown that 20% of
all heroin addicts entering methadone maintenance
treatment were also chronic abusers of alcohol and
that approximately the same percentage of these
patients continued to abuse alcohol on a chronic
basis during methadone maintenance treatment (Kreek
1978A). In other studies, it has been shown that
from 20 to 50% of heroin addicts entering treatment
for narcotic addiction and chronic methadone
maintained patients, including both youthful drug
abusers who have become chronic long-term heroin
addicts and thus have been admitted to methadone
maintenance treatment and adult heroin addicts who
have been entered into methadone maintenance
treatment, remain chronic abusers of alcohol (Beverly
et al. 1980; Hartman et al.1983; Novick et al.1985A).
Several studies have shown that the prevalence
of all hepatitis B markers in heroin addicts and
methadone maintenance patients is around 95% and that
about 12% of heroin addicts and patients in the early
years of methadone maintenance treatment are chronic
carriers of hepatitis B antigen. (Kreek 1973A; Kreek
1978A; Kreek et al. 1972; Novick et al.1981A).
Studies of methadone disposition have been carried
out in patients with moderately severe, but fully
compensated, chronic liver disease of a cirrhotic
type. Each of these patients had been treated with
chronic methadone maintenance for extended periods of
time. In these studies, it was shown that the
apparent plasma terminal half-life of methadone was
prolonged to 35.5 +/- 7.6 hours in patients with
compensated alcoholic and/or viral cirrhosis, as
compared to 18.8 +/- 3.0 hours in the contrast group
(Novick et al.1981B). It was also found that plasma
levels of methadone were not increased in cases of
severe liver disease, as had been anticipated from
studies of the effects of chronic liver disease on
the disposition of other drugs. In more recent
studies of patients with very severe liver disease,
performed to determine the disposition of methadone
in that setting, the plasma levels of methadone
appear to be even lower than those in otherwise
healthy patients receiving similar doses of
methadone (Novick et al.1985C). These findings are of
considerable interest because they are the opposite
of what might have been anticipated.
Methadone is metabolized primarily by the hepatic
P450-dependent microsomal drug-metabolizing enzymes.
Methdone is first N-demethylated to form an inactive
205
pyrrolidine metabolite--the major metabolite of
methadone --which in turn undergoes, in part, a second
N-demethylation to form a second inactive metabolite,
a pyrroline. There are also several minor meta-
bolites of methadone, only two of which, accounting
for less that 2% of the administered dose, are
pharmacologically active compounds (see figure 7).
The liver plays two important roles in the dis-
position of methadone: first, it is the major site
of biotransformation of methadone: and, second, it
has been shown to be an important site for non-
specific storage and release of unchanged methadone.
The liver thus serves as a reservoir for methadone,
probably accounting in large part for the long-acting
pharmacokinetic properties of methadone (Kreek et al.
1978). Using an isolated perfused rabbit liver
preparation, it has been found that methadone is
avidly extracted by the liver, but after extraction,
it is extensively bound non-specifically to plasma
membranes where it is stored for subsequent release
in an unchanged form (Kreek et al. 1978). Only a
small proportion of methadone is metabolized during
its first pass through the liver (Kreek et al. 1978).
Therefore, although methadone is avidly extracted by
the liver, it does not undergo the classical "first
pass" effect, implying uptake followed at once by
Figure 7
Structures of Methadol, Methadone, Pyrrolidine,
Pyrroline, Pyrrolidone Metabolite of Methadone.
Copyright 1983, Biomedical Mass Spec, John Wiley
& Sons Ltd. Kreek et al. 1983.
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biotransformation usually to inactive forms, and
excretion. Similarly, using a whole rat model, it
has been shown that a single dose of methadone may
persist in various tissues for up to 6 weeks and
that, at all time points studied, the liver contains
both the highest concentrations and the highest total
amounts of methadone (Harte et al. 1977; Siring et al.
1981A; Ziring et al. 1981B). Thus, the liver appears
to be the major reservoir for methadone storage in
tissue and subsequent release. In the setting of
very severe chronic liver disease (such as severe
cirrhosis), the profoundly decreased hepatocellular
mass with resultant decreased reservoir capacity
plays an even greater role in altering methadone
disposition than does the reduction in hepatic
P450-dependent microsomal drug-metabolizing enzyme
capacity, which, though probably very compromised in
a setting of severe chronic liver disease, may
remain adequate to carry out the biotransformation of
methadone, since this drug is metabolized very
gradually by the liver over a 24-to-48-hour period,
as contrasted to short-acting drugs which are very
rapidly metabolized by the hepatic microsomal P450
drug-metabolizing enzymes.
Other studies have been carried out to determine the
effects of chronic liver disease of varying types and
degrees of severity on the urine and fecal excretion
of methadone and its metabolites. For this work,
techniques have been developed using direct probe
chemical ionization mass spectrometry, in which the
stable isotope-labeled methadone octadeuteromethadone
is used as an internal standard for the quantitation
of unlabeled methadone and its metabolites, but with-
out the administration of stable isotope-labeled
compounds for use as in vivo tracers in these
studies (Kreek et al. 1980A; Kreek et al. 1983A). In
these studies, it was shown that from 46 to 55% of an
oral daily dose of methadone is excreted in urine as
the sum of unchanged methadone and its metabolites;
the major pyrrolidine metabolite accounts for 24 to
29% of urine clearance of the daily methadone dose,
whereas unchanged methadone accounts for 10 to 26% of
the total amount (Kreek et al. 1980A). In otherwise
healthy patients, a mean of 48% of the daily dose of
methadone is excreted by the urinary route of
methadone plus all methadone metabolites; whereas, in
patients with chronic liver disease of varying types
and degrees of severity, there was a significant
decrease in the total amounts of methadone and
metabolites excreted in urine, with a mean of 31% of
the daily dose being excreted by that route (Kreek et
al. 1980A) (see figure 8). In additional studies
which also used direct probe chemical mass
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spectrometry, it was shown that, in a setting of
chronic liver disease, increased amounts of both
unchanged methadone and its metabolites are excreted
in feces. This suggests that, in the setting of
decreased hepatic reservoir capacity, methadone is
either more extensively biotransformed or passed as
unchanged methadone into the bile after hepatic
uptake and, thus, eliminated in feces (Kreek et al.
1983A) (see figure 9). In all of these studies, no
patients were observed to have any symptoms of
relative narcotic overdose. This fact is of clinical
importance, since patients who have stable chronic
liver disease may thus be treated with methadone
without undue concern about accumulation of drug in
plasma and, therefore, excessive amounts of active
compounds at various receptor sites. Thus, any
possible adverse central nervous system effects would
not be expected to occur in the setting of severe
chronic liver disease. These findings also should be
considered when planning and conducting studies of
drug interactions in narcotic-dependent persons, or
other parenteral drug abusers, in whom chronic liver
disease of one or more types is known to be of high
prevalence.
Figure 8
Urinary Excretion of Methadone and Its Metabolites in
Humans as Studied by Direct Probe Chemical Ionization
Mass Spectrometry
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Limited studies have also been carried out to deter-
mine the effects of compromised renal function on
methadone disposition. In these limited studies, it
has been shown that both in a setting of oliguria in
a patient maintained on hemodialysis, as well as
following renal transplantation, there was no
evidence of accumulation of methadone in plasma
(Kreek et al. 1980B). Plasma levels of methadone in
those settings were found to be within the range
expected in otherwise healthy subjects for the dose
of methadone administered. Also in these studies
it was found that there were marked increases in the
fecal excretion of methadone, which accounted for
essentially the total elimination of methadone in
patients with oliguria or anuria.
Controlled clinical studies have also shown that
methadone disposition becomes significantly altered
during late pregnancy (Kreek et al. 1974; Kreek 1979;
Pond et al. 1985). In early observations and study
Figure 9
Fecal Excretion of Methadone and Its Metabolites in
Humans, as Studied by Direct Probe Chemical
Ionization Mass Spectrometry
209
of one case, it was found that, for a given dose of
methadone, the plasma levels of methadone during the
third trimester of pregnancy were significantly lower
than would be expected for the dose administered and,
yet, the levels returned to anticipated levels for
dose shortly following delivery (Kreek et al. 1974).
Subsequently, prospective studies have been carried
out in several methadone-maintained patients who were
documented to be free of any alcohol or polydrug
abuse and who had minimal to no evidence of chronic
liver disease (Kreek 1979) Pond et al. 1985). In
these studies, it was shown that, during the last
trimester of pregnancy, the plasma levels of
methadone become progressively lowered with
concomitant lowering of the area under the plasma
concentration time curve coupled with increased
nonrenal clearance of methadone (Kreek 1979; Pond et
al. 1985).
Although albumin levels are normally lowered in late
pregnancy, globulin levels become increased. Metha-
done binds to both albumin and globular fractions.
Specific binding studies were performed which showed
that the percentage of free methadone did not change
significantly and, thus, could not account for the
observed lowering of plasma levels and enhanced
clearance of methadone during late pregnancy (Pond et
al. 1985). In these studies, it was also shown that,
in the postpartum period, plasma levels of methadone
resulting from administration of a constant dose
increased promptly back to the normal anticipated
range (Pond et al. 1985). Each patient served as her
own control in this study, thus minimizing any
interindividual variation. In these studies, as well
as in all of our other controlled studies, we have
shown that both in otherwise normal healthy subjects
and in patients with chronic liver disease and
altered physiological states, there is very little
intraindividual variation of plasma levels of
methadone when studies are carried out on different
days but in a clinical research setting, where time
of day, time of dosing, and circadian factors, along
with careful monitoring of patients for use and abuse
of other substances which might alter drug dis-
position, can all be controlled. However, all of our
studies have indicated that there is highly signi-
ficant interindividual variation with respect to
plasma levels of methadone after any given dose.
Both the lowering of plasma levels of methadone in
drug interactions discussed below, and the lowering
of plasma levels of methadone during late pregnancy,
exceeded what one would expect to see, even given the
range of interindividual variations in levels and,
far beyond expectation, given the very limited range
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of intraindividual variation. In these studies,
since each patient served as her own control, it was
possible to see both the progressive lowering of
plasma levels and the area under the plasma concen-
tration time curve as pregnancy progressed and, then,
a return to normal range of these indices in the
postpartum period (Kreek 1979; Kreek et al. 1974; Pond
et al. 1985). It is assumed, though not proven, that
the hormonal milieu of pregnancy resulting in an
enhanced biotransformation of methadone is a major
factor accounting for the reduction in plasma levels
of methadone. This formulation is supported in part
by the finding of increased urinary excretion of the
major pyrrolidine metabolite relative to the excre-
tion of unchanged methadone during pregnancy. It has
been shown by others that progestins, which are
present at very high levels during late pregnancy,
may enhance the hepatic microsomal P450-dependent
enzyme activities for some substrates. Also, the
biotransformation of methadone to inactive compounds
by the placenta and the fetal liver may have contri-
buted in part to the apparent enhancement of metha-
done metabolism and lowering of plasma levels
observed during late pregnancy.
The first clinical observations and documentation of
interaction of any other drug with a narcotic drug
were the observations of the profound interactions
between the antituberculosis drug, rifampin, and the
long-acting narcotic methadone, being used on a
chronic basis in the maintenance treatment of
addiction (Kreek et al. 1976A). Rifampin has been
shown to have several effects on the liver, including
a hepatocellular toxic effect resulting in non-
specific hepatitis in some cases and an effect on
hepatic uptake and biliary clearance of a variety of
substances. Also of specific importance for this
discussion, it has been shown that rifampin is a
potent enhancer of hepatic microsomal P450-dependent
drug-metabolizing enzyme activities. Based on
knowledge of this action of rifampin, it was
postulated that this drug, and also phenobarbital,
which similarly is a potent enhancer of hepatic
microsomal P450-dependent drug-metabolizing enzyme
activities, might result in acceleration of
metabolism of a drug such as methadone, which
normally is dependent upon the hepatic P450
microsomal enzymes for its biotransformation. The
first clinical observations of such an interaction
were made in a special clinic for the simultaneous
management of heroin addiction, by use of chronic
methadone maintenance treatment, and tuberculosis, by
use of a variety of anti-tuberculosis agents. Severe
signs and symptoms of narcotic withdrawal ensued when
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the then experimental new drug rifampin was added to
the therapeutic regimen of some of the methadone-
maintained patients who, up to that point, had been
successfully stabilized on both methadone maintenance
and anti-tuberculosis treatment, but who needed
additional antituberculosis treatment because of far
advanced resistant disease. Thirty of the 86
patients in this special treatment program for
tuberculosis and narcotic addiction were treated with
rifampin and, of these, signs and symptoms of
narcotic withdrawal developed in 21 cases, or 70%.
Of the 21 patients who developed narcotic withdrawal
symptoms, 14 had mild symptoms of withdrawal whereas,
in 7, severe withdrawal symptoms ensued. Mild
withdrawal symptoms included abdominal cramps,
rhinorrhea, lacrimation, yawning, and irritability:
in the severe cases, additional symptoms included
nausea, vomiting, anorexia, joint pains, chills,
tremulousness, insomnia, and severe anxiety (Kreek et
al. 1976A). Most of the severely affected patients
developed withdrawal symptoms within the first week
of combined rifampin and methadone treatment.
Studies were carried out to determine whether there
were any dispositional or pharmacokinetic inter-
actions between methadone and rifampin in six of
these patients with severe narcotic withdrawal symp-
toms during combined treatment (Kreek et al. 1976A).
Each patient was studied while receiving methadone
alone, and while receiving methadone plus rifampin.
A highly significant lowering of plasma levels of
methadone, along with a decreased area under the
plasma concentration time curve, was observed in each
of the six patients studied during the combined
rifampin and methadone treatment as compared to the
period of treatment with methadone alone (see figure
10). Also in each case, the symptoms of narcotic
withdrawal reappeared when rifampin treatment was
reinstituted for study purposes. The apparent plasma
terminal half-life of methadone was not significantly
altered during combined rifampin treatment, despite
the fact that the plasma levels and area under the
plasma concentration curves were significantly
lowered. Further studies showed increased urinary
excretion of the N-demethylated pyrrolidine
metabolite in urine and great increases in fecal
excretion of the N-demethylated inactive metabolites
during combined rifampin and methadone treatment
(Kreek et al. 1976A; Kreek et al. 1976B). The results
of these studies indicate that when rifampin must be
added to the antituberculosis therapeutic regimen of
a patient receiving methadone on a chronic basis for
treatment of addiction or for the management of
chronic pain, the patient should be carefully
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observed; increases in doses of methadone and/or
increases in frequency of doses will probably be
needed to sustain the desired effects of methadone in
this observed and documented interaction between
rifampin and methadone. The effectiveness of careful
clinical observations, followed by controlled
clinical research studies which elucidate both the
phenomena and the probable mechanisms of the drug
interaction, was demonstrated in this observed and
documented interaction between rifampin and
methadone. This is a kind of approach which may be
most effective from all standpoints in identifying
and elucidating interactions between drugs of abuse
or between drugs, such as methadone, used to
pharmacologically treat drug abusers and other drugs
of abuse or therapeutic agents, such as rifampin.
Figure 10
Plasma Concentration-Time Curves for Methadone During
Treatment with Methadone Alone and During Concomitant
Treatment with Methadone and Rifampin in 6 Patients.
Copyright 1976, New England Journal of Medicine
294:1104-1106, 1976. Kreek et al. 1976.
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A second clinically very significant drug interaction
with methadone has also been observed clinically and
then studied in a controlled setting (Tong et al.
1981). It was noted that when the anticonvulsant
drug phenytoin (Dilantin) was added to the
therapeutic regimen of patients receiving methadone
on a chronic basis, symptoms of narcotic withdrawal
would frequently appear within 1 to 4 days,
suggesting that phenytoin enhances methadone
metabolism. A study was carried out in volunteer
chronic methadone-maintained patients without
polydrug abuse, alcohol abuse, or significant liver
disease. The disposition and pharmacokinetics of
methadone were studied in these volunteer subjects
while being treated with methadone alone and, then,
while also receiving the anticonvulsant drug
phenytoin in therapeutic doses (1000 mg in two
divided doses on the first day, followed by a single
daily dose of 300 mg on the second through fifth
day). Moderate to severe symptoms of narcotic
withdrawal appeared in each of these subjects by the
third or fourth day of concomitant phenytoin and
methadone administration. The drug disposition
studies showed that plasma levels of methadone became
significantly reduced during concomitant phenytoin
treatment as compared to treatment with methadone
alone (Tong et al. 1981) (see figure 11). Quan-
titative analyses of methadone and its metabolites
in urine documented that, during concomitant
phenytoin treatment, there was a very significant
increase in the relative amount of the inactive
N-demethylated pyrrolidine metabolite of methadone,
thus showing enhanced urinary excretion of the
biotransformation products of methadone during phen-
ytoin treatment (Tong et al. 1981) (see figure 12).
Thus, both in clinical observations and in controlled
studies carried out in a clinical research setting,
it was shown that phenytoin enhances methadone
clearance, resulting in lower plasma levels of
methadone at all time points and a reduction in the
the area under plasma concentration time curves.
These changes in methadone disposition are accom-
panied by highly significant clinical signs and
symptoms of moderate to severe narcotic withdrawal.
Thus, again, as recommended in the case of rifampin,
when phenytoin is added to the therapeutic regimen of
a patient receiving methadone treatment on a chronic
basis, whether for the maintenance treatment of
addiction or for the management of chronic pain, it
is essential to observe the patient carefully and
adjust the dose or dosing intervals of methadone as
needed (Kreek et al. 1976A; Kreek et al. 1976B; Tong et
al. 1981).
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Figure 11
Effects of Phenytoin (Dilantin) on Plasma
Levels of Methadone
Figure 12
Effects of Phenytoin (Dilantin) on Urinary
Excretion of Methadone and its Major
N-Demethylated Pyrrolidine Metabolite
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Other clinical observations have suggested that
possibly the pharmacological agent used in an attempt
to manage alcohol abuse, disulfiram (Antabuse), might
cause dispositional interactions with methadone. A
study was carried out in seven male volunteer sub-
jects, all of whom were receiving chronic methadone
maintenance treatment and none of whom had any alco-
hol or polydrug abuse or significant liver disease
(Tong et al. 1980). Dispositional studies of metha-
done metabolism were carried out first while subjects
received methadone alone and, then, while they re-
ceived methadone plus disulfiram in therapeutic
doses. There were no significant changes in plasma
levels of methadone during combined disulfiram treat-
ment, and the areas under the plasma concentration
time curves were not altered in the setting of com-
bined treatment (Tong et al. 1980). However, quanti-
tative analyses of the excretion of methadone and its
metabolites in urine showed that there was a relative
increase in urinary excretion of the N-demethylated
pyrrolidine metabolite of methadone during
concomitant disulfiram treatment as compared to
treatment with methadone alone, suggesting that some
minor dispositional interaction between methadone and
disulfiram had occurred. There were no clinical
signs and symptoms of narcotic withdrawal in the
study subjects (Tong et al. 1980). However, with the
suggestion that some minor dispositional interaction
might have occurred, it will probably be necessary to
carry out similar studies to determine whether there
are any significant dispositional interactions
between disulfiram and methadone in patients who are
former alcohol abusers in chronic methadone treatment
and, thus, might be receiving this combination of drugs,
including both those subjects without and also with
alcohol-induced liver disease or mixed type of liver
disease of varying degrees of severity.
Studies have also been carried out in humans to de-
termine whether the acute social use of alcohol would
have any effect on either methadone disposition or
action (Cushman et al. 1978). For these studies,
chronic methadone-maintained volunteers without a
history of either alcohol abuse or polydrug abuse and
without significant chronic liver disease were
selected. Plasma levels of methadone were determined
during treatment with methadone alone and during
administration of an acute dose of 90 ml of ethanol
in juice solution. There were no significant changes
in plasma levels of methadone during combined
treatment as compared to treatment with methadone
alone (Cushnan et al. 1978). Also, there were no
unexpected or enhanced effects of either ethanol or
methadone observed clinically in this setting
(Cushman et al. 1978).
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Studies are currently in progress to determine if
there are any significant interactions between
methadone and ethanol in the setting of chronic
alcohol abuse by chronic methadone-maintained
patients (Kreek 1984). Based on studies carried out
for other drugs, primarily in animal models, with
respect to possible interactions with ethanol, it has
been suggested that two types of dispositional
interactions may occur during chronic ethanol use or
abuse. When ethanol is administered in high doses
(probably doses too high to be tolerated by any
animal or human who is not already tolerant and
dependent on ethanol), inhibition of the metabolism
of a second drug may occur at the hepatic microsomal
P450-dependent enzyme activity level, since ethanol,
to an extent of approximately 30% of an administered
dose undergoes biotransformation by that system and
since the microsomal system is more extensively
utilized in the metabolism of alcohol in the setting
of high blood levels resulting from consumption or
administration of large amounts of ethanol. Con-
versely, it has been well documented that chronic
ethanol administration causes enhancement of the
hepatic microsomal P450-dependent enzyme activities;
therefore, when alcohol itself has been cleared from
the body, drugs which are normally metabolized by the
hepatic microsomal P450-dependent enzymes are
metabolized more rapidly than normal because of this
enhancement by ethanol. Thus, a biphasic effect of
ethanol on the metabolism of another drug occurs.
Whether or not each of these types of dispositional
drug interactions occur when large amounts of ethanol
are ingested by chronic alcohol-abusing methadone-
maintained patients has yet to be established and is
currently under study by our laboratory group.
In each of these examples, it has been amply demon-
strated that studies of drug interactions between
methadone and a second drug may be carried out in a
controlled clinical research setting and that the re-
sults have immediate and enormous clinical relevance.
However, it is essential sometimes either to conduct
pilot studies using an animal model or to use an
animal model to elucidate mechanism of action of such
drug interactions. In our laboratory, we have used
both whole animal models, primarily involving admini-
stration of one or two drugs to rats, as well as
isolated perfused liver preparations. Using organ
models, we have shown, for instance, that acute per-
fusion with ethanol does not significantly affect the
hepatic uptake of methadone, nor does it affect the
immediate metabolism of methadone (Kreek et al. 1981).
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We have also shown that hepatic perfusion with
ethanol does not affect the immediate hepatic uptake
of other narcotics, including morphine (Kreek et al.
1981). Thus, the observed inhibition of drug
metabolism by ethanol is probably due to a sustained
action of competitive inhibition by ethanol of the
second drug at the hepatic microsomal drug-metabol-
izing enzyme. In studies carried out in the whole
rat, we have shown that, when animals have been
treated with both ethanol and methadone, or with
methadone alone on a chronic basis, and determination
of plasma levels of methadone is carried out 24 hours
following the last dose of ethanol and 1 hour follow-
ing dosing with methadone (a time point which con-
forms with what is now known about the pharmacoki-
netics of methadone in the rat), significant re-
ductions in plasma levels of methadone are observed
in the animals which have been treated with both
ethanol and methadone as compared to animals treated
with methadone alone (see figure 13). Thus, chronic
ethanol treatment does result in acceleration of
methadone metabolism in the whole rat model. How-
ever, if other time points had been selected for
study, other interpretations might have ensued simply
Figure 13
Plasma Levels of Methadone in Rats Treated with
Methadone Alone as Compared with Methadone and
Ethanol on Chronic Basis
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because of the pharmacokinetic properties of metha-
done in a rat, i.e., the very rapid metabolism of
methadone in this animal (Kreek 1981, Kreek 1978).
Similarly, studies have been carried out using the
whole rat model to determine possible interactions
between phenobarbital and methadone. Again, in these
studies, animals are treated chronically with metha-
done plus phenobarbital or with methadone alone
(Kreek 1978B). These studies have shown that plasma
levels of methadone at 1 hour after dose administra-
tion are significantly lower in animals treated with
methadone plus phenobarbital than in animals treated
with methadone alone (Kreek 1978B) (see figure 14).
It was also shown that the fecal excretion of metha-
done plus metabolites was significantly enhanced in
phenobarbital-treated animals as compared to animals
treated with methadone alone. Furthermore, it was
critical to fully appreciate the pharmacokinetics of
both methadone and phenobarbital in the rat model
before this interaction could be properly studied.
Figure 14
Plasma Levels of Methadone in Rats Treated with
Methadone Alone as Compared with Methadone and
Phenobarbital on a Chronic Basis. Copyright 1978,
Raven Press, N.Y. Kreek 1978B.
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These studies were carried out because phenobarbital
is the most potent enhancer of hepatic microsomal
P450-dependent drug-metabolizing enzyme activity of
all agents categorized as enhancers or "inducers" of
hepatic P450-dependent drug-metabolizing enzyme
systems.
This is an example of the use of animal models to
study the effect of a model drug, with a known type
of mechanism of action, on the disposition of a
second drug. Prom these studies, it was predicted
that, should any patient be placed on phenobarbital
treatment, or abuse phenobarbital, while on chronic
methadone treatment, methadone plasma levels probably
would be significantly reduced and, probably, nar-
cotic withdrawal symptoms would ensue. Thus, it was
predicted that a drug interaction between methadone
and phenobarbital would occur similar to that clini-
cally observed and documented to occur between metha-
done and rifampin, and between methadone and phen-
ytoin, with the same resultant precipitation of the
narcotic abstinance syndrome. The first clinical
report of such an interaction between phenobarbital
and methadone in a chronically maintalned patient was
published recently (Liu and Wang 1984). In this report,
careful clinical observations, coupled with multiple
determinations of methadone plasma levels, were made
in a single patient observed to develop symptoms of
narcotic withdrawal while in chronic methadone main-
tenance treatment, first unexplained, and later docu-
mented and verified to be due to chronic phenobarbi-
tal abuse. In this patient, it was shown that, dur-
ing the period of phenobarbital abuse, plasma levels
of methadone and the area under the plasma concentra-
tion time curve of methadone were significantly re-
duced as compared to similar indices of methadone
disposition when that same patient was studied both
before and some time following cessation of pheno-
barbital abuse, while taking methadone alone (Liu
and Wang 1984).
In developing a strategy to identify, define, and
elucidate the mechanisms of any drug interactions be-
tween drugs of abuse, or drugs of use and abuse, or
agents used therapeutically in the treatment of drug
abuse with other agents of use or abuse--although it
may often be appropriate and suitable to use animal
models or in vitro models--clearly, the most urgently
needed studies are those which can be carried out in
human beings and, thus, directly document the pre-
sence or absence of any pharmacokinetic or pharma-
codynamic interactions of clinical significance in
the human species. Such work is extremely difficult
to carry out and is frustrating for a multitude of
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reasons; this type of clinical research frequently is
not perceived by critics, at least in advance of
performance of such studies, to be of merit.
Nevertheless, it is quite clear that once performed,
especially when positive findings are made, clinical
studies are the basis for not only more appropriate
therapeutic management, or prevention, of the effects
of concomitant use of two interacting agents, but
also serve as the basis for making predictions of
future drug interactions which may be of clinical
significance in humans. Thus, properly conducted
studies of drug interactions in humans using
rigorously and appropriately selected study subjects
should be encouraged and supported.
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Arthur Carr, Ph.D. NCDAI out of stock
GPO out of stock NTIS PB #82-133117 $16.95
41 PROBLEMS OF DRUG DEPENDENCE, 1981: PROCEEDINGS OF THE 43RD
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
Not available from GPO NTIS PB #82-190760 $40.95
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42 THE ANALYSIS OF CANNABINOIOS IN BIOLOGICAL FLUIDS. Richard L.
Hawks, Ph.D., eo. Not available from NCDAI.
GPO Stock #017-024-01151-7 $5 NTIS PB #83-136044 $16.95
43 PROBLEMS OF DRUG DEPENDENCE, 1982: PROCEEDINGS OF THE 44TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
GPO out of stock NTIS PB #83-252-692/AS $40.95
44 MARIJUANA EFFECTS ON THE ENDOCRINE AND REPRODUCTIVE SYSTEMS.
Monique C. Braude, Ph.D., and Jacqueline P. Ludford, M.S., eds. A
RAUS Review Report.
GPO Stock 6017-024-01202-5 $4 NTIS PB #85-150563/AS $16.95
45 CONTEMPORARY RESEARCH Ih PAIN AND ANALGESIA, 1983. Roger M.
Brown, Ph.D.; Theodore M. Pinkert, M.D., J.D.; and Jacqueline P.
Ludford, M.S., eds. A RAUS Review Report.
GPO Stock #017-024-01191-6 $2.75 NTIS PB #84-184670/AS $11.95
46 BEHAVIORAL INTERVENTION TECHNIQUES IN DRUG ABUSE TREATMENT. John
Grabowski, Ph.D.; Maxine L. Stitzer, Ph.D., and Jack E.
Henningfield, Ph.D., eds.
GPO Stock #017-024-01192-4 $4.25 NTIS PB #84-184688/AS $16.95
47 PREVENTING ADOLESCENT DRUG ABUSE: INTERVENTION STRATEGIES.
Thomas J. Glynn, Ph.D.; Carl G. Leukefeld, D.S.W.; and
Jacqueline P. Ludford, M.S., eds. A RAUS Review Report.
GPO Stock 8017-024-01180-1 $5.50 NTIS PB #85-159663/AS $22.95
48 MEASUREMENT IN THE ANALYSIS AND TREATMENT OF SMOKING BEHAVIOR.
John Grabowski, Ph.D., and Catherine S. Bell, M.S., eds.
GPO Stock #017-024-01181-9 $4.50 NTIS PB 84-145-184 $16.95
49 PROBLEMS OF DRUG DEPENDENCE, 1983: PROCEEDINGS OF THE 45TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-01158-3 $12 NTIS PB 85-151553/AS $34.95
50 COCAINE: PHARMACOLOGY, EFFECTS, AND TREATMENT OF ABUSE. John
Grabowski, Ph.D., ed.
GPO Stock #017-020-01214-9 $4.50 NTIS PB 85-150381/AS $16.95
51 DRUG ABUSE TREATMENT EVALUATION: STRATEGIES, PROGRESS, AND
PROSPECTS. Frank M. Tims. Ph.D., ed.
GPO Stock #0l7-020-01218-1 $4.50 NTIS PB 85-150365/AS $16.95
52 TESTING DRUGS FOR PHYSICAL DEPENDENCE POTENTIAL AND ABUSE
LIABILITY. Joseph V. Brady, Ph.D., and Scott E. Lukas, Ph.D., eds.
GPO Stock #017-024-0204-1 $4.25 NTIS PB 85-150373/AS $16.95
53 PHARMACOLOGICAL ADJUNCTS IN SMOKING CESSATION. John Grabowski,
Ph.D., and Sharon M. Hall, Ph.D., eds.
GPO Stock #017-024-01266-1 $3.50 NTIS PB No. to be assigned
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54 MECHANISMS OF TOLERANCE AND DEPENDENCE. Charles Wm. Sharp,
Ph.D., ed. NCDAI out of stock
GPO Stock #017-024-01213-1 $8.50
55 PROBLEMS OF DRUG DEPENDENCE, 1984. PROCEEDINGS OF THE 46TH
ANNUAL SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG
DEPENDENCE, INC. Louis S. Harris, Ph.D., ed.
GPO Stock 6017-024-01242-4 $9.50
56 ETIOLOGY OF DRUG ABUSE: IMPLICATIONS FOR PREVENTION. Coryl LaRue
Jones, Ph.D., and Robert J. Battjes, D.S.W., eds.
GPO Stock #017-024-01250-5 $6.50
57 SELF-REPORT METHODS OF ESTIMATING DRUG USE: MEETING CURRENT
CHALLENGES TO VALIDITY. Beatrice A. Rouse, Ph.D., Nicholas J.
Kozel, M.S., and Louise G. Richards, Ph.D., eds.
GPO Stock #017-014-01246-7 $4.25
58 PROGRESS IN THE DEVELOPMENT OF COST-EFFECTIVE TREATMENT FOR DRUG
ABUSERS. Rebecca S. Ashery, D.S.W., ed.
GPO Stock 6017-024-01247-5 $4.25
59 CURRENT RESEARCH ON THE CONSEQUENCES OF MATERNAL DRUG ABUSE.
Theodore M. Pinkert, M.D., J.D., ed.
GPO Stock #017-024-01249-1 $2.50
60 PRENATAL DRUG EXPOSURE: KINETICS AND DYNAMICS. C. Nora Chiang,
Ph.D., and Charles C. Lee, Ph.D., eds.
GPO Stock 1017-024-01257-7 $3.50
61 COCAINE USE IN AMERICA: EPIOEMIOLDGIC AND CLINICAL PERSPECTIVES.
Nicholas J. Kozel, M.S., and Edgar H. Adams, M.S., eds.
GPO Stock #O17-024-01258-1 $5
67 NEUROSCIENCE METHODS IN DRUG ABUSE RESEARCH. Roger M. Brown,
Ph.D., and David P. Friedman, Ph.D., eds.
GPO Stock #017-024-01260-2 $3.50
63 PREVENTION RESEARCH: DETERRING DRUG ABUSE AMONG CHILDREN AND
ADOLESCENTS. Catherine S. Bell, M.S., and Robert Battjes,
D.S.W., eds.
GPO Stock #017-024-01263-7 $5.50
64 PHENCYCLIDINE: AN UPDATE. Doris H. Clouet, Ph.D., ed.
GPO Stock #017-024-01281-5 $6.50
65 WOMEN AND DRUGS: A NEW ERA FOR RESEARCH. Barbara A. Ray, Ph.D.,
and Monique C. Braude, Ph.D., eds.
GPO Stock #017-024-01283-1 $3.25
66 GENETIC AND BIOLOGICAL MARKERS IN ORUG ABUSE AND ALCOHOLISM.
Monique C. Braude, Ph.D., and Helen M. Chao, Ph.D. eds. In press.
67 PROBLEMS OF DRUG DEPENDENCE, 1985. PROCEEDINGS OF THE 47TH ANNUAL
SCIENTIFIC MEETING, THE COMMITTEE ON PROBLEMS OF DRUG DEPENDEHCE,
INC. Louis S. Harris, Ph.D., ed. In press.
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